Adeno-associated virus vector delivery for muscular dystrophy

Combining AAV vectors with immunosuppressants and TPE in gene therapy for muscular dystrophy optimizes vector delivery and immune response, enhancing muscle strength and reducing fibrosis.

JP7948841B2Active Publication Date: 2026-11-11RES INST AT NATIONWIDE CHILDRENS HOSPITAL +1
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2022577296
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2021-05-13
Filing Date
2021-06-15
Publication Date
2026-11-11
Estimated Expiration
2041-06-15

AI Technical Summary

Technical Problem

Current gene therapies for muscular dystrophy, such as Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophy (LGMD), face challenges in optimizing vector delivery and immunosuppressive effects, leading to muscle damage and fibrosis due to immune responses against adeno-associated virus (AAV) vectors.

Method used

A combination therapy using AAV vectors expressing microdystrophin or β-sarcoglycan genes in skeletal muscle, accompanied by immunosuppressants like anti-inflammatory steroids and anti-CD20 antibodies, alongside therapeutic plasma exchange (TPE) to remove antibodies, enhances gene expression and reduces fibrosis.

Benefits of technology

The approach increases muscle strength, reduces fibrosis, and improves muscle function by optimizing AAV vector delivery and immune suppression, addressing the limitations of existing therapies.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007948841000039
    Figure 0007948841000039
  • Figure 0007948841000040
    Figure 0007948841000040
  • Figure 0007948841000041
    Figure 0007948841000041
Patent Text Reader

Abstract

The present disclosure provides methods of treating muscular dystrophy in a subject in need thereof, comprising administering a gene therapy vector, such as an adeno-associated virus (AAV) vector expressing a miniaturized human micro-dystrophin gene, in combination with suppressing the subject's immune system.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] This application claims priority to U.S. Provisional Application No. 63 / 039,252 filed on 15 June 2020, U.S. Provisional Application No. 63 / 083,953 filed on 27 September 2020, U.S. Provisional Application No. 63 / 160,376 filed on 12 March 2021, and U.S. Provisional Application No. 63 / 188,266 filed on 13 May 2021, each of which is incorporated herein by reference in its entirety.

[0002] Integration by referencing electronically submitted documents This application includes a computer-readable sequence listing, which is incorporated in its entirety by reference as a separate part of the present disclosure, and is recognized as filename: 55714_Seqlisting.txt, size: 83,380 bytes, created: June 7, 2021.

[0003] This disclosure provides a method for treating diseases such as muscular dystrophy in a target subject, comprising administering a gene therapy vector such as an adeno-associated virus (AAV) vector, and expressing a target transgene such as a miniaturized human microdystrophin gene or a β-sarcoglycan gene in combination with a step of suppressing the target's immune system. [Background technology]

[0004] The importance of muscle mass and strength for daily activities such as exercise and breathing, as well as for overall metabolism, is clear. Deficiencies in muscle function lead to muscular dystrophy (MD), characterized by decreased muscle strength and wasting, and severely impacting quality of life. The best-characterized MDs are caused by mutations in genes encoding members of the dystrophin-binding protein complex (DAPC). These MDs are due to membrane fragility associated with the loss of muscle cell membrane-cytoskeleton anchoring by DAPC. Duchenne muscular dystrophy (DMD) is one of the most devastating muscle diseases, affecting 1 in 5,000 newborn males.

[0005] DMD is caused by mutations in the DMD gene, resulting in a decrease in mRNA and the absence of dystrophin, a 427kD muscle cell membrane protein that binds to the dystrophin-binding protein complex (DAPC) (Hoffman et al., Cell 51(6):919-28, 1987). The DAPC is composed of several proteins of the muscle cell membrane and forms a structural link between the extracellular matrix (ECM) and the cytoskeleton via dystrophin, an actin-binding protein, and alpha-dystroglycan, a laminin-binding protein. These structural links stabilize the muscle cell membrane during contraction and protect it from contractile damage. The loss of dystrophin leads to membrane fragility, resulting in muscle cell membrane rupture and calcium influx, causing calcium-activated protease and segmental fiber necrosis (Straub et al., Curr Opin. Neurol. 10(2):168-75, 1997). This uncontrolled cycle of muscle degeneration and regeneration eventually depletes the muscle stem cell population (Sacco et al., Cell, 2010.143(7):p.1059-71; Wallace et al., Annu Rev Physiol, 2009.71:p.37-57), leading to progressive muscle weakness, endomysitis, and fibrous scarring.

[0006] Without membrane stabilization by dystrophin or microdystrophin, DMD exhibits an uncontrolled cycle of tissue damage and repair, ultimately replacing lost muscle fibers with fibrous scar tissue through the proliferation of connective tissue. Fibrosis is characterized by excessive deposition of ECM matrix proteins, including collagen and elastin. ECM proteins are primarily produced from cytokines such as TGFβ, released by activated fibroblasts in response to stress and inflammation. While the main pathological features of DMD are muscle fiber degeneration and necrosis, fibrosis as a pathological consequence has an equivalent impact. The overproduction of fibrous tissue limits muscle regeneration and contributes to progressive muscle weakness in DMD patients. In one study, the presence of fibrosis in early DMD muscle biopsies was highly correlated with poor motor outcomes at 10-year follow-up (Desguerre et al., J Neuropathol Exp Neurol, 2009.68(7):p.762-7). These results indicate that fibrosis is a major cause of DMD muscle dysfunction and highlight the need for early intervention before overt fibrosis develops.

[0007] Another group of MDs is limb-girdle muscular dystrophy (LGMD). LGMD is a rare condition, and symptoms vary from person to person in terms of age of onset, area of ​​weakness, involvement of the cardiovascular and respiratory systems, rate of progression, and severity. LGMD can begin in childhood, adolescence, young adulthood, or later. Both sexes are equally affected. LGMD causes weakness in the shoulder and pelvic girdle, and the muscles near the upper limbs and arms may also weaken over time. Leg weakness often appears before arm weakness. Facial muscles are usually unaffected. As the condition progresses, people may have difficulty walking and may need to use a wheelchair over time. When the shoulder and arm muscles are involved, it may become difficult to raise the arms overhead or lift objects. Depending on the type of LGMD, the cardiovascular and respiratory muscles may also be involved.

[0008] [Table 1]

[0009] Specialized testing for LGMD is now available through the National Commissioning Group (NCG), a nationwide program for diagnosis. As gene therapies are developed to treat muscular dystrophy such as DMD or LGMD, it is necessary to optimize these therapies and evaluate the immunosuppressive effects of optimized gene therapy vectors on the expression of microdystrophin transgenes. [Prior art documents] [Non-patent literature]

[0010] [Non-Patent Document 1] Hoffman et al., Cell 51(6):919-28,1987 [Non-Patent Document 2] Straub et al.,Curr Opin.Neurol.10(2):168-75,1997 [Non-Patent Document 3] Sacco et al.,Cell,2010.143(7):p.1059-71 [Non-Patent Document 4] Wallace et al.,Annu Rev Physiol,2009.71:p.37-57 [Non-Patent Document 5] Desguerre et al.,J Neuropathol Exp Neurol,2009.68(7):p.762-7 [Overview of the Initiative] [Means for solving the problem]

[0011] This disclosure relates to gene therapy vectors, such as AAV, that express a target transgene in skeletal muscle in combination with the administration of immunosuppressants to treat muscular dystrophy. In addition, this disclosure includes a method for readjusting AAV gene therapy to a subject, wherein the subject's plasma is subjected to therapeutic plasma exchange (TPE) to remove AAV antibodies produced in response to the initial dose of AAV gene therapy.

[0012] This disclosure relates to a gene therapy vector, e.g., AAV, which expresses the microdystrophin gene in skeletal muscle, including the diaphragm and cardiac muscle, to protect muscle fibers from damage, increase muscle strength, and reduce and / or prevent fibrosis in combination with the administration of immunosuppressants. In addition, this disclosure includes a method for readjusting AAV gene therapy to a subject, wherein the subject's plasma is subjected to therapeutic plasma exchange (TPE) for antibodies present in the subject to remove AAV antibodies produced in response to the initial dose of AAV gene therapy.

[0013] In addition, this disclosure relates to a gene therapy vector, such as AAV, that expresses a β-sarcoglycan gene in skeletal muscle, including the diaphragm and cardiac muscle, in combination with the administration of an immunosuppressant. Furthermore, this disclosure includes a method for readjusting AAV gene therapy to a subject, wherein the subject's plasma is subjected to therapeutic plasma exchange (TPE) for antibodies present in the subject to remove AAV antibodies produced in response to the initial administration of AAV gene therapy.

[0014] This disclosure provides therapies and approaches to increase muscle strength and / or muscle mass by delivering microdystrophin using a gene therapy vector to address the gene deficiency observed in DMD. In particular, this disclosure provides studies demonstrating the gene expression of systemic delivery of rAAVrh74.MHCK7.microdystrophin in non-human primate models using different immunosuppressive therapies with modified duration, dose, and type of immunosuppression. This disclosure also provides studies demonstrating microdystrophin transgene expression after removing AAV virus antibodies from previously administered non-human primates using TPE and then systemically re-administering rAAVrh74.MHCK7.microdystrophin to the primates.

[0015] This disclosure also provides an approach for treating human subjects suffering from DMD with an anti-AAVrh.74 antibody prior to administration of rAAVrh74.MHCK7.microdystrophin, in which the subjects are subjected to multiple sessions of TPE prior to administration of rAAVrh74.MHCK7.microdystrophin.

[0016] This disclosure provides nucleic acid molecules comprising the nucleotide sequence of SEQ ID NO: 3, 8, or 9. This disclosure also provides rAAVs comprising the nucleic acid sequence of SEQ ID NO: 9, or nucleotides 1-4977 of SEQ ID NO: 8, or nucleotides 55-5021 of SEQ ID NO: 3, and rAAV particles comprising the nucleic acid sequence of SEQ ID NO: 9, nucleotides 1-4977 of SEQ ID NO: 8, or nucleotides 55-5021 of SEQ ID NO: 3.

[0017] Another aspect of this disclosure provides rAAVs comprising the nucleic acid sequence of SEQ ID NO: 3, 8, or 9, the nucleic acid sequence of SEQ ID NO: 9, or nucleotides 1-4977 of SEQ ID NO: 8, or nucleotides 55-5021 of SEQ ID NO: 3, and rAAV particles comprising the nucleic acid sequence of SEQ ID NO: 9, or nucleotides 1-4977 of SEQ ID NO: 8, or nucleotides 55-5021 of SEQ ID NO: 3. Any of the methods disclosed herein can be carried out using these compositions.

[0018] In addition, the present disclosure provides a composition comprising a nucleic acid containing one of the following rAAV genomes: AAVrh.74.tMCK.CAP N3, rAAVrh.74.MHCK7.DYSF, scAAVrh.74.MHCK7.hSGCG, AAVrh74.tMCK.hSCGA, scAAVrh74.MHCK7.HSGCB, and rAAVrh.74.MHCK7.huAN05.

[0019] This disclosure provides a method for treating muscular dystrophy in human subjects requiring treatment of muscular dystrophy, comprising the step of administering recombinant adenovirus-related (rAAV)rAAV.MHCK7.microdystrophin and an anti-inflammatory steroid. In addition, this disclosure provides the use of a combination therapy comprising recombinant adenovirus-related (rAAV)rAAV.MHCK7.microdystrophin and an anti-inflammatory steroid for the preparation of a drug for treating muscular dystrophy in human subjects requiring treatment of muscular dystrophy, such that rAAV and the anti-inflammatory steroid are administered simultaneously or separately. This disclosure also provides a combination therapy for treating muscular dystrophy, which comprises recombinant adenovirus-related (rAAV)rAAV.MHCK7.microdystrophin and an anti-inflammatory steroid, and the rAAV and the anti-inflammatory steroid are administered separately, such as simultaneously or separately. For example, the muscular dystrophy is DMD or Becker muscular dystrophy. For example, the anti-inflammatory steroid is a glucocorticoid. In some embodiments, the anti-inflammatory steroid is prednisone, prednisolone, betamethasone, dexamethasone, hydrocortisone, methylprednisolone, or deflazacort. In some embodiments, the anti-inflammatory steroid is administered orally. The anti-inflammatory steroid may be administered both before and after administration of rAAV. Alternatively, the anti-inflammatory steroid may be administered only before or only after administration of rAAV.

[0020] In addition, the present disclosure provides a method for treating limb-girdle muscular dystrophy in human subjects requiring treatment for limb-girdle muscular dystrophy, comprising the step of administering recombinant adenovirus-associated (rAAV) and an anti-inflammatory steroid, wherein the rAAV is selected from the group consisting of AAVrh.74.tMCK.CAPN3, rAAVrh.74.MHCK7.DYSF, scAAVrh.74.MHCK7.hSGCG, AAVrh74.tMCK.hSCGA, scAAVrh74.MHCK7.HSGCB, and rAAVrh.74.MHCK7.huAN05. In addition, the present disclosure provides the use of combination therapy comprising recombinant adenovirus-related (rAAV) and anti-inflammatory steroids for the preparation of agents for treating limb-girdle muscular dystrophy in human subjects requiring treatment for limb-girdle muscular dystrophy, wherein the rAAV is selected from the group consisting of AAVrh.74.tMCK.CAPN3, rAAVrh.74.MHCK7.DYSF, scAAVrh.74.MHCK7.hSGCG, AAVrh74.tMCK.hSCGA, scAAVrh74.MHCK7.HSGCB, and rAAVrh.74.MHCK7.huAN05, such that the agents rAAV and anti-inflammatory steroids are administered separately, for example, simultaneously or sequentially, wherein the rAAV is selected from the group consisting of AAVrh.74.tMCK.CAPN3, rAAVrh.74.MHCK7.DYSF, scAAVrh.74.MHCK7.hSGCG, AAVrh74.tMCK.hSCGA, scAAVrh74.MHCK7.HSGCB, and rAAVrh.74.MHCK7.huAN05. This disclosure also provides combination therapies for treating limb-girdle muscular dystrophy, the combination therapies comprising recombinant adenovirus-associated (rAAV) and anti-inflammatory steroids, the rAAV being selected from the group consisting of AAVrh.74.tMCK.CAPN3, rAAVrh.74.MHCK7.DYSF, scAAVrh.74.MHCK7.hSGCG, AAVrh74.tMCK.hSCGA, scAAVrh74.MHCK7.HSGCB, and rAAVrh.74.MHCK7.huAN05, the rAAV and anti-inflammatory steroids being administered separately in combination, for example, simultaneously or sequentially. For example, the anti-inflammatory steroid is a glucocorticoid. In some embodiments, the anti-inflammatory steroid is prednisone, prednisolone, betamethasone, dexamethasone, hydrocortisone, methylprednisolone, or deflazacort.In some embodiments, anti-inflammatory steroids are administered orally. Anti-inflammatory steroids may be administered both before and after administration of rAAV. Alternatively, anti-inflammatory steroids may be administered either only before or only after administration of rAAV.

[0021] For example, in any of the methods, uses, or combination therapies disclosed herein, the anti-inflammatory steroid is administered approximately 12 hours before administration of rAAV, or approximately 24 hours before administration of rAAV, or approximately 36 hours before administration of rAAV, or approximately 48 hours before administration of rAAV, or approximately 60 hours before administration of rAAV, or approximately 72 hours before administration of rAAV, or approximately 96 hours before administration of rAAV. In some embodiments, inflammatory steroids are administered approximately 5 days before the administration of rAAV, approximately 6 days before the administration of rAAV, approximately 7 days before the administration of rAAV, or approximately 8 days before the administration of rAAV, or approximately 9 days before the administration of rAAV, or approximately 10 days before the administration of rAAV, or approximately 11 days before the administration of rAAV, or approximately 12 days before the administration of rAAV, or approximately 13 days before the administration of rAAV, or approximately 14 days before the administration of rAAV, or approximately 30 days before the administration of rAAV.

[0022] In addition, in any of the disclosed methods, uses, or combination therapies, the anti-inflammatory steroid is administered at least once daily about 7 days before administration of rAAV, or at least once daily about 14 days before administration of rAAV, or at least once daily about 21 days before administration of rAAV, or at least once daily about 28 days before administration of rAAV, or at least once daily about 30 days before administration of rAAV, or at least once daily about 45 days before administration of rAAV, or at least once daily about 60 days before administration of rAAV. In some embodiments, the anti-inflammatory steroid is administered 30 to 60 days before administration of rAAV.

[0023] For example, in any of the disclosed methods, uses, or combination therapies, the anti-inflammatory steroid is administered prior to the administration of rAAV, and the anti-inflammatory steroid is administered at least once daily from day 1 to day 30 after the administration of rAAV, at least once daily from day 1 to day 60 after the administration of rAAV, or at least once daily from day 1 to day 7 after the administration of rAAV, or at least once daily from day 1 to day 14 after the administration of rAAV, or at least once daily from day 1 to day 21 after the administration of rAAV, or at least once daily from day 1 to day 24 after the administration of rAAV, or at least once daily from day 1 to day 28 after the administration of rAAV, or at least from day 1 to day 30 after the administration of rAAV, or at least from day 30 to day 60 after the administration of rAAV.

[0024] In any of the methods, uses, or combination therapies disclosed herein, the anti-CD20-specific antibody is administered prior to the administration of rAAV. In some embodiments, the anti-CD20-specific antibody is administered at least 7 days prior to the administration of rAAV. The term anti-CD20-specific antibody refers to an antibody that specifically binds to CD20 or inhibits or reduces the expression or activity of CD20. Exemplary anti-CD20 antibodies include rituximab, ocrelizumab, or ofatumumab.

[0025] In any of the disclosed methods, uses, or combination therapies, the anti-CD20-specific antibody is administered approximately 60 days before administration of rAAV, or approximately 45 days before administration of rAAV, or approximately 30 days before administration of rAAV, approximately 14 days before administration of rAAV, approximately 7 days before administration of rAAV, and within approximately 24 hours before administration of rAAV. In some embodiments, the anti-CD20 antibody is administered 30 to 60 days before administration of rAAV. In some embodiments, the anti-CD20-specific antibody is administered after administration of rAAV. For example, the anti-CD20-specific antibody is administered both before and after administration of rAAV. Alternatively, the anti-CD20-specific antibody is administered before administration of rAAV, or after administration of rAAV.

[0026] In addition, any of the disclosed methods, uses, or combination therapies may include the administration of an immunosuppressive macrolide. The term immunosuppressive macrolide refers to a macrolide agent that suppresses or modulates the immune system of a subject. Macrolides are a class of agents that contain a large macrocyclic lactone ring to which one or more deoxy sugars, such as cladinose or desamine, are attached. The lactone ring is usually 14, 15, or 16 members. Macrolides belong to the polyketide class of agents and may be natural products. Examples of immunosuppressive macrolides include tacrolimus, pimecrolimus, and sirolimus. In some embodiments, the immunosuppressive macrolide is administered orally to the subject. In some embodiments, the immunosuppressive macrolide may be administered both before and after the administration of rAAV. Alternatively, the immunosuppressive macrolide may be administered before administration, or either rAAV or the immunosuppressive macrolide may be administered after the administration of rAAV.

[0027] In some embodiments, the immunosuppressive macrolide is administered at least once daily at least 3 days prior to the administration of rAAV, or at least 4 days prior to the administration of rAAV, or at least 5 days prior to the administration of rAAV, or at least 6 days prior to the administration of rAAV, or at least 7 days prior to the administration of rAAV, or at least 10 days prior to the administration of rAAV, or at least 14 days prior to the administration, or at least 30 days prior to the administration of rAAV, or at least 45 days prior to the administration of rAAV, or at least 60 days prior to the administration of rAAV. In some embodiments, the immunosuppressive macrolide is administered 30 to 60 days prior to the administration of rAAV.

[0028] The disclosure also provides a method for treating muscular dystrophy in human subjects requiring treatment of muscular dystrophy, comprising administering recombinant adenovirus-related (rAAV) rAAV.MHCK7.microdystrophin and an immunosuppressive regimen, wherein the immunosuppressive regimen comprises administering one or more of the following: an anti-inflammatory steroid, an anti-CD20 antibody, and an immunosuppressive macrolide. The disclosure also provides the use of combination therapy comprising recombinant adenovirus-related (rAAV) rAAV.MHCK7.microdystrophin and an immunosuppressive regimen for the preparation of a drug for treating muscular dystrophy in human subjects requiring treatment, wherein the immunosuppressive regimen comprises administering one or more of the following: an anti-inflammatory steroid, an anti-CD20 antibody, and an immunosuppressive macrolide, for example, in the disclosed drug, rAAV and one or more components of the immunosuppressive regimen are administered separately in combination, for example, rAAV and one or more components of the immunosuppressive regimen are administered simultaneously or sequentially in combination. This disclosure also provides combination therapies for treating muscular dystrophy in human subjects where it is needed, comprising recombinant adenovirus-associated (rAAV) rAAV.MHCK7.microdystrophin and an immunosuppressive regimen, wherein rAAV and the immunosuppressive regimen are administered separately, or, for example, rAAV and one or more components of the immunosuppressive regimen are administered simultaneously or sequentially. The term immunosuppressive regimen refers to a method of treatment or therapy that suppresses or modulates the immune system of a subject. This regimen comprises the administration of one or more immunosuppressants. In some embodiments, the immunosuppressive regimen comprises the administration of an anti-inflammatory steroid, an anti-CD20 antibody, and an immunosuppressive macrolide.

[0029] The disclosure also provides a method for treating limb-girdle muscular dystrophy in human subjects requiring treatment of limb-girdle muscular dystrophy, comprising administering a recombinant adenovirus-associated (rAAV) selected from the group consisting of AAVrh.74.tMCK.CAPN3, rAAVrh.74.MHCK7.DYSF, scAAVrh.74.MHCK7.hSGCG, AAVrh74.tMCK.hSCGA, scAAVrh74.MHCK7.HSGCB, and rAAVrh.74.MHCK7.huAN05, along with an immunosuppressive regimen, wherein the immunosuppressive regimen comprises administering one or more of the following: an anti-inflammatory steroid, an anti-CD20 antibody, and an immunosuppressive macrolide. This disclosure also provides the use of combination therapy comprising rAAV and an immunosuppressive regimen for the preparation of a drug for treating limb-girdle muscular dystrophy in human subjects in need, wherein rAAV comprises recombinant adeno-associated virus (rAAV) selected from the group consisting of AAVrh.74.tMCK.CAPN3, rAAVrh.74.MHCK7.DYSF, scAAVrh.74.MHCK7.hSGCG, AAVrh74.tMCK.hSCGA, scAAVrh74.MHCK7.HSGCB, and rAAVrh.74.MHCK7.huAN05, and the immunosuppressive regimen comprises administering one or more of the following: anti-inflammatory steroids, anti-CD20 antibodies, and immunosuppressive macrolides, for example, in the disclosed drug, rAAV and one or more components of the immunosuppressive regimen are administered separately in combination, or for example, rAAV and one or more components of the immunosuppressive regimen are administered simultaneously or sequentially in combination.This disclosure also provides a combination therapy for treating limb-girdle muscular dystrophy in human subjects requiring treatment for limb-girdle muscular dystrophy, the combination therapy comprising recombinant adenovirus-associated (rAAV) selected from the group consisting of AAVrh.74.tMCK.CAPN3, rAAVrh.74.MHCK7.DYSF, scAAVrh.74.MHCK7.hSGCG, AAVrh74.tMCK.hSCGA, scAAVrh74.MHCK7.HSGCB, and rAAVrh.74.MHCK7.huAN05, and an immunosuppressive regimen comprising the administration of one or more of the following: anti-inflammatory steroids, anti-CD20 antibodies, and immunosuppressive macrolides, the rAAV and one or more components of the immunosuppressive regimen being administered separately, for example, the rAAV and one or more components of the immunosuppressive regimen being administered simultaneously or sequentially. In some embodiments, the immunosuppressive regimen includes administering an anti-inflammatory steroid, an anti-CD20 antibody, and an immunosuppressive macrolide.

[0030] In one exemplary immunosuppressive regimen, anti-inflammatory steroids are administered approximately 24 hours before rAAV administration. In another exemplary immunosuppressive regimen, anti-inflammatory steroids are administered before rAAV administration and at least once daily from day 1 to day 30 after rAAV administration, or at least once daily from day 1 to day 60 after rAAV administration.

[0031] In any of the immunosuppressive regimens disclosed, the anti-inflammatory steroid is a glucocorticoid such as prednisone, prednisolone, betamethasone, dexamethasone, hydrocortisone, methylprednisolone, or deflazacort. In some embodiments, the anti-inflammatory steroid is administered orally.

[0032] Further exemplary immunosuppressive regimens involve the administration of an anti-CD20-specific antibody prior to rAAV administration. For example, the anti-CD20 antibody is administered by intravascular infusion. Exemplary anti-CD20-specific antibodies include rituximab, ocrelizumab, or ofatumumab.

[0033] In one embodiment, the anti-CD20-specific antibody is administered at least 14 days before the administration of rAAV. In another embodiment, the anti-CD20-specific antibody is administered approximately 60 days before, approximately 45 days before, approximately 30 days before, 14 days before, approximately 7 days before, and within approximately 24 hours before the administration of rAAV. In addition, the anti-CD20-specific antibody is administered for 30 to 60 days prior to the administration of rAAV. The disclosed immunosuppressive regimen also includes administering the anti-CD20-specific antibody after the administration of rAAV.

[0034] In addition, the disclosed immunosuppressive regimens include administering an immunosuppressive macrolide at least once daily for at least three days prior to the administration of rAAV. The immunosuppressive regimens may also include administering an immunosuppressive macrolide after the administration of rAAV. In any of the disclosed immunosuppressive regimens, the immunosuppressive macrolide is administered orally. Exemplary immunosuppressive macrolides include tacrolimus, pinecrolimus, or sirolimus.

[0035] In some embodiments, the disclosed immunosuppressive regimen is administered 30 to 60 days before rAAV administration. In addition, the immunosuppressive regimen is administered approximately 60 days, 45 days, 30 days, 14 days, 7 days, and 24 hours before rAAV administration.

[0036] In certain embodiments, the Disclosure provides a method for treating muscular dystrophy in human subjects requiring treatment of muscular dystrophy, comprising administering recombinant adenovirus-associated (rAAV) rAAV.MHCK7.microdystrophin and an immunosuppressive regimen, the immunosuppressive regimen comprising i) orally administering an anti-inflammatory steroid about 24 hours before administration of rAAV, and administering an anti-inflammatory steroid at least once daily from day 1 to day 30 after administration of rAAV, or administration of rAAV. The procedure includes the steps of: ii) administering an anti-inflammatory steroid at least once a day from day 1 to day 60; ii) intravenously administering an anti-CD20 antibody approximately 14 days before administration of rAAV, approximately 7 days before administration of rAAV, and within approximately 24 hours, and optionally administering the anti-CD20 antibody after administration of rAAV; and iii) orally administering an immunosuppressive macrolide at least once a day for at least 3 days before administration of rAAV, and optionally administering the immunosuppressive macrolide after administration of rAAV. For example, the anti-inflammatory steroid is prednisone, prednisolone, betamethasone, dexamethasone, hydrocortisone, methylprednisolone, or deflazacort, and the anti-CD20 specific antibody is rituximab, ocrelizumab, or ofatumumabon, or any other anti-inflammatory steroid, anti-CD20 antibody, or immunosuppressive macrolide, and the immunosuppressive macrolide is tacrolimus, pinecrolimus, or sirolimus. In exemplary embodiments, the immunosuppressive regimen comprises the anti-inflammatory steroid prednisone or prednisolone, the anti-CD20 antibody rituximab, and the immunosuppressive macrolide sirolimus.

[0037] Furthermore, the use of combination therapy including rAAV and immunosuppressive regimens for the preparation of drugs to treat muscular dystrophy in human subjects requiring treatment for muscular dystrophy is also provided, where rAAV is rAAV.MHCK7.microdystrophin, and the immunosuppressive regimen is i) oral administration of anti-inflammatory steroids approximately 24 hours before administration of rAAV, and administration of anti-inflammatory steroids at least once a day from day 1 to day 30 after administration of rAAV, or day 1 after administration of rAAV The treatment includes: ii) administering an anti-inflammatory steroid at least once a day from day 1 to day 60; ii) intravenously administering an anti-CD20 antibody approximately 14 days before administration of rAAV, approximately 7 days before administration of rAAV, and within approximately 24 hours of administration of rAAV, with the option to administer the anti-CD20 antibody after administration of rAAV; and iii) orally administering an immunosuppressive macrolide at least once a day for at least 3 days before administration of rAAV, with the option to administer the immunosuppressive macrolide after administration of rAAV. For example, the anti-inflammatory steroid is prednisone, prednisolone, betamethasone, dexamethasone, hydrocortisone, methylprednisolone, or deflazacort, and the anti-CD20 specific antibody is rituximab, ocrelizumab, or ofatumumabon, or any other anti-inflammatory steroid, anti-CD20 antibody, or immunosuppressive macrolide, and the immunosuppressive macrolide is tacrolimus, pinecrolimus, or sirolimus. In exemplary embodiments, the immunosuppressive regimen comprises the anti-inflammatory steroid prednisone or prednisolone, the anti-CD20 antibody rituximab, and the immunosuppressive macrolide sirolimus.

[0038] This disclosure provides a combination therapy comprising rAAV and an immunosuppressive regimen for the treatment of muscular dystrophy in human subjects requiring treatment for muscular dystrophy, wherein the rAAV is rAAV.MHCK7.microdystrophin, and the immunosuppressive regimen comprises: ii) orally administering an anti-inflammatory steroid approximately 24 hours before administration of rAAV and orally administering an anti-inflammatory steroid at least once daily from day 1 to day 30 after administration of rAAV, or administering an anti-inflammatory steroid at least once daily from day 1 to day 60 after administration of rAAV; ii) intravenously administering an anti-CD20 antibody approximately 14 days before administration of rAAV, approximately 7 days before administration of rAAV, and approximately 24 hours after administration of rAAV, and optionally administering an anti-CD20 antibody after administration of rAAV; and iii) orally administering an immunosuppressive macrolide at least once daily for at least 3 days before administration of rAAV, and optionally administering an immunosuppressive macrolide after administration of rAAV. For example, the anti-inflammatory steroid is prednisone, prednisolone, betamethasone, dexamethasone, hydrocortisone, methylprednisolone, or deflazacort, and the anti-CD20 specific antibody is rituximab, ocrelizumab, or ofatumumabon, or any other anti-inflammatory steroid, anti-CD20 antibody, or immunosuppressive macrolide, and the immunosuppressive macrolide is tacrolimus, pinecrolimus, or sirolimus. In exemplary embodiments, the immunosuppressive regimen comprises the anti-inflammatory steroid prednisone or prednisolone, the anti-CD20 antibody rituximab, and the immunosuppressive macrolide sirolimus.

[0039] In another specific embodiment, the Disclosure provides a method for treating limb-girdle muscular dystrophy in human subjects requiring treatment of limb-girdle muscular dystrophy, comprising administering a recombinant adenovirus-associated (rAAV) selected from the group consisting of AAVrh.74.tMCK.CAPN3, rAAVrh.74.MHCK7.DYSF, scAAVrh.74.MHCK7.hSGCG, AAVrh74.tMCK.hSCGA, scAAVrh74.MHCK7.HSGCB, and rAAVrh.74.MHCK7.huAN05, along with an immunosuppressive regimen, wherein the immunosuppressive regimen includes i) an anti-inflammatory steroid approximately 24 hours prior to the administration of the rAAV. The procedure includes the steps of: ii) administering an anti-inflammatory steroid orally at least once a day from day 1 to day 30 after rAAV administration, or administering an anti-inflammatory steroid at least once a day from day 1 to day 60 after rAAV administration; ii) intravenously administering an anti-CD20 antibody approximately 14 days before rAAV administration, 7 days before rAAV administration, and within approximately 24 hours after rAAV administration, and optionally administering the anti-CD20 antibody after rAAV administration; and iii) orally administering an immunosuppressive macrolide at least once a day for at least 3 days before rAAV administration, and optionally administering the immunosuppressive macrolide after rAAV administration.

[0040] In another specific embodiment, the Disclosure provides the use of a combination therapy comprising rAAV and an immunosuppressive regimen for the preparation of a drug for treating limb-girdle muscular dystrophy in human subjects requiring treatment for limb-girdle muscular dystrophy, wherein the rAAV is selected from the group consisting of AAVrh.74.tMCK.CAPN3, rAAVrh.74.MHCK7.DYSF, scAAVrh.74.MHCK7.hSGCG, AAVrh74.tMCK.hSCGA, scAAVrh74.MHCK7.HSGCB, and rAAVrh.74.MHCK7.huAN05, and the immunosuppressive regimen is i) anti-inflammatory approximately 24 hours prior to the administration of rAAV. ii) administering an anti-inflammatory steroid orally at least once a day from day 1 to day 30 after rAAV administration, or administering an anti-inflammatory steroid at least once a day from day 1 to day 60 after rAAV administration; ii) administering an anti-CD20 antibody intravenously approximately 14 days before rAAV administration, approximately 7 days before rAAV administration, and within approximately 24 hours after rAAV administration, and optionally administering an anti-CD20 antibody after rAAV administration; and iii) administering an immunosuppressive macrolide orally at least once a day for at least 3 days before rAAV administration, and optionally administering an immunosuppressive macrolide after rAAV administration.

[0041] In another specific embodiment, the Disclosure provides a combination therapy comprising rAAV and an immunosuppressive regimen for treating limb-girdle muscular dystrophy in human subjects requiring treatment for limb-girdle muscular dystrophy, wherein the rAAV is selected from the group consisting of AAVrh.74.tMCK.CAPN3, rAAVrh.74.MHCK7.DYSF, scAAVrh.74.MHCK7.hSGCG, AAVrh74.tMCK.hSCGA, scAAVrh74.MHCK7.HSGCB, and rAAVrh.74.MHCK7.huAN05, and the immunosuppressive regimen is i) administered via an anti-inflammatory steroid approximately 24 hours prior to rAAV administration. ii) Oral administration of an anti-inflammatory steroid at least once a day from day 1 to day 30 after rAAV administration, or administration of an anti-inflammatory steroid at least once a day from day 1 to day 60 after rAAV administration; ii) Intravenous administration of an anti-CD20 antibody approximately 14 days before rAAV administration, approximately 7 days before rAAV administration, and approximately 24 hours after rAAV administration, and optionally administration of the anti-CD20 antibody after rAAV administration; iii) Oral administration of an immunosuppressive macrolide at least once a day for at least 3 days before rAAV administration, and optionally administration of the immunosuppressive macrolide after rAAV administration.

[0042] In another embodiment, the Disclosure provides a method for treating muscular dystrophy in a human subject requiring treatment for muscular dystrophy, comprising providing the subject's plasma to at least one therapeutic plasmapheresis (TPE) prior to the administration of a second dose of adenovirus-associated (rAAV) rAAV.MHCK7.microdystrophin, wherein the subject has been administered a first dose of rAAV prior to being subjected to TPE.

[0043] In another embodiment, the present disclosure provides the use of a combination therapy for treating muscular dystrophy in a human subject requiring treatment for muscular dystrophy, the combination therapy comprising subject plasma being subjected to at least one therapeutic plasmapheresis (TPE) prior to administration of a second dose of adenovirus-associated (rAAV) rAAV.MHCK7.microdystrophin, the subject having been administered a first dose of rAAV before being subjected to TPE.

[0044] In another embodiment, the present disclosure provides a combination therapy for treating muscular dystrophy in a human subject requiring treatment for muscular dystrophy, the combination therapy comprising administering the subject's plasma to at least one therapeutic plasmapheresis (TPE) prior to the administration of a second dose of adenovirus-associated (rAAV) rAAV.MHCK7.microdystrophin, the subject having been administered a first dose of rAAV before being subjected to TPE.

[0045] This disclosure provides a method for treating muscular dystrophy in a human subject requiring treatment for muscular dystrophy, comprising providing the subject's plasma to at least one therapeutic plasmapheresis (TPE) before administering a second dose of recombinant adenovirus-related (rAAV) selected from the group consisting of AAVrh.74.tMCK.CAPN3, rAAVrh.74.MHCK7.DYSF, scAAVrh.74.MHCK7.hSGCG, AAVrh74.tMCK.hSCGA, scAAVrh74.MHCK7.HSGCB, and rAAVrh.74.MHCK7.huAN05, wherein the subject has been administered a first dose of rAAV before being subjected to TPE.

[0046] In further embodiments, the Disclosure provides a method for treating muscular dystrophy in a human subject requiring treatment for muscular dystrophy, comprising the steps of: a) administering a first dose of recombinant adenovirus-associated (rAAV) rAAV.MHCK7.microdystrophin; b) administering the subject plasma in at least one therapeutic plasma exchange (TPE); and c) administering a second dose of rAAV. In any of the disclosed methods, the subject plasma is subjected to at least two or at least three TPEs before administration of the second dose or rAAV. In some embodiments, the subject plasma is subjected to at least four TPEs before administration of the second dose of rAAV, or the subject plasma is subjected to five TPEs before administration of the second dose of rAAV, or the subject plasma is subjected to six TPEs before administration of the second dose of rAAV, or the subject plasma is subjected to seven TPEs before administration of the second dose of rAAV.

[0047] In another embodiment, the present disclosure relates to a method for treating limb-girdle muscular dystrophy in human subjects requiring treatment for limb-girdle muscular dystrophy, The present invention provides a method comprising the steps of: a) administering a first dose of recombinant adenovirus-related selected from the group consisting of AAVrh.74.tMCK.CAPN3, rAAVrh.74.MHCK7.DYSF, scAAVrh.74.MHCK7.hSGCG, AAVrh74.tMCK.hSCGA, scAAVrh74.MHCK7.HSGCB, and rAAVrh.74.MHCK7.huAN05; b) providing the target plasma for at least one therapeutic plasma exchange (TPE); and c) administering a second dose or rAAV. In any of the disclosed methods, the target plasma is subjected to at least two or at least three TPEs prior to the administration of the second dose or rAAV. In some embodiments, the plasma is subjected to at least four TPEs before administration of a second dose of rAAV, or five TPEs before administration of a second dose of rAAV, or six TPEs before administration of a second dose of rAAV, or seven TPEs before administration of a second dose of rAAV.

[0048] In further embodiments, the disclosure provides a method for treating muscular dystrophy in a human subject requiring treatment for muscular dystrophy, comprising the steps of: a) providing the subject's plasma for at least one therapeutic plasma exchange (TPE) before administering recombinant adenovirus-associated (rAAV) rAAV.MHCK7.microdystrophin; and b) administering rAAV. In any of the disclosed methods, the subject's plasma is subjected to at least two TPEs, at least three TPEs, at least four TPEs, at least five TPEs, at least six TPEs, or at least seven TPEs before administering rAAV. In these disclosed methods, the subject is administered an anti-inflammatory steroid approximately 24 hours before the administration of rAAV. In addition, in some embodiments, the subject is administered an anti-inflammatory steroid at least once daily from day 1 to day 60 after the administration of rAAV. For example, anti-inflammatory steroids are administered orally. In addition, anti-inflammatory steroids include glucocorticoids such as prednisone, prednisolone, betamethasone, dexamethasone, hydrocortisone, methylprednisolone, or deflazacort.

[0049] In addition, the present disclosure provides a method for treating limb-girdle muscular dystrophy in human subjects requiring treatment for limb-girdle muscular dystrophy, comprising the steps of: a) providing the subject's plasma to at least one therapeutic plasma exchange (TPE) before administering a recombinant adenovirus (rAAV) selected from the group consisting of AAVrh.74.tMCK.CAPN3, rAAVrh.74.MHCK7.DYSF, scAAVrh.74.MHCK7.hSGCG, AAVrh74.tMCK.hSCGA, scAAVrh74.MHCK7.HSGCB, and rAAVrh.74.MHCK7.huAN05; and b) administering the rAAV. In any of the disclosed methods, the subject plasma is subjected to at least two TPEs before administering rAAV, at least three TPEs before administering rAAV, at least four TPEs before administering rAAV, at least five TPEs before administering rAAV, at least six TPEs before administering rAAV, or at least seven TPEs before administering rAAV. In these disclosed methods, the subject is administered an anti-inflammatory steroid approximately 24 hours before administering rAAV. In addition, in some embodiments, the subject is administered an anti-inflammatory steroid at least once daily from day 1 to day 60 after administering rAAV. For example, the anti-inflammatory steroid is administered orally. In addition, the anti-inflammatory steroid is a glucocorticoid such as prednisone, prednisolone, betamethasone, dexamethasone, hydrocortisone, methylprednisolone, or deflazacort.

[0050] In any of the disclosed methods, the subject plasma is subjected to TPE for at least 9 days prior to rAAV administration, at least 7 days prior to administration, 5 days prior to administration, or 2 days prior to administration. In addition, there is approximately 24 to 48 hours between TPE sessions performed on the subject plasma prior to rAAV administration. In certain embodiments, the subject plasma is subjected to at least two TPE sessions prior to rAAV administration, with approximately 48 hours between TPE sessions.

[0051] In any of the methods described herein, the subject has an anti-AAVrh.74 antibody level of approximately 1:400 or less at the time of rAAV administration. For example, the subject has an anti-AAVrh.74 antibody level of approximately 1:100 to approximately 1:400, or approximately 1:100 to 1:300, or approximately 1:100 to 1:200, or approximately 1:250 to 1:500, or approximately 1:200 to 1:400 at the time of rAAV administration. The antibody titer is determined as the total antibody-binding titer. In any of the disclosed methods for treating muscular dystrophy, these methods further include the step of determining the presence of anti-AAVrh.74 antibodies in the serum or plasma of the subject. The step of determining the presence of anti-AAVrh.74 antibodies may be performed before administration of rAAV, after administration of rAAV, before an immune response or adverse event is observed, or after an immune response or adverse event is observed. In addition, this determination step may be performed before the step of administering an immunosuppressive regimen or TPE. For example, this determination step may be performed before administration of any AAV to the subject, or before administration of any AAVrh.74 to the subject.

[0052] The disclosure also provides a method further comprising the step of comparing the level of anti-AAVrh.74 antibody in the serum or plasma of the subject with that level of anti-AAVrh.74 antibody to a positive control. For example, the positive control may utilize anti-AAVrh.74 monoclonal antibody.

[0053] In any of the disclosed methods, the presence of anti-AAVrh.74 may be determined by immunofluorescence assay, immunohistochemical assay, Western blot, direct enzyme-linked immunosorbent assay (ELISA), indirect ELISA, sandwich ELISA, competitive ELISA, reverse ELISA, chemiluminescence assay, radioimmunoassay, or immunoprecipitation assay.

[0054] In any of the disclosed methods, the step of determining the presence of an anti-AAVrh.74 antibody involves using a monoclonal antibody containing a VH CDR1 amino acid sequence selected from the group consisting of NYGMN (SEQ ID NO: 20), DYGMN (SEQ ID NO: 22), YTFTNYGMN (SEQ ID NO: 21), and YTFTKYGMN (SEQ ID NO: 23), or a monoclonal antibody containing a VH CDR2 amino acid sequence selected from the group consisting of WINTYTGEPTYADDFKG (SEQ ID NO: 24), WINTNTGEPTEPTYGDDFKG (SEQ ID NO: 25), and WMGWINTYTGEPTY (SEQ ID NO: 26), or a VH antibody selected from the group consisting of GVAHYSDSRFAFDY (SEQ ID NO: 27), GNAHPGGSAFVY (SEQ ID NO: 28), RGSYYYDSSPAWFAY (SEQ ID NO: 29), RGVDSSGYGAFAY (SEQ ID NO: 30), and TRGTSTMISTFAFVY (SEQ ID NO: 31). This involves using a monoclonal antibody containing a CDR3 amino acid sequence, or a monoclonal antibody containing a VL CDR1 amino acid sequence selected from the group consisting of SVSSSVSYMH (SEQ ID NO: 32), SASSGVTYMH (SEQ ID NO: 33), SSVSYMH (SEQ ID NO: 34), and SSVRYMH (SEQ ID NO: 35), or a monoclonal antibody containing a VL CDR2 amino acid sequence selected from the group consisting of YTSNLAS (SEQ ID NO: 36), RTSNLAS (SEQ ID NO: 37), LWIYSTSNLAS (SEQ ID NO: 38), and VWIYSTSNLAS (SEQ ID NO: 39), or a monoclonal antibody containing a VH CDR3 amino acid sequence selected from the group consisting of QQRSSYPFT (SEQ ID NO: 40), QQRSTYPF (SEQ ID NO: 41), QQRSFYPF (SEQ ID NO: 42), and QQRTYYPF (SEQ ID NO: 43).

[0055] In exemplary embodiments, the disclosed method includes the step of determining the presence of an anti-AAVrh.74 antibody using an anti-AAVrh.74 monoclonal antibody, such as a monoclonal antibody containing a variable heavy chain (VH) sequence as shown in SEQ ID NO: 10, 12, 14, 16, or 18, or a monoclonal antibody containing a variable light chain (VL) sequence as shown in SEQ ID NO: 11, 13, 15, 17, or 19.

[0056] In further embodiments, the disclosed methods comprise the step of utilizing an anti-AAVrh.74 monoclonal antibody comprising the variable heavy chain (VH) sequence set forth in SEQ ID NO: 10, 12, 14, 16, or 18, and the variable light chain (VL) sequence set forth in SEQ ID NO: 11, 13, 15, 17, or 19 to determine the presence of the anti-AAVrh.74 antibody.

[0057] In any of the disclosed methods, the step of determining the presence of the anti-AAVrh.74 antibody is quantitative, the subject is identified as seropositive for the anti-AAVrh.74 antibody based on the quantitation, and the immunosuppressive regimen or TPE is selectively administered to the seropositive subject. In any of the methods disclosed herein, the rAAV is about 5.0×10 12 vg / kg to about 1.0×10 15 vg / kg, administered via a systemic route of administration. The muscular dystrophy can be Duchenne muscular dystrophy or Becker muscular dystrophy.

[0058] For example, the dose of rAAV administered is about 5.0x10 12 vg / kg to about 1.0x10 14 vg / kg, or about 5.0x10 12 vg / kg to 1.0x10 14 vg / kg, or about 5.0x10 12 vg / kg to about 2.0x10 14 vg / kg, or about 5.0x10 12 vg / kg to about 1.0x10 14 vg / kg, or about 5.0x10 12 vg / kg to about 5.0x10 13 vg / kg, or about 5.0x10 12 vg / kg to about 2.0x10 13 vg / kg, or about 5.0x10 12 vg / kg to about 1.0x10 13 vg / kg, or 1.0x10 14 vg / kg to about 1.0x10 15 vg / kg, or 1.0x10 13 vg / kg to about 1.0x10 14vg / kg, or approximately 1.0 x 10 13 vg / kg ~ approx. 1.0x10 14 vg / kg, or approximately 1.0 x 10 13 vg / kg~approx.2.0x10 14 vg / kg, or approximately 1.0 x 10 13 vg / kg ~ approx. 1.0x10 14 vg / kg, or approximately 1.0 x 10 13 vg / kg~approx.5.0x10 13 vg / kg, or approximately 1.0 x 10 13 vg / kg~approx.3.0x10 14 vg / kg, or approximately 1.0 x 10 13 vg / kg~approx.5.0x10 14 vg / kg, or approximately 1.0 x 10 13 vg / kg~approx.6.0x10 14 vg / kg, or 1.0 x 10 13 vg / kg ~ approx. 1.0x10 15 vg / kg, or 5.0x10 13 vg / kg ~ approx. 1.0x10 14 vg / kg, or approximately 5.0 x 10 13 vg / kg~1.0x10 14 vg / kg, or approximately 5.0 x 10 13 vg / kg~approx.2.0x10 14 vg / kg, or approximately 5.0 x 10 13 vg / kg ~ approx. 1.0x10 14 vg / kg, or approximately 5.0 x 10 13 vg / kg~approx.3.0x10 14 vg / kg, or approximately 5.0 x 10 13 vg / kg~approx.5.0x10 14 vg / kg, or approximately 5.0 x 10 13 vg / kg~approx.6.0x10 14 vg / kg, or 5.0x10 13 vg / kg ~ approx. 1.0x10 15 vg / kg, or 1.0 x 10 14 vg / kg~approx.6.0x10 14 vg / kg, or 1.0 x 10 14 vg / kg~approx.5.0x10 14 vg / kg, or 1.0 x 10 14vg / kg to about 4.0x10 14 vg / kg, or 1.0x10 14 vg / kg to about 1.0x10 15 vg / kg, or 1.0x10 14 vg / kg to about 3.0x10 14 vg / kg, or about 1.0x10 14 vg / kg to about 2.5x10 14 vg / kg, or 1.0x10 14 vg / kg to about 2.0x10 14 vg / kg, or about 1.25x10 14 vg / kg to about 3.75x10 14 vg / kg, or about 1.25x10 14 vg / kg to 6.0x10 14 , or about 1.25x10 14 vg / kg to 5.0x10 14 , or about 1.25x10 14 vg / kg to 4.0x10 14 , or about 1.25x10 14 vg / kg to 1.0x10 15 , or about 1.25x10 14 vg / kg to about 3.5x10 14 vg / kg, or about 1.25x10 14 vg / kg to about 3.0x10 14 vg / kg, or about 1.25x10 14 vg / kg to about 2.75x10 14 vg / kg, or about 1.25x10 14 vg / kg to about 2.5x10 14 vg / kg, or about 1.25x10 14 vg / kg to about 2.0x10 14 vg / kg, or 1.25x10 14 vg / kg to about 3.75x10 14 vg / kg, or about 1.25x10 14 vg / kg to about 3.5x10 14 vg / kg, or 1.5x10 14 vg / kg to 1.0x10 15 vg / kg, or about 1.5x10 14 vg / kg to 6.0x10 14 , or about 1.5x1014 vg / kg~5.0x10 14 , or about 1.5x10 14 vg / kg~4.0x10 14 , or about 1.5x10 14 vg / kg~about 3.75x10 14 , or about 1.5x10 14 vg / kg~about 3.5x10 14 vg / kg, or about 1.5x10 14 vg / kg~about 3.25x10 14 vg / kg, or about 1.5x10 14 vg / kg~about 3.0x10 14 vg / kg, or about 1.5x10 14 vg / kg~about 2.75x10 14 vg / kg, or about 1.5x10 14 vg / kg~about 2.5x10 14 vg / kg, or about 1.5x10 14 vg / kg~about 2.0x10 14 vg / kg, or 1.75x10 14 vg / kg~about 1.0x10 15 vg / kg, or about 1.75x10 14 vg / kg~6.0x10 14 , or about 1.75x10 14 vg / kg~5.0x10 14 , or about 1.75x10 14 vg / kg~4.0x10 14 , or about 1.75x10 14 vg / kg~about 3.75x10 14 vg / kg, or about 1.75x10 14 vg / kg~about 3.5x10 14 vg / kg, or about 1.75x10 14 vg / kg~about 3.25x10 14 vg / kg, or about 1.75x10 14 vg / kg~about 3.0x10 14 vg / kg, or about 1.75x10 14 vg / kg~about 2.75x10 14 vg / kg, or about 1.75x10 14 vg / kg~about 2.5x10 14vg / kg, or approximately 1.75 x 10 14 vg / kg~approx.2.25x10 14 vg / kg, or approximately 1.75 x 10 14 vg / kg~approx.2.0x10 14 vg / kg, or approximately 2.0 x 10 14 vg / kg ~ approx. 1.0x10 15 , or approximately 2.0 x 10 14 vg / kg~6.0x10 14 , or approximately 2.0 x 10 14 vg / kg~5.0x10 14 , or approximately 2.0 x 10 14 vg / kg ~ approx. 4.0x10 14 vg / kg, or approximately 2.0 x 10 14 vg / kg~approx.3.75x10 14 vg / kg, or approximately 2.0 x 10 14 vg / kg~approx.3.5x10 14 vg / kg, or approximately 2.0 x 10 14 vg / kg~approx.3.25x10 14 It is vg / kg.

[0059] In one embodiment, the method of the present disclosure comprises systemic administration of rAAV, the systemic route of administration being intravenous, and the dose of rAAV administered being approximately 2.0 × 10⁻⁶ 14 The value is vg / kg. In another embodiment, the method of the present disclosure comprises systemic administration of rAAV, the systemic route of administration being intravenous, and the dose of rAAV administered is approximately 5.0 × 10⁻⁶ 12 vg / kg, or approximately 6.0 × 10⁻⁶ 12 vg / kg, or approximately 7.0 × 10⁻⁶ 12 vg / kg, or approximately 8.0 × 10⁻⁶ 12 vg / kg, or approximately 9.0 × 10⁻⁶ 12 vg / kg, or approximately 1.0 × 10⁻⁶ 13 vg / kg, or approximately 1.25 × 10⁻⁶ 13 vg / kg, or approximately 1.5 × 10⁻⁶ 13 vg / kg, or approximately 1.75 × 10⁻⁶ 13 vg / kg, or approximately 2.25 × 10⁻⁶ 13 vg / kg, or approximately 2.5 × 10⁻⁶ 13 vg / kg, or approximately 2.75 × 10⁻⁶13 vg / kg, or approximately 3.0 × 10⁻⁶ 13 vg / kg, or approximately 3.25 × 10⁻⁶ 13 vg / kg, or approximately 3.5 × 10⁻⁶ 13 vg / kg, or approximately 3.75 × 10⁻⁶ 13 vg / kg, or approximately 4.0 × 10 13 vg / kg, or approximately 5.0 × 10⁻⁶ 13 vg / kg, or approximately 6.0 × 10⁻⁶ 13 vg / kg, or approximately 7.0 × 10⁻⁶ 13 vg / kg, or approximately 8.0 × 10⁻⁶ 13 vg / kg, or approximately 9.0 × 10⁻⁶ 13 vg / kg, or approximately 1.0 × 10⁻⁶ 14 vg / kg, or approximately 1.25 × 10⁻⁶ 14 vg / kg, or approximately 1.5 × 10⁻⁶ 14 vg / kg, or approximately 1.75 × 10⁻⁶ 14 vg / kg, or approximately 2.25 × 10⁻⁶ 14 vg / kg, or approximately 2.5 × 10⁻⁶ 14 vg / kg, or approximately 2.75 × 10⁻⁶ 14 vg / kg, or approximately 3.0 × 10⁻⁶ 14 vg / kg, or approximately 3.25 × 10⁻⁶ 14 vg / kg, or approximately 3.5 × 10⁻⁶ 14 vg / kg, or approximately 3.75 × 10⁻⁶ 14 vg / kg, or approximately 4.0 × 10⁻⁶ 14 vg / kg, or approximately 5.0 × 10⁻⁶ 14 vg / kg, or approximately 6.0 × 10⁻⁶ 14 vg / kg, or approximately 1 × 10⁻⁶ 15 The value is vg / kg. In one embodiment, rAAV is AAVrh74.MHCK7.microdystrophin or AAVrh74.MCK.microdystrophin. In one embodiment, rAAV is AAVrh74.MHCK7.microdystrophin of SEQ ID NO: 9, nucleotides 55-5021 of SEQ ID NO: 3, nucleotides 1-4977 of SEQ ID NO: 8, or nucleotides 56-5022 of SEQ ID NO: 6. In one embodiment, rAAV is AAVrh74.MCK.microdystrophin of nucleotides 56-4820 of SEQ ID NO: 5.

[0060] In any of the methods, combination therapies, or uses described herein, the dose of rAAV may be administered at approximately 5 mL / kg to approximately 15 mL / kg, or approximately 8 mL / kg to approximately 12 mL / kg, or 8 mL / kg to approximately 10 mL / kg, or 5 mL / kg to approximately 10 mL / kg, or approximately 10 mL / kg to approximately 12 mL / kg, or approximately 10 mL / kg to approximately 15 mL / kg, or 10 mL / kg to approximately 20 mL / kg. In certain embodiments, the dose or rAAV is administered at approximately 10 mL / kg. In one embodiment, rAAV is AAVrh74.MHCK7.microdystrophin or AAVrh74.MCK.microdystrophin. In one embodiment, rAAV is AAVrh74.MHCK7.microdystrophin of SEQ ID NO: 9, nucleotides 55-5021 of SEQ ID NO: 3, nucleotides 1-4977 of SEQ ID NO: 8, or nucleotides 56-5022 of SEQ ID NO: 6. In one embodiment, rAAV is AAVrh74.MCK.microdystrophin, nucleotides 56-4820 of SEQ ID NO: 5.

[0061] In any of the methods, combination therapies, or agents of this disclosure, the dose of rAAV may be administered by injection, infusion, or implantation. For example, the dose of rAAV may be administered by infusion over approximately one hour. In addition, the dose of rAAV may be administered by intravenous routes through peripheral limb veins, such as the peripheral brachial vein or peripheral leg vein. Alternatively, the infusion may be administered over approximately 30 minutes, or approximately 1.5 hours, or approximately 2 hours, or approximately 2.5 hours, or approximately 3 hours. In one embodiment, rAAV is AAVrh74.MHCK7.microdystrophin. In one embodiment, AAVrh74.MHCK7.microdystrophin is AAVrh74.MHCK7.microdystrophin of SEQ ID NO: 9, nucleotides 55-5021 of SEQ ID NO: 3, nucleotides 1-4977 of SEQ ID NO: 8, or nucleotides 56-5022 of SEQ ID NO: 6. In one embodiment, rAAV is AAVrh74.MCK.microdystrophin. In one embodiment, AAVrh74.MCK.microdystrophin is the AAVrh74.MCK.microdystrophin of nucleotides 56-4820 of SEQ ID NO: 5.

[0062] The rAAV administered by any of the methods, combination therapy, or use of the Disclosure may include the human microdystrophin nucleotide sequence of SEQ ID NO: 1, the MHCK7 promoter sequence of SEQ ID NO: 2, or SEQ ID NO: 7. In addition, the rAAV administered by any of the methods of the Disclosure may include the human microdystrophin nucleotide sequence of SEQ ID NO: 1 and the MHCK7 promoter sequence of SEQ ID NO: 2 or SEQ ID NO: 7. For example, the rAAV may include the AAVrh74.MHCK7.microdystrophin construct nucleotide sequence of SEQ ID NO: 9, nucleotides 55-5021 of SEQ ID NO: 3, nucleotides 1-4977 of SEQ ID NO: 8, or nucleotides 56-5022 of SEQ ID NO: 6. In one embodiment, the rAAV is AAVrh74.MHCK7.microdystrophin. In one embodiment, AAVrh74.MHCK7.microdystrophin is AAVrh74.MHCK7.microdystrophin of SEQ ID NO: 9, nucleotides 55-5021 of SEQ ID NO: 3, nucleotides 1-4977 of SEQ ID NO: 8, or nucleotides 56-5022 of SEQ ID NO: 6.

[0063] In one embodiment, rAAV is AAVrh74.MCK.microdystrophin. In one embodiment, AAVrh74.MCK.microdystrophin is AAVrh74.MCK.microdystrophin of nucleotides 56-4820 of SEQ ID NO: 5.

[0064] In any of the methods, combination therapies, or uses disclosed herein, the rAAV administered is of the serotype for AAVrh.74.

[0065] In some embodiments, the methods, combination therapies, or uses of the present disclosure treat Duchenne muscular dystrophy or Becker muscular dystrophy. An exemplary embodiment is a method, combination therapy, or agent for treating Duchenne muscular dystrophy or Becker muscular dystrophy requiring treatment, comprising the step of administering a dose of recombinant adenovirus-associated (rAAV) rAAV.MHCK7.microdystrophin, wherein the route of administration is intravenous infusion, and the dose of rAAV administered is approximately 2 × 10 over approximately 1 hour. 14 The rAAV vector is vg / kg and consists of the AAVrh74.MHCK7.microdystrophin construct nucleotide sequence 55-5021 of SEQ ID NO: 9 or SEQ ID NO: 3, nucleotides 1-4977 of SEQ ID NO: 8, or nucleotides 56-5022 of SEQ ID NO: 6. In one embodiment, the rAAV is AAVrh74.MHCK7.microdystrophin. In one embodiment, the AAVrh74.MHCK7.microdystrophin consists of nucleotides 55-5021 of SEQ ID NO: 9 or SEQ ID NO: 3, nucleotides 1-4977 of SEQ ID NO: 8, or nucleotides 56-5022 of SEQ ID NO: 6. In one embodiment, the rAAV is AAVrh74.MCK.microdystrophin. In one embodiment, the AAVrh74.MCK.microdystrophin consists of nucleotides 56-4820 of SEQ ID NO: 5.

[0066] In one embodiment, the disclosure provides an rAAV comprising a nucleotide sequence of a muscle-specific regulatory element and a nucleotide sequence encoding a microdystrophin protein. For example, the nucleotide sequence encodes a functional microdystrophin protein, and the nucleotide has sequence identity with respect to SEQ ID NO: 1, for example, at least 65%, at least 70%, at least 75%, at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, or 89%, more typically at least 90%, 91%, 92%, 93%, or 94%, and even more typically at least 95%, 96%, 97%, 98%, 99%, or 100%, and the protein retains microdystrophin activity. The microdystrophin protein provides stability to the muscle membrane during muscle contraction, for example, microdystrophin functions as a shock absorber during muscle contraction. In one embodiment, the rAAV is AAVrh74.MHCK7.microdystrophin. In one embodiment, AAVrh74.MHCK7.microdystrophin is AAVrh74.MHCK7.microdystrophin of nucleotides 55-5021 of SEQ ID NO: 9 or SEQ ID NO: 3, nucleotides 1-4977 of SEQ ID NO: 8, or nucleotides 56-5022 of SEQ ID NO: 6. In one embodiment, rAAV is AAVrh74.MCK.microdystrophin. In one embodiment, AAVrh74.MCK.microdystrophin is AAVrh74.MCK.microdystrophin of nucleotides 56-4820 of SEQ ID NO: 5.

[0067] The present invention also provides an rAAV comprising a nucleotide sequence that hybridizes to the nucleic acid sequence of SEQ ID NO: 1 under stringent conditions, or its complement, and which encodes a functional microdystrophin protein.

[0068] In one embodiment, rAAV is a non-replicating recombinant adeno-associated virus (AAV) referred to as AAVrh74.MHCK7.microdystrophin in SEQ ID NO: 9, nucleotides 55-5021 in SEQ ID NO: 3, nucleotides 1-4977 in SEQ ID NO: 8, or nucleotides 56-5022 in SEQ ID NO: 6. This vector genome contains the minimum elements necessary for gene expression, including an AAV2-terminal inversion sequence (ITR) under the control of the MHCK7 promoter / enhancer, microdystrophin, SV40 intron (SD / SA), and a synthetic polyadenylation (PolyA) signal. A schematic diagram of the genome and expression cassette is shown in Figure 1. The AAVrh74 serotype may be used to achieve efficient gene transfer in skeletal and cardiac muscle after IV administration.

[0069] In another embodiment, the present disclosure provides a method for treating limb-girdle muscular dystrophy in a human subject requiring treatment of limb-girdle muscular dystrophy, comprising administering rAAV containing the nucleotide sequence of SEQ ID NO: 44.

[0070] In another aspect, the disclosure relates to a method, combination therapy, or use for treating limb-girdle muscular dystrophy in a subject requiring it, based on a supercoiled plasmid as a quantitative standard, approximately 5.0 × 10⁶ 13 vg / kg or approximately 2.0 × 10 14 vg / kg, or approximately 1.85 × 10⁶ based on linearized plasmids as a quantitative standard. 13 vg / kg or approximately 7.41 × 10 13The present disclosure provides a method, combination therapy, or use comprising administering rAAV intravenously to a target at a dose of vg / kg over approximately 1-2 hours, wherein the rAAV comprises the nucleotide sequence of SEQ ID NO: 44. In another aspect, the disclosure describes a method for expressing a beta-sarcoglycan gene in target cells, comprising administering to a target scAAVrh74.MHCK7.hSGCB construct comprising a nucleotide sequence at least 90%, 95%, or 99% identical to SEQ ID NO: 19. In one aspect, the disclosure provides a method for increasing beta-sarcoglycan-positive fibers and / or decreasing CK levels in target muscle tissue, comprising administering to a target scAAVrh74.MHCK7.hSGCB construct nucleotide sequence at least 90%, 95%, or 99% identical to SEQ ID NO: 44.

[0071] In another embodiment, recombinant AAV vectors comprising a polynucleotide sequence encoding β-sarcoglycan are described herein. In some embodiments, the polynucleotide sequence encoding β-sarcoglycan comprises, for example, at least 65%, at least 70%, at least 75%, at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, or 89%, more typically 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more identical sequences to the nucleotide sequence described in SEQ ID NO: 45, and encodes a protein that retains β-sarcoglycan activity. In some embodiments, the polynucleotide sequence encoding β-sarcoglycan comprises the nucleotide sequence described in SEQ ID NO: 45. In some embodiments, the polynucleotide sequence encoding β-sarcoglycan consists of the nucleotide sequence described in SEQ ID NO: 45.

[0072] In another embodiment, the recombinant AAV vector described herein comprises a polynucleotide sequence encoding a β-sarcoglycan that is sequence-identical to the amino acid sequence of SEQ ID NO: 46 by at least 65%, at least 70%, at least 75%, at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, or 89%, more typically at least 90%, 91%, 92%, 93%, or 94%, and more generally at least 95%, 96%, 97%, 98%, or 99%, and the protein retains β-sarcoglycan activity.

[0073] In another embodiment, the recombinant AAV vector described herein comprises a polynucleotide sequence encoding a β-sarcoglycan having the amino acid sequence of SEQ ID NO: 46.

[0074] In another embodiment, recombinant AAV vectors comprising a polynucleotide sequence encoding a functional β-sarcoglycan, or its complement, which includes a nucleotide sequence that hybridizes to the nucleic acid sequence of SEQ ID NO: 45 under stringent conditions, are described herein.

[0075] In certain embodiments, the Disclosure provides methods, combination therapies, or uses for treating LGMD2E in human subjects requiring treatment of LGMD2E, including administering rAAV scAAVrh74.MHCK7.HSGCB. For example, in any method of treating LGMD2E, scAAVrh74.MHCK7.HSGCB is present in an amount of approximately 0.5 × 10⁻⁶. 14 vg / kg or approximately 2 × 10⁻⁶ 14 It is administered by intravenous infusion at a dose of vg / kg. The doses described herein in relation to scAAVrh74.MHCK7.HSGCB, including the one immediately preceding it, are based on the use of supercoiled qPCR standards. Each is 0.5 x 10⁻¹⁶. 14 vg / kg and 2x10 14 The value of vg / kg, when measured using a linear qPCR standard, is 1.85 × 10⁻⁶. 13 and 7.41 × 10 13 Supports vg / kg

[0076] In certain embodiments, in any of the methods, combination therapies or uses for treating limb-girdle muscular dystrophy in a human subject, the human subject suffers from LGMD2E, and the rAAV is about 2×10 14 administered by intravenous infusion at a dose of vg / kg, and the rAAV comprises scAAVrh74.MHCK7.HSGCB, which is an rAAV comprising the nucleotide sequence of SEQ ID NO: 44.

[0077] In a related embodiment, the human subject suffers from muscular dystrophy LGMD2E, and the rAAV is about 2x10 14 scAAVrh74.MHCK7.HSGCB administered by intravenous infusion at a dose of vg / kg, and the method further comprises administering 1 mg / kg / day of prednisone to the subject, which is initiated 1 day (12 to 24 hours) prior to administration of the rAAV and continues for 60 days with or without tapering.

[0078] In another related embodiment, the human subject suffers from muscular dystrophy LGMD2E, and the rAAV is about 0.5×10 14 scAAVrh74.MHCK7.HSGCB administered by intravenous infusion at a dose of vg / kg, and the method further comprises administering 1 mg / kg / day of prednisone to the subject, which is initiated 1 day (12 to 24 hours) prior to administration of the rAAV and continues for 30 days with or without tapering.

[0079] It is recognized that the 30-day and 60-day administrations of prednisone may be tapered by those skilled in the art according to the particular clinical symptoms of the subject, and as otherwise further described herein.

[0080] The term "stringent" is used to refer to conditions that are generally understood as stringent in the art. Hybridization stringency is primarily determined by temperature, ionic strength, and the concentration of denaturing agents such as formamide. Examples of stringent conditions for hybridization and washing are 0.015 M sodium chloride, 0.0015 M sodium citrate at 65–68°C or 0.015 M sodium chloride, 0.0015 M sodium citrate, and 50% formamide at 42°C. See Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory, (Cold Spring Harbor, NY 1989). More stringent conditions (higher temperature, lower ionic strength, higher formamide, or other denaturing agents, etc.) can also be used, but the rate of hybridization will be affected. When deoxyoligonucleotide hybridization is involved, examples of additional stringent hybridization conditions include washing with 6×SSC 0.05% sodium pyrophosphate at 37°C (for 14-base oligos), 48°C (for 17-base oligos), 55°C (for 20-base oligos), and 60°C (for 23-base oligos).

[0081] To reduce nonspecific and / or background hybridization, other agents may be included in the hybridization and washing buffers. Examples include 0.1% bovine serum albumin, 0.1% polyvinylpyrrolidone, 0.1% sodium pyrophosphate, 0.1% sodium dodecyl sulfate, NaDodSO4, (SDS), Ficol, Denhardt's solution, sonicated salmon sperm DNA (or other non-complementary DNA), and dextran sulfate, but other suitable agents may also be used. The concentrations and types of these additives may be changed without substantially affecting the stringency of the hybridization conditions. Hybridization experiments are typically performed at pH 6.8–7.4, but under typical ionic strength conditions, the rate of hybridization is largely pH-independent. See Anderson et al., Nucleic Acid Hybridisation: A Practical Approach, Ch.4, IRL Press Limited (Oxford, England). Hybridization conditions can be adjusted by those skilled in the art to allow DNAs of different sequence similarities to form hybrids, taking these variables into consideration.

[0082] The term "muscle-specific regulatory element" refers to a nucleotide sequence that regulates the expression of a coding sequence that is specific to expression in muscle tissue. These regulatory elements include enhancers and promoters. This disclosure provides a construct comprising a muscle-specific regulatory element MCKH7 promoter, an MCK promoter, and an MCK enhancer.

[0083] In one embodiment, the present disclosure provides rAAV, in which the muscle-specific regulatory element is a human skeletal actin gene element, a cardiac actin gene element, a muscle cell-specific enhancer-binding factor (MEF), muscle creatine kinase (MCK), truncated MCK (tMCK), myosin heavy chain (MHC), hybrid α-myosin heavy chain enhancer / MCK enhancer promoter (MHCK7), C5-12, mouse creatine kinase enhancer factor, fast-twitch skeletal muscle troponin c gene element, slow-twitch muscle cardiac troponin c gene element, slow-twitch muscle troponin i gene element, hypoxia-inducible nuclear factor, steroid-inducible element, or glucocorticoid-response element (GRE).

[0084] For example, the muscle-specific regulatory element is SEQ ID NO: 2 of the MHCK7 promoter nucleotide sequence, or the muscle-specific regulatory element is SEQ ID NO: 4 of the MCK nucleotide sequence. In addition, in any of the rAAV vectors of this disclosure, the muscle-specific regulatory element nucleotide sequence, for example, the MHCK7 or MCK nucleotide sequence, is operably ligated to a nucleotide sequence encoding a microdystrophin protein. For example, the MHCK7 promoter nucleotide sequence (SEQ ID NO: 2 or SEQ ID NO: 7) is operably ligated to a human microdystrophin coding sequence (SEQ ID NO: 1) as described in the construct presented in Figure 1 or Figure 2 (SEQ ID NO: 3) or Figure 13 (SEQ ID NO: 9). In another example, the MCK promoter (SEQ ID NO: 4) is operably ligated to a human microdystrophin coding sequence (SEQ ID NO: 1) as described in the construct presented in Figure 5 or Figure 6 (SEQ ID NO: 5). In another embodiment, this disclosure provides an rAAV vector comprising the nucleotide sequences of SEQ ID NO: 1 and SEQ ID NO: 2, or SEQ ID NO: 1 and SEQ ID NO: 7. The present invention also provides an rAAV vector comprising the nucleotide sequences of SEQ ID NO: 1 and SEQ ID NO: 4.

[0085] In a further embodiment, the disclosure provides rAAV constructs contained in plasmids comprising the nucleotide sequences of SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 6, or SEQ ID NO: 8. For example, the AAVrh74.MHCK7.microdystrophin vector is located within and comprises the ITR of SEQ ID NO: 3 and includes the nucleotide sequence shown in Figure 2. The rAAV vector comprises a coding sequence for the 5' ITR, MHCK7 promoter, chimeric intron sequence, human microdystrophin gene, poly(A), and 3' ITR. In one embodiment, the vector comprises nucleotides 55-5021 of SEQ ID NO: 3. The plasmid shown in SEQ ID NO: 3 further comprises a pGEX plasmid backbone having ampicillin resistance and a pBR322 origin of replication.

[0086] In another embodiment, the disclosure provides an rAAV comprising the nucleotide sequence of SEQ ID NO: 9, for example, the AAVrh74.MHCK7.microdystrophin vector construct comprising the nucleotide sequence of SEQ ID NO: 9, as shown in Figure 7. This rAAV vector construct comprises the MHCK7 promoter, a chimeric intron sequence, a coding sequence for the human microdystrophin gene, and poly(A). In one embodiment, the rAAV vector construct further comprises ITR5' in the promoter and ITR3' in poly(A). In one embodiment, the rAAV is AAVrh74.

[0087] In another embodiment, for example, the AAVrh74.MHCK7.microdystrophin vector is located within and contains the ITR of SEQ ID NO: 8, and includes the nucleotide sequence shown in Figure 9. The rAAV vector includes the 5' ITR, the MHCK7 promoter, the chimeric intron sequence, the human I microdystrophin gene, poly(A), and the coding sequence for the 3' ITR. In one embodiment, this vector contains nucleotides 1-4977 of SEQ ID NO: 9. The plasmid shown in SEQ ID NO: 3 further includes a pGEX plasmid backbone having kanamycin resistance and a pBR322 origin of replication.

[0088] In another embodiment, the disclosure provides a plasmid comprising the AAVrh74.MHCK7.microdystrophin vector construct. In one embodiment, the plasmid comprises a coding sequence for the 5'ITR, MHCK7 promoter, chimeric intron sequence, human microdystrophin gene, poly(A), and 3'ITR. In one embodiment, the plasmid comprises kanamycin resistance and optionally comprises a pGEX plasmid backbone having a pBR322 origin of replication. In a particular embodiment, the plasmid is shown in Sequence ID No. 8 and is shown in Figures 8 and 9.

[0089] This disclosure provides a recombinant AAV vector comprising the human microdystrophin nucleotide sequence of SEQ ID NO: 1 and the MHCK7 promoter nucleotide sequence of SEQ ID NO: 2 or SEQ ID NO: 7. This rAAV vector is AAV serotype AAVrh.74.

[0090] This disclosure also provides an rAAV comprising the AAVrh74.MHCK7.microdystrophin vector construct nucleotide sequence contained in and including SEQ ID NO: 3, the nucleotide sequence contained in and including including in SEQ ID NO: 8, or the nucleotide sequence shown in SEQ ID NO: 9. This rAAV vector is AAV serotype AAVrh.74.

[0091] The rAAV vectors of this disclosure may be any AAV serotype, such as AAVrh.74, AAV1, AAV2, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, or AAV13.

[0092] The Disclosure also provides pharmaceutical compositions (or, as sometimes referred to herein simply as “Compositions”) comprising any of the rAAV vectors of the Disclosure.

[0093] In another embodiment, the Disclosure provides a method for producing rAAV vector particles, comprising culturing cells transfected with any of the rAAV vectors of the Disclosure and recovering rAAV particles from the supernatant of the transfected cells. The Disclosure also provides viral particles comprising any of the recombinant AAV vectors of the Disclosure.

[0094] In any method of treating muscular dystrophy, the level of the target transgene, such as the expression of the beta-sarcoglycan gene or the microdystrophin gene, increases in the target cells after administration of rAAV. Transgene expression of the target gene in cells is detected by measuring the level of the target protein by Western blotting in muscle biopsies taken before and after rAAV administration. In particular, the level of the target protein increases by at least approximately 70% to at least approximately 80%, or at least approximately 70% to at least approximately 90%, or at least approximately 80% to at least approximately 90%, after rAAV administration compared to the level of the target protein before rAAV administration. For example, the level of the target protein increases by at least approximately 70%, at least approximately 71%, at least approximately 72%, at least approximately 73%, at least approximately 74%, at least approximately 75%, at least approximately 76%, at least approximately 77%, at least approximately 78%, at least approximately 79%, at least approximately 80%, at least approximately 81%, at least approximately 82%, at least approximately 83%, at least approximately 84%, or at least approximately 85% after administration of rAAV, compared to the level of the target protein before administration of rAAV.

[0095] In addition, intracellular microdystrophin gene expression is detected by measuring the level of the target protein by immunohistochemistry in muscle biopsies before and after rAAV administration. The level of the target protein increases by at least approximately 70% to at least approximately 80%, or at least approximately 70% to at least approximately 90%, or at least approximately 80% to at least approximately 90%, compared to the level of the target protein before rAAV administration. For example, the level of the target protein increases by at least approximately 70%, at least approximately 71%, at least approximately 72%, at least approximately 73%, at least approximately 74%, at least approximately 75%, at least approximately 76%, at least approximately 77%, at least approximately 78%, at least approximately 79%, at least approximately 80%, at least approximately 81%, at least approximately 82%, at least approximately 83%, at least approximately 84%, or at least approximately 85%, compared to the level of the target protein before rAAV administration.

[0096] In any method, combination therapy, or use for treating muscular dystrophy, serum CK levels in subjects decrease after rAAV administration compared to serum CK levels before rAAV administration. For example, by 60 days after rAAV administration, subjects' serum CK levels decrease by approximately 65% ​​to 90%, 65% to 95%, 75% to 90%, 80% to 90%, 85% to 95%, 87% to 95%, or 87% to 90% compared to serum CK levels before rAAV administration. In particular, in any of the methods, combination therapies, or uses for treating muscular dystrophy described herein, the serum CK level in the subject decreases by approximately 87% by 60 days after rAAV administration compared to the serum CK level before rAAV administration, or in any of the methods, combination therapies, or uses for treating muscular dystrophy described herein, the serum CK level in the subject decreases by approximately 72 The serum CK level decreases by approximately 73% by 60 days after rAAV administration compared to the serum CK level before rAAV administration, or in any of the methods, combination therapies, or uses for treating muscular dystrophy described herein, the serum CK level in the subject decreases by approximately 78% by 60 days after rAAV administration compared to the serum CK level before rAAV administration, or in any of the methods, combination therapies, or uses for treating muscular dystrophy described herein, the serum CK level in the subject decreases by approximately 95% by 60 days after rAAV administration compared to the serum CK level before rAAV administration. In any of the methods, combination therapies, or uses for treating muscular dystrophy, the number of muscle fibers positive for the target protein in the subject's muscle tissue increases after rAAV administration compared to the number of muscle fibers positive for the target protein before rAAV administration. For example, the number of muscle fibers positive for the target protein can be detected by measuring the level of the target protein in the positive muscle fibers using Western blotting or immunohistochemistry in muscle biopsies taken before and after rAAV administration.

[0097] In any of the methods, combination therapies or uses for treating muscular dystrophy, administration of rAAV upregulates the expression of DAPC proteins such as alpha-sarcoglycan or beta-sarcoglycan. For example, the level of alpha-sarcoglycan in a subject increases after administration of rAAV as compared to the level of alpha-sarcoglycan prior to administration of rAAV. In addition, the level of beta-sarcoglycan in the subject increases after administration of rAAV as compared to the level of beta-sarcoglycan prior to administration of rAAV. The level of alpha-sarcoglycan is detected by measuring the alpha-sarcoglycan protein level or the beta-sarcoglycan protein level by Western blot or immunohistochemistry in muscle biopsies before and after rAAV administration.

[0098] In any of the methods, combination therapies or uses for treating muscular dystrophy, disease progression in a subject is delayed after administration of rAAV, as measured by any of the 6-minute walk test, rise time, 4-step ascent, 4-step ascent and descent, North Star Ambulatory Assessment (NSAA), 10-meter timed test, 100-meter timed test, handheld dynamometry (HHD), Timed Up and Go, and / or Gross Motor Subtest Scaled (Bayley-III) score.

[0099] For example, in all methods, combination therapy, or use, subjects have an improvement of at least 6 points in their NSAA score at least 270 days after rAAV administration compared to their NSAA score before rAAV administration. Furthermore, in all methods, combination therapy, or use, subjects have an improvement of at least approximately 0.8 seconds in their rise time at least 270 days after rAAV administration compared to their rise time before rAAV administration. In addition, in all methods, combination therapy, or use, subjects have an improvement of at least approximately 1.2 seconds in their 4-step rise time test at least 270 days after rAAV administration compared to their 4-step rise time test before rAAV administration. In addition, in all methods, combination therapy, or use, subjects have an improvement of at least approximately 7 seconds in their 100m timing test at least 270 days after rAAV administration compared to their 100m timing test before rAAV administration.

[0100] In another embodiment, the Disclosure provides a method, composition, combination therapy, or use for expressing the microdystrophin gene in a patient's cells, comprising administering to the patient the nucleotide sequence of the AAVrh74.MHCK7.microdystrophin construct of SEQ ID NO: 9, nucleotides 55-5021 of SEQ ID NO: 3, nucleotides 1-4977 of SEQ ID NO: 8, or nucleotides 56-5022 of SEQ ID NO: 6. For example, the expression of the microdystrophin gene in a patient's cells is detected by measuring the microdystrophin protein level by Western blotting or immunohistochemistry in muscle biopsies before and after administration of the rAAV.MHCK7.microdystrophin construct. In addition, the expression of the microdystrophin gene is measured in the patient by detecting more than one vector genome per nucleus, where one vector genome per nucleus corresponds to approximately 50% microdystrophin expression, and more than one copy per nucleus corresponds to the microdystrophin expression level. For example, a cell may have 1.2 vector copies per nucleus, or 1.3 vector copies per nucleus, or 1.4 vector copies per nucleus, or 1.5 vector copies per nucleus, or 1.6 vector copies per nucleus, or 1.7 vector copies per nucleus, or 1.8 vector copies per nucleus, or 1.9 vector copies per nucleus.

[0101] In further embodiments, the Disclosure provides a method, composition, combination therapy or use for reducing serum CK levels in a patient requiring a reduction in serum CK levels, the method comprising administering to the patient the AAVrh74.MHCK7.microdystrophin construct nucleotide sequence of SEQ ID NO: 9, nucleotides 55-5021 of SEQ ID NO: 3, nucleotides 1-4977 of SEQ ID NO: 8, or nucleotides 56-5022 of SEQ ID NO: 6. For example, the patient's serum CK level is reduced by at least about 65% to about 90%, or about 65% to about 95%, or about 75% to about 90%, or about 80% to about 90%, or about 85% to about 95%, or about 87% to about 95%, or about 87% to about 90%, compared to the serum CK level before administration of rAAV, by 60 days after administration of rAAV. In particular, the serum CK level in the subjects decreases by approximately 87% by 60 days after rAAV administration compared to the serum CK level before rAAV administration, or in any of the methods, compositions, combination therapies, or uses for treating muscular dystrophy disclosed herein, the serum CK level in the subjects decreases by approximately 72% by 60 days after rAAV administration compared to the serum CK level before rAAV administration, or in any of the methods, compositions, combination therapies, or uses for treating muscular dystrophy disclosed herein, the serum CK level in the subjects decreases by approximately 87% by 60 days after rAAV administration compared to the serum CK level before rAAV administration. Compared to Bell, serum CK levels decrease by approximately 73% by 60 days after administration of rAAV, or in any of the methods, compositions, combination therapies, or uses for treating muscular dystrophy described herein, serum CK levels in subjects decrease by approximately 78% by 60 days after administration of rAAV compared to serum CK levels before administration of rAAV, or in any of the methods, compositions, combination therapies, or uses for treating muscular dystrophy described herein, serum CK levels in subjects decrease by approximately 95% by 60 days after administration of rAAV compared to serum CK levels before administration of rAAV.

[0102] This disclosure also provides methods, compositions, combination therapies, or uses for increasing microdystrophin-positive fibers in a patient's muscle cells, including administering to the patient the AAVrh74.MHCK7.microdystrophin construct nucleotide sequence of SEQ ID NO: 9, nucleotides 55-5021 of SEQ ID NO: 3, nucleotides 1-4977 of SEQ ID NO: 8, or nucleotides 56-5022 of SEQ ID NO: 6. For example, the number of beta-sarcoglycan-positive fibers is detected by measuring dystrophin protein levels by Western blotting or immunohistochemistry in muscle biopsies before and after rAAV administration. In addition, microdystrophin gene expression is measured in patients by detecting more than one vector genome per nucleus, where one vector genome per nucleus corresponds to approximately 50% microdystrophin expression, and more than one copy per nucleus corresponds to a microdystrophin expression level. For example, a cell may have 1.2 vector copies per nucleus, or 1.3 vector copies per nucleus, or 1.4 vector copies per nucleus, or 1.5 vector copies per nucleus, or 1.6 vector copies per nucleus, or 1.7 vector copies per nucleus, or 1.8 vector copies per nucleus, or 1.9 vector copies per nucleus.

[0103] In another embodiment, the Disclosure provides a method, composition, combination therapy, or use for increasing alpha-sarcoglycan expression in patients requiring increased alpha-sarcoglycan expression, comprising administering to the patient the AAVrh74.MHCK7.microdystrophin construct nucleotide sequence of SEQ ID NO: 9, nucleotides 55-5021 of SEQ ID NO: 3, nucleotides 1-4977 of SEQ ID NO: 8, or nucleotides 56-5022 of SEQ ID NO: 6. For example, alpha-sarcoglycan levels are detected by measuring alpha-sarcoglycan protein levels by Western blotting or immunohistochemistry in muscle biopsies before and after administration of rAAV.

[0104] In addition, this disclosure provides methods, compositions, combination therapies or uses for increasing beta-sarcoglycan expression in patients requiring increased beta-sarcoglycan expression, including administering to the patient the AAVrh74.MHCK7.microdystrophin construct nucleotide sequence of SEQ ID NO: 9, nucleotides 55-5021 of SEQ ID NO: 3, nucleotides 1-4977 of SEQ ID NO: 8, or nucleotides 56-5022 of SEQ ID NO: 6. For example, beta-sarcoglycan levels are detected by measuring beta-sarcoglycan protein levels by Western blotting or immunohistochemistry in muscle biopsies before and after rAAV administration.

[0105] The disclosure also provides methods, compositions, combination therapies or uses for treating patients with Duchenne muscular dystrophy or Becker muscular dystrophy, comprising administering to the patient the AAVrh74.MHCK7.microdystrophin construct nucleotide sequence of SEQ ID NO: 9, nucleotides 55-5021 of SEQ ID NO: 3, nucleotides 1-4977 of SEQ ID NO: 8, or nucleotides 56-5022 of SEQ ID NO: 6, to delay disease progression in the subject, if the disease progression in the subject is measured by any of the following: 6-minute walk test, stand-up time, 4-step rise, 4-step rise, North Star Ambulatory Assessment (NSAA), 10-meter timed test, 100-meter timed test, handheld dynamometry (HHD), Timed Up and Go, and / or Gross Motor Subtest Scaled (Bayley-III) score.

[0106] For example, in any of the methods, compositions, combination therapies, or uses, subjects have an improvement of at least 6 points in their NSAA score at least 270 days after rAAV administration compared to their NSAA score before rAAV administration. Furthermore, in any of the methods, subjects have an improvement of at least approximately 0.8 seconds in their rise time at least 270 days after rAAV administration compared to their rise time before rAAV administration. In addition, in any of the methods, subjects have an improvement of at least approximately 1.2 seconds in their four-step rise time test at least 270 days after rAAV administration compared to their four-step rise time test before rAAV administration. In addition, in any of the methods, subjects have an improvement of at least approximately 7 seconds in their 100m timing test at least 270 days after rAAV administration compared to their 100m timing test before rAAV administration.

[0107] "Fibrosis" refers to the abnormal tissue repair process following excessive or disordered deposition and damage of extracellular matrix (ECM) components, including those in skeletal muscle, cardiac muscle, liver, lungs, kidneys, and pancreas. The deposited ECM components include fibronectin and collagen, such as collagen 1, collagen 2, or collagen 3.

[0108] The disclosure also provides a method for reducing or preventing fibrosis in subjects suffering from muscular dystrophy, comprising administering a therapeutically effective amount of rAAV containing the human microdystrophin nucleotide sequence of SEQ ID NO: 1 and the MHCK7 promoter nucleotide sequence of SEQ ID NO: 2, or a therapeutically effective amount of rAAV vector containing the AAVrh74.MHCK7.microdystrophin construct nucleotide sequence of SEQ ID NO: 9, nucleotides 55-5021 of SEQ ID NO: 3, nucleotides 1-4977 of SEQ ID NO: 8, or nucleotides 56-5022 of SEQ ID NO: 6. In one embodiment, the rAAV is AAVrh74.MHCK7.microdystrophin. In one embodiment, the AAVrh74.MHCK7.microdystrophin is AAVrh74.MHCK7.microdystrophin of nucleotides 55-5021 of SEQ ID NO: 3. In another embodiment, the AAVrh74.MHCK7.microdystrophin is AAVrh74.MHCK7.microdystrophin of SEQ ID NO: 9. In another embodiment, AAVrh74.MHCK7.microdystrophin is AAVrh74.MHCK7.microdystrophin of nucleotides 1-4977 of SEQ ID NO: 8 or nucleotides 56-5066 of SEQ ID NO: 6. In yet another embodiment, rAAV is AAVrh74.MCK.microdystrophin. In one embodiment, AAVrh74.MCK.microdystrophin is AAVrh74.MCK.microdystrophin of nucleotides 56-4820 of SEQ ID NO: 5.

[0109] In another embodiment, the Disclosure provides a method for preventing fibrosis in subjects requiring prevention of fibrosis, comprising administering an rAAV vector containing a therapeutically effective amount of the human microdystrophin nucleotide sequence of SEQ ID NO: 1 and the MHCK7 promoter nucleotide sequence of SEQ ID NO: 2 or SEQ ID NO: 7, or the AAV74.MHCK7.microdystrophin construct nucleotide sequence of SEQ ID NO: 9, nucleotides 55-5021 of SEQ ID NO: 3, nucleotides 1-4977 of SEQ ID NO: 8, or nucleotides 56-5022 of SEQ ID NO: 6. For example, any of the rAAVs of the Disclosure may be administered to subjects with muscular dystrophy to prevent fibrosis, for example, an rAAV expressing the human microdystrophin protein may be administered before fibrosis is observed in the subject. In addition, the rAAVs of the Disclosure expressing the human microdystrophin gene may be administered to subjects at risk of developing fibrosis, such as subjects with or diagnosed with muscular dystrophy, for example, DMD. The rAAVs of this disclosure can be administered to subjects with muscular dystrophy to prevent new-onset fibrosis in these subjects.

[0110] This disclosure aims to administer rAAV before fibrosis is observed in subjects. In addition, rAAV can be administered to subjects at risk of developing fibrosis, such as subjects with or diagnosed with muscular dystrophy, for example, DMD. rAAV can be administered to subjects with muscular dystrophy who have already developed fibrosis to prevent new cases of fibrosis in these subjects.

[0111] The disclosure also provides a method for increasing muscle strength and / or muscle mass in subjects suffering from muscular dystrophy, comprising administering a therapeutically effective amount of rAAV containing the human microdystrophin nucleotide sequence of SEQ ID NO: 1 and the MHCK7 promoter nucleotide sequence of SEQ ID NO: 2 or SEQ ID NO: 7, or the AAVrh74.MHCK7.microdystrophin construct nucleotide sequence of SEQ ID NO: 9, nucleotides 55-5021 of SEQ ID NO: 3, nucleotides 1-4977 of SEQ ID NO: 8, or nucleotides 56-5022 of SEQ ID NO: 6.

[0112] The present invention aims to administer the rAAV vector of the present invention to patients diagnosed with DMD before fibrosis is observed in the subject, or before muscle strength or muscle mass decreases.

[0113] The disclosure also includes preventing new fibrosis in or reducing fibrosis in subjects with muscular dystrophy who have already developed fibrosis by administering rAAV containing the human microdystrophin nucleotide sequence of SEQ ID NO: 1 and the MHCK7 promoter nucleotide sequence of SEQ ID NO: 2 or SEQ ID NO: 7, or the AAVrh74.MHCK7.microdystrophin construct nucleotide sequence of SEQ ID NO: 9, nucleotides 55-5021 of SEQ ID NO: 3, nucleotides 1-4977 of SEQ ID NO: 8, or nucleotides 56-5022 of SEQ ID NO: 6. The disclosure also includes protecting muscles from further damage by administering rAAV containing the human microdystrophin nucleotide sequence of SEQ ID NO: 1 and the MHCK7 promoter nucleotide sequence of SEQ ID NO: 2 or SEQ ID NO: 7, or the AAVrh74.MHCK7.microdystrophin construct nucleotide sequence of SEQ ID NO: 9, nucleotides 55-5021 of SEQ ID NO: 3, nucleotides 1-4977 of SEQ ID NO: 8, or nucleotides 56-5022 of SEQ ID NO: 6 to subjects suffering from muscular dystrophy who already have reduced muscle strength or reduced muscle mass.

[0114] In any of the methods described herein, the subject may have a muscular dystrophy, such as DMD or any other dystrophin-related muscular dystrophy.

[0115] In any other embodiment of the methods of the present disclosure described herein, the serum CK level in the subject decreases by a percentage level selected from the group below after administration of rAAV, compared to the serum CK level before administration of rAAV: a) At least 78% within 90, 180, or 270 days after administration; b) At least 46, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, or 85% within 270 days after administration; c) At least 72, 73, 74, or 95% within 180 days after administration; d) At least 87%, 88%, 93%, or 95% within 90 days after administration; e) At least 70% within 270 days after administration; f) 70-95% within 90, 180, or 270 days after administration; g) at least about 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, or 95% by 90, 180, or 270 after administration; and h) At least approximately 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, or 95% by 90, 180, or 270 days after administration.

[0116] In another embodiment, the Disclosure provides a composition for treating muscular dystrophy in a human subject as needed, the composition comprising a dose of recombinant adenovirus-associated (rAAV) rAAV.MHCK7.microdystrophin, the composition being formulated for a systemic route of administration, and the dose of rAAV is approximately 1 × 10⁻⁶ 14 vg / kg ~ approx. 4×10 14 The value is vg / kg. In one embodiment, rAAV is AAVrh74.MHCK7.microdystrophin. In one embodiment, AAVrh74.MHCK7.microdystrophin is AAVrh74.MHCK7.microdystrophin of SEQ ID NO: 9, nucleotides 55-5021 of SEQ ID NO: 3, nucleotides 1-4977 of SEQ ID NO: 8, or nucleotides 56-5022 of SEQ ID NO: 6. In one embodiment, rAAV is AAVrh74.MCK.microdystrophin. In one embodiment, AAVrh74.MCK.microdystrophin is AAVrh74.MCK.microdystrophin of nucleotides 56-4820 of SEQ ID NO: 5.

[0117] For example, the composition of this disclosure is approximately 5.0 x 10 12 vg / kg ~ approx. 1.0x10 14 vg / kg, or approximately 5.0 x 10 12 vg / kg~1.0x10 14 vg / kg, or approximately 5.0 x 10 12 vg / kg~approx.2.0x10 14 vg / kg, or approximately 5.0 x 10 12 vg / kg ~ approx. 1.0x10 14 vg / kg, or approximately 5.0 x 10 12 vg / kg~approx.5.0x10 13 vg / kg, or approximately 5.0 x 10 12 vg / kg~approx.2.0x10 13 vg / kg, or approximately 5.0 x 10 12 vg / kg ~ approx. 1.0x10 13 vg / kg, or 1.0 x 10 14 vg / kg ~ approx. 1.0x10 15 vg / kg, or 1.0 x 10 13 vg / kg ~ approx. 1.0x1014 vg / kg, or approximately 1.0 x 10 13 vg / kg~1.0x10 14 vg / kg, or approximately 1.0 x 10 13 vg / kg~approx.2.0x10 14 vg / kg, or approximately 1.0 x 10 13 vg / kg ~ approx. 1.0x10 14 vg / kg, or approximately 1.0 x 10 13 vg / kg~approx.5.0x10 13 vg / kg, or approximately 1.0 x 10 13 vg / kg~approx.3.0x10 14 vg / kg, or approximately 1.0 x 10 13 vg / kg~approx.5.0x10 14 vg / kg, or approximately 1.0 x 10 13 vg / kg~approx.6.0x10 14 vg / kg, or 1.0 x 10 13 vg / kg ~ approx. 1.0x10 15 vg / kg, or 5.0x10 13 vg / kg ~ approx. 1.0x10 14 vg / kg, or approximately 5.0 x 10 13 vg / kg~1.0x10 14 vg / kg, or approximately 5.0 x 10 13 vg / kg~approx.2.0x10 14 vg / kg, or approximately 5.0 x 10 13 vg / kg ~ approx. 1.0x10 14 vg / kg, or approximately 5.0 x 10 13 vg / kg~approx.3.0x10 14 vg / kg, or approximately 5.0 x 10 13 vg / kg~approx.5.0x10 14 vg / kg, or approximately 5.0 x 10 13 vg / kg~approx.6.0x10 14 vg / kg, or 5.0x10 13 vg / kg ~ approx. 1.0x10 15 vg / kg, or 1.0 x 10 14 vg / kg~approx.6.0x10 14 vg / kg, or 1.0 x 10 14 vg / kg~approx.5.0x10 14 vg / kg, or 1.0 x 10 14vg / kg ~ approx. 4.0x10 14 vg / kg, or 1.0 x 10 14 vg / kg ~ approx. 1.0x10 15 vg / kg, or 1.0 x 10 14 vg / kg~approx.3.0x10 14 vg / kg, or approximately 1.0 x 10 14 vg / kg ~ approx. 2.5x10 14 vg / kg, or 1.0 x 10 14 vg / kg~approx.2.0x10 14 vg / kg, or approximately 1.25 x 10 14 vg / kg~approx.3.75x10 14 vg / kg, or approximately 1.25 x 10 14 vg / kg~6.0x10 14 , or approximately 1.25 x 10 14 vg / kg~5.0x10 14 , or approximately 1.25 x 10 14 vg / kg~4.0x10 14 , or approximately 1.25 x 10 14 vg / kg~1.0x10 15 , or approximately 1.25 x 10 14 vg / kg~approx.3.5x10 14 vg / kg, or approximately 1.25 x 10 14 vg / kg~approx.3.0x10 14 vg / kg, or approximately 1.25 x 10 14 vg / kg~approx.2.75x10 14 vg / kg, or approximately 1.25 × 10⁻⁶ 14 vg / kg ~ approx. 2.5×10 14 vg / kg, or approximately 1.25 x 10 14 vg / kg ~ approx. 2.0×10 14 vg / kg, or 1.25x10 14 vg / kg~approx.3.75x10 14 vg / kg, or approximately 1.25 x 10 14 vg / kg ~ approx. 3.5×10 14 vg / kg, or 1.5x10 14 vg / kg ~ approx. 1.0x10 15 vg / kg, or approximately 1.5 x 10 14 vg / kg~6.0x10 14 , or approximately 1.5 x 1014 vg / kg~5.0x10 14 , or approximately 1.5 x 10 14 vg / kg~4.0x10 14 , or approximately 1.5 x 10 14 vg / kg~approx.3.75x10 14 vg / kg, or approximately 1.5 x 10 14 vg / kg~approx.3.5x10 14 vg / kg, or approximately 1.5 x 10 14 vg / kg~approx.3.25x10 14 vg / kg, or approximately 1.5 x 10 14 vg / kg~approx.3.0x10 14 vg / kg, or approximately 1.5 x 10 14 vg / kg~approx.2.75x10 14 vg / kg, or approximately 1.5 x 10 14 vg / kg ~ approx. 2.5x10 14 vg / kg, or approximately 1.5 x 10 14 vg / kg~approx.2.0x10 14 vg / kg, or 1.75 x 10 14 vg / kg ~ approx. 1.0x10 15 vg / kg, or approximately 1.75 x 10 14 vg / kg~6.0x10 14 , or approximately 1.75 x 10 14 vg / kg~5.0x10 14 , or approximately 1.75 x 10 14 vg / kg~4.0x10 14 , or approximately 1.75 x 10 14 vg / kg~approx.3.75x10 14 vg / kg, or approximately 1.75 x 10 14 vg / kg~approx.3.5x10 14 vg / kg, or approximately 1.75 x 10 14 vg / kg~approx.3.25x10 14 vg / kg, or approximately 1.75 x 10 14 vg / kg~approx.3.0x10 14 vg / kg, or approximately 1.75 x 10 14 vg / kg~approx.2.75x10 14 vg / kg, or approximately 1.75 x 10 14 vg / kg ~ approx. 2.5x10 14vg / kg, or approximately 1.75 x 10 14 vg / kg~approx.2.25x10 14 vg / kg, or approximately 1.75 x 10 14 vg / kg~approx.2.0x10 14 vg / kg, or approximately 2.0 x 10 14 vg / kg~1.0x10 15 , or approximately 2.0 x 10 14 vg / kg~6.0x10 14 , or approximately 2.0 x 10 14 vg / kg~5.0x10 14 , or approximately 2.0 x 10 14 vg / kg ~ approx. 4.0x10 14 vg / kg, or approximately 2.0 x 10 14 vg / kg~approx.3.75x10 14 vg / kg, or approximately 2.0 x 10 14 vg / kg~approx.3.5x10 14 vg / kg, or approximately 2.0 x 10 14 vg / kg~approx.3.25x10 14 The dosage of rAAV is vg / kg. In one embodiment, rAAV is AAVrh74.MHCK7.microdystrophin. In one embodiment, AAVrh74.MHCK7.microdystrophin is AAVrh74.MHCK7.microdystrophin of SEQ ID NO: 9, nucleotides 55-5021 of SEQ ID NO: 3, nucleotides 1-4977 of SEQ ID NO: 8, or nucleotides 56-5022 of SEQ ID NO: 6. In one embodiment, rAAV is AAVrh74.MCK.microdystrophin. In one embodiment, AAVrh74.MCK.microdystrophin is AAVrh74.MCK.microdystrophin of nucleotides 56-4820 of SEQ ID NO: 5.

[0118] In one embodiment, the composition disclosed herein is formulated for intravenous administration and is approximately 2.0 × 10 14 The present invention includes a dose of rAAV in vg / kg. In another embodiment, the composition is formulated for intravenous administration and is approximately 5.0 x 10 12 vg / kg, or approximately 6.0 x 10 12 vg / kg, or approximately 7.0 x 10 12vg / kg, or approximately 8.0 x 10 12 vg / kg, or approximately 9.0 x 10 12 vg / kg, or approximately 1.0 x 10 13 vg / kg, or approximately 1.25 x 10 13 vg / kg, or approximately 1.5 x 10 13 vg / kg, or approximately 1.75 x 10 13 vg / kg, or approximately 2.25 x 10 13 vg / kg, or approximately 2.5 x 10 13 vg / kg, or approximately 2.75 x 10 13 vg / kg, or approximately 3.0 x 10 13 vg / kg, or approximately 3.25 x 10 13 vg / kg, or approximately 3.5 x 10 13 vg / kg, or approximately 3.75 x 10 13 vg / kg, or approximately 4.0 x 10 13 vg / kg, or approximately 5.0 x 10 13 vg / kg, or approximately 6.0 x 10 13 vg / kg, or approximately 7.0 x 10 13 vg / kg, or approximately 8.0 x 10 13 vg / kg, or approximately 9.0 x 10 13 vg / kg, or approximately 1.0 x 10 14 vg / kg, or approximately 1.25 x 10 14 vg / kg, or approximately 1.5 x 10 14 vg / kg, or approximately 1.75 x 10 14 vg / kg, or approximately 2.25 x 10 14 vg / kg, or approximately 2.5 x 10 14 vg / kg, or approximately 2.75 x 10 14 vg / kg, or approximately 3.0 x 10 14 vg / kg, or approximately 3.25 x 10 14 vg / kg, or approximately 3.5 x 10 14 vg / kg, or approximately 3.75 x 10 14 vg / kg, or approximately 4.0 x 10 14 vg / kg, or approximately 5.0 x 10 14 vg / kg, or approximately 6.0 x 10 14 vg / kg, or approximately 1 x 10⁻⁶ 15The dosage of rAAV is vg / kg. In one embodiment, rAAV is AAVrh74.MHCK7.microdystrophin. In one embodiment, AAVrh74.MHCK7.microdystrophin is AAVrh74.MHCK7.microdystrophin of SEQ ID NO: 9, nucleotides 55-5021 of SEQ ID NO: 3, nucleotides 1-4977 of SEQ ID NO: 8, or nucleotides 56-5022 of SEQ ID NO: 6. In another embodiment, rAAV is AAVrh74.MCK.microdystrophin. In one embodiment, AAVrh74.MCK.microdystrophin is AAVrh74.MCK.microdystrophin of nucleotides 56-4820 of SEQ ID NO: 5.

[0119] In any of the compositions of this disclosure, the dose of rAAV is delivered at approximately 5 mL / kg to approximately 15 mL / kg, or approximately 8 mL / kg to approximately 12 mL / kg, or 8 mL / kg to approximately 10 mL / kg, or 5 mL / kg to approximately 10 mL / kg, or approximately 10 mL / kg to approximately 12 mL / kg, or approximately 10 mL / kg to approximately 15 mL / kg, or 10 mL / kg to approximately 20 mL / kg. In certain embodiments, the composition contains a dose of rAAV delivered at approximately 10 mL / kg. In one embodiment, rAAV is AAVrh74.MHCK7.microdystrophin. In one embodiment, AAVrh74.MHCK7.microdystrophin is AAVrh74.MHCK7.microdystrophin of SEQ ID NO: 9, nucleotides 55-5021 of SEQ ID NO: 3, nucleotides 1-4977 of SEQ ID NO: 8, or nucleotides 56-5022 of SEQ ID NO: 6. In another embodiment, rAAV is AAVrh74.MCK.microdystrophin. In one embodiment, AAVrh74.MCK.microdystrophin is AAVrh74.MCK.microdystrophin of nucleotides 56-4820 of SEQ ID NO: 5.

[0120] The compositions of this disclosure are formulated for administration by injection, infusion, or transplantation. For example, the compositions are formulated for administration by infusion over approximately one hour. In addition, the compositions of this disclosure are formulated for intravenous administration via peripheral limb veins, such as the peripheral brachial vein or peripheral leg vein. Alternatively, the infusion may be administered over approximately 30 minutes, or approximately 1.5 hours, or approximately 2 hours, or approximately 2.5 hours, or approximately 3 hours.

[0121] Any of the compositions of this disclosure includes an rAAV comprising the human microdystrophin nucleotide sequence of SEQ ID NO: 1 and the MHCK7 promoter sequence of SEQ ID NO: 2 or SEQ ID NO: 7, or an rAAV comprising the microdystrophin construct nucleotide sequence of AAVrh74.MHCK7 of SEQ ID NO: 9, nucleotides 55-5021 of SEQ ID NO: 3, nucleotides 1-4977 of SEQ ID NO: 8, or nucleotides 56-5022 of SEQ ID NO: 6.

[0122] In particular, the compositions of this disclosure are for the treatment of Duchenne muscular dystrophy or Becker muscular dystrophy. For example, this disclosure provides a composition for the treatment of Duchenne muscular dystrophy or Becker muscular dystrophy in human subjects requiring treatment of Duchenne muscular dystrophy or Becker muscular dystrophy, the composition comprising a dose of recombinant adenovirus-associated (rAAV) rAAV.MHCK7.microdystrophin, the composition being formulated for administration by intravenous infusion over approximately 1 hour, and the dose of rAAV administered is approximately 2 × 10⁻⁶ 14 The value is vg / kg, and rAAV contains the AAVrh74.MHCK7.microdystrophin construct nucleotide sequence of SEQ ID NO: 9, nucleotides 55-5021 of SEQ ID NO: 3, nucleotides 1-4977 of SEQ ID NO: 8, or nucleotides 56-5022 of SEQ ID NO: 6.

[0123] In another embodiment, the disclosure also provides compositions comprising rAAV for reducing fibrosis in subjects requiring reduction of fibrosis. Furthermore, the disclosure provides compositions comprising rAAV vectors for preventing fibrosis in subjects suffering from muscular dystrophy.

[0124] The Disclosure also provides compositions comprising rAAV for increasing muscle strength and / or muscle mass in subjects suffering from muscular dystrophy. In a further embodiment, the Disclosure provides compositions comprising any of the rAAVs of the Disclosure for the treatment of muscular dystrophy.

[0125] In any other embodiment of the compositions of this disclosure, after administration of the composition to a human subject requiring treatment for muscular dystrophy, the serum CK level in the subject decreases by a percentage level selected from the group consisting of the following, compared to the serum CK level before administration of the composition: a) At least 78% within 90, 180, or 270 days after administration; b) At least 46%, 55%, 70%, or 85% within 270 days after administration; c) At least 72, 73, 74, or 95% within 180 days after administration; d) At least 87%, 99%, 93%, or 95% within 90 days after administration; e) At least 70% within 270 days after administration; f) 70-95% within 90, 180, or 270 days after administration; g) at least 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, or 95% within 90, 180, or 270 days after administration; and h) 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, or 95% by 90, 180, or 270 days after administration.

[0126] In another embodiment, the disclosure provides the use of a dose of recombinant adenovirus-associated (rAAV) rAAV.MHCK7.microdystrophin for the preparation of a drug for the treatment of muscular dystrophy in human subjects requiring treatment of muscular dystrophy, wherein the drug is formulated for a systemic route of administration, and the dose of rAAV is approximately 1 × 10⁻⁶ 14 vg / kg ~ approx. 4×10 14 The value is vg / kg. In one embodiment, rAAV is AAVrh74.MHCK7.microdystrophin. In one embodiment, AAVrh74.MHCK7.microdystrophin is AAVrh74.MHCK7.microdystrophin of SEQ ID NO: 9, nucleotides 55-5021 of SEQ ID NO: 3, nucleotides 1-4977 of SEQ ID NO: 8, or nucleotides 56-5022 of SEQ ID NO: 6. In one embodiment, rAAV is AAVrh74.MCK.microdystrophin. In one embodiment, AAVrh74.MCK.microdystrophin is AAVrh74.MCK.microdystrophin of nucleotides 56-4820 of SEQ ID NO: 5.

[0127] For example, the drug is approximately 5.0 × 10 12 vg / kg ~ approx. 1.0×10 14 vg / kg, or approximately 5.0 × 10⁻⁶ 12 vg / kg~1.0×10 14 vg / kg, or approximately 5.0 × 10⁻⁶ 12 vg / kg ~ approx. 2.0×10 14 vg / kg, or approximately 5.0 × 10⁻⁶ 12 vg / kg ~ approx. 1.0×10 14 vg / kg, or approximately 5.0 × 10⁻⁶ 12 vg / kg ~ approx. 5.0×10 13 vg / kg, or approximately 5.0 × 10⁻⁶ 12 vg / kg ~ approx. 2.0×10 13 vg / kg, or approximately 5.0 × 10⁻⁶ 12 vg / kg ~ approx. 1.0×10 13 vg / kg, or 1.0 × 10 14 vg / kg ~ approx. 1.0×10 15 vg / kg, or 1.0 × 10 13 vg / kg ~ approx. 1.0×1014 vg / kg, or approximately 1.0 × 10⁻⁶ 13 vg / kg~1.0×10 14 vg / kg, or approximately 1.0 × 10⁻⁶ 13 vg / kg ~ approx. 2.0×10 14 vg / kg, or approximately 1.0 × 10⁻⁶ 13 vg / kg ~ approx. 1.0×10 14 vg / kg, or approximately 1.0 × 10⁻⁶ 13 vg / kg ~ approx. 5.0×10 13 vg / kg, or approximately 1.0 × 10⁻⁶ 13 vg / kg ~ approx. 3.0×10 14 vg / kg, or approximately 1.0 × 10⁻⁶ 13 vg / kg ~ approx. 5.0×10 14 vg / kg, or approximately 1.0 × 10⁻⁶ 13 vg / kg ~ approx. 6.0×10 14 vg / kg, or 1.0 × 10 13 vg / kg ~ approx. 1.0×10 15 vg / kg, or 5.0 × 10 13 vg / kg ~ approx. 1.0×10 14 vg / kg, or approximately 5.0 × 10⁻⁶ 13 vg / kg~1.0×10 14 vg / kg, or approximately 5.0 × 10⁻⁶ 13 vg / kg ~ approx. 2.0×10 14 vg / kg, or approximately 5.0 × 10⁻⁶ 13 vg / kg ~ approx. 1.0×10 14 vg / kg, or approximately 5.0 × 10⁻⁶ 13 vg / kg ~ approx. 3.0×10 14 vg / kg, or approximately 5.0 × 10⁻⁶ 13 vg / kg ~ approx. 5.0×10 14 vg / kg, or approximately 5.0 × 10⁻⁶ 13 vg / kg ~ approx. 6.0×10 14 vg / kg, or 5.0 × 10 13 vg / kg ~ approx. 1.0×10 15 vg / kg, or 1.0 × 10 14 vg / kg ~ approx. 6.0×10 14 vg / kg, or 1.0 × 10 14 vg / kg ~ approx. 5.0×10 14 vg / kg, or 1.0 × 10 14vg / kg ~ approx. 4.0×10 14 vg / kg, or 1.0 × 10 14 vg / kg ~ approx. 1.0×10 15 vg / kg, or 1.0 × 10 14 vg / kg ~ approx. 3.0×10 14 vg / kg, or approximately 1.0 × 10⁻⁶ 14 vg / kg ~ approx. 2.5×10 14 vg / kg, or 1.0 × 10 14 vg / kg ~ approx. 2.0×10 14 vg / kg, or approximately 1.25 × 10⁻⁶ 14 vg / kg ~ approx. 3.75×10 14 vg / kg, or approximately 1.25 × 10⁻⁶ 14 vg / kg~6.0×10 14 , or approximately 1.25 × 10 14 vg / kg~5.0×10 14 , or approximately 1.25 × 10 14 vg / kg~4.0×10 14 , or approximately 1.25 × 10 14 vg / kg~1.0×10 15 , or approximately 1.25 × 10 14 vg / kg ~ approx. 3.5×10 14 vg / kg, or approximately 1.25 × 10⁻⁶ 14 vg / kg ~ approx. 3.0×10 14 vg / kg, or approximately 1.25 × 10⁻⁶ 14 vg / kg ~ approx. 2.75×10 14 vg / kg, or approximately 1.25 × 10⁻⁶ 14 vg / kg ~ approx. 2.5×10 14 vg / kg, or approximately 1.25 × 10⁻⁶ 14 vg / kg ~ approx. 2.0×10 14 vg / kg, or 1.25 × 10⁻⁶ 14 vg / kg ~ approx. 3.75×10 14 vg / kg, or approximately 1.25 × 10⁻⁶ 14 vg / kg ~ approx. 3.5×10 14 vg / kg, or 1.5 × 10⁻⁶ 14 vg / kg ~ approx. 1.0×10 15 vg / kg, or approximately 1.5 × 10⁻⁶ 14 vg / kg~6.0×10 14 , or approximately 1.5 × 1014 vg / kg~5.0×10 14 , or approximately 1.5 × 10 14 vg / kg~4.0×10 14 , or approximately 1.5 × 10 14 vg / kg ~ approx. 3.75×10 14 vg / kg, or approximately 1.5 × 10⁻⁶ 14 vg / kg ~ approx. 3.5×10 14 vg / kg, or approximately 1.5 × 10⁻⁶ 14 vg / kg ~ approx. 3.25×10 14 vg / kg, or approximately 1.5 × 10⁻⁶ 14 vg / kg ~ approx. 3.0×10 14 vg / kg, or approximately 1.5 × 10⁻⁶ 14 vg / kg ~ approx. 2.75×10 14 vg / kg, or approximately 1.5 × 10⁻⁶ 14 vg / kg ~ approx. 2.5×10 14 vg / kg, or approximately 1.5 × 10⁻⁶ 14 vg / kg ~ approx. 2.0×10 14 vg / kg, or 1.75 × 10⁻⁶ 14 vg / kg ~ approx. 1.0×10 15 vg / kg, or approximately 1.75 × 10⁻⁶ 14 vg / kg~6.0×10 14 , or approximately 1.75 × 10 14 vg / kg~5.0×10 14 , or approximately 1.75 × 10 14 vg / kg~4.0×10 14 , or approximately 1.75 × 10 14 vg / kg ~ approx. 3.75×10 14 vg / kg, or approximately 1.75 × 10⁻⁶ 14 vg / kg ~ approx. 3.5×10 14 vg / kg, or approximately 1.75 × 10⁻⁶ 14 vg / kg ~ approx. 3.25×10 14 vg / kg, or approximately 1.75 × 10⁻⁶ 14 vg / kg ~ approx. 3.0×10 14 vg / kg, or approximately 1.75 × 10⁻⁶ 14 vg / kg ~ approx. 2.75×10 14 vg / kg, or approximately 1.75 × 10⁻⁶ 14 vg / kg ~ approx. 2.5×10 14vg / kg, or approximately 1.75 × 10⁻⁶ 14 vg / kg ~ approx. 2.25×10 14 vg / kg, or approximately 1.75 × 10⁻⁶ 14 vg / kg ~ approx. 2.0×10 14 vg / kg, or approximately 2.0 × 10⁻⁶ 14 vg / kg~1.0×10 15 , or approximately 2.0 × 10 14 vg / kg~6.0×10 14 , or approximately 2.0 × 10 14 vg / kg~5.0×10 14 , or approximately 2.0 × 10 14 vg / kg ~ approx. 4.0×10 14 vg / kg, or approximately 2.0 × 10⁻⁶ 14 vg / kg ~ approx. 3.75×10 14 vg / kg, or approximately 2.0 × 10⁻⁶ 14 vg / kg ~ approx. 3.5×10 14 vg / kg, or approximately 2.0 × 10⁻⁶ 14 vg / kg ~ approx. 3.25×10 14 The dosage of rAAV is vg / kg. In one embodiment, rAAV is AAVrh74.MHCK7.microdystrophin. In one embodiment, AAVrh74.MHCK7.microdystrophin is AAVrh74.MHCK7.microdystrophin of SEQ ID NO: 9, nucleotides 55-5021 of SEQ ID NO: 3, nucleotides 1-4977 of SEQ ID NO: 8, or nucleotides 56-5022 of SEQ ID NO: 6. In one embodiment, rAAV is AAVrh74.MCK.microdystrophin. In one embodiment, AAVrh74.MCK.microdystrophin is AAVrh74.MCK.microdystrophin of nucleotides 56-4820 of SEQ ID NO: 5.

[0128] In one embodiment, the drug of the present disclosure is administered via an intravenous route, and the dose of rAAV administered is approximately 2.0 × 10⁶ 14 The drug is formulated for systemic administration of a dose of rAAV of vg / kg. In another embodiment, the drug of the present disclosure is formulated for a systemic route of administration, the systemic route of administration being an intravenous route, and the dose of rAAV is approximately 5.0 × 10⁻⁶ 12vg / kg, or approximately 6.0 × 10⁻⁶ 12 vg / kg, or approximately 7.0 × 10⁻⁶ 12 vg / kg, or approximately 8.0 × 10⁻⁶ 12 vg / kg, or approximately 9.0 × 10⁻⁶ 12 vg / kg, or approximately 1.0 × 10⁻⁶ 13 vg / kg, or approximately 1.25 × 10⁻⁶ 13 vg / kg, or approximately 1.5 × 10⁻⁶ 13 vg / kg, or approximately 1.75 × 10⁻⁶ 13 vg / kg, or approximately 2.25 × 10⁻⁶ 13 vg / kg, or approximately 2.5 × 10⁻⁶ 13 vg / kg, or approximately 2.75 × 10⁻⁶ 13 vg / kg, or approximately 3.0 × 10⁻⁶ 13 vg / kg, or approximately 3.25 × 10⁻⁶ 13 vg / kg, or approximately 3.5 × 10⁻⁶ 13 vg / kg, or approximately 3.75 × 10⁻⁶ 13 vg / kg, or approximately 4.0 × 10⁻⁶ 13 vg / kg, or approximately 5.0 × 10⁻⁶ 13 vg / kg, or approximately 6.0 × 10⁻⁶ 13 vg / kg, or approximately 7.0 × 10⁻⁶ 13 vg / kg, or approximately 8.0 × 10⁻⁶ 13 vg / kg, or approximately 9.0 × 10⁻⁶ 13 vg / kg, or approximately 1.0 × 10⁻⁶ 14 vg / kg, or approximately 1.25 × 10⁻⁶ 14 vg / kg, or approximately 1.5 × 10⁻⁶ 14 vg / kg, or approximately 1.75 × 10⁻⁶ 14 vg / kg, or approximately 2.25 × 10⁻⁶ 14 vg / kg, or approximately 2.5 × 10⁻⁶ 14 vg / kg, or approximately 2.75 × 10⁻⁶ 14 vg / kg, or approximately 3.0 × 10⁻⁶ 14 vg / kg, or approximately 3.25 × 10⁻⁶ 14 vg / kg, or approximately 3.5 × 10⁻⁶ 14 vg / kg, or approximately 3.75 × 10⁻⁶ 14 vg / kg, or approximately 4.0 × 10⁻⁶ 14 vg / kg, or approximately 5.0 × 10⁻⁶ 14 vg / kg, or approximately 6.0 × 10⁻⁶ 14vg / kg, or approximately 1 × 10⁻⁶ 15 The rAAV is formulated for systemic administration at a dose of vg / kg. In one embodiment, rAAV is AAVrh74.MHCK7.microdystrophin. In one embodiment, AAVrh74.MHCK7.microdystrophin is AAVrh74.MHCK7.microdystrophin of SEQ ID NO: 9, nucleotides 55-5021 of SEQ ID NO: 3, nucleotides 1-4977 of SEQ ID NO: 8, or nucleotides 56-5022 of SEQ ID NO: 6. In one embodiment, rAAV is AAVrh74.MCK.microdystrophin. In one embodiment, AAVrh74.MCK.microdystrophin is AAVrh74.MCK.microdystrophin of nucleotides 56-4820 of SEQ ID NO: 5.

[0129] In any use of this disclosure, the agent comprises a dose of rAAV of approximately 5 mL / kg to approximately 15 mL / kg, or approximately 8 mL / kg to approximately 12 mL / kg, or 8 mL / kg to approximately 10 mL, or 5 mL / kg to approximately 10 mL / kg, or approximately 10 mL / kg to approximately 12 mL / kg, or approximately 10 mL / kg to approximately 15 mL / kg, or 10 mL / kg to approximately 20 mL / kg. In certain embodiments, the dose of rAAV is approximately 10 mL / kg. In one embodiment, rAAV is AAVrh74.MHCK7.microdystrophin. In one embodiment, AAVrh74.MHCK7.microdystrophin is AAVrh74.MHCK7.microdystrophin of SEQ ID NO: 9, nucleotides 55-5021 of SEQ ID NO: 3, nucleotides 1-4977 of SEQ ID NO: 8, or nucleotides 56-5022 of SEQ ID NO: 6. In one embodiment, rAAV is AAVrh74.MCK.microdystrophin. In one embodiment, AAVrh74.MCK.microdystrophin is AAVrh74.MCK.microdystrophin of nucleotides 56-4820 of SEQ ID NO: 5.

[0130] In any use of this disclosure, the drug is formulated for administration by injection, infusion, or implantation. For example, the drug is formulated for administration by infusion over approximately one hour. In addition, the drug is formulated for intravenous administration via peripheral limb veins, such as the brachial or leg veins. Alternatively, the infusion may be administered over approximately 30 minutes, or approximately 1.5 hours, or approximately 2 hours, or approximately 2.5 hours, or approximately 3 hours.

[0131] In any use of this disclosure, the drug comprises an rAAV containing the human microdystrophin nucleotide sequence of SEQ ID NO: 1 and the MHCK7 promoter sequence of SEQ ID NO: 2 or SEQ ID NO: 7, or the AAVrh74.MHCK7 microdystrophin construct nucleotide sequence of SEQ ID NO: 9, nucleotides 55-5021 of SEQ ID NO: 3, nucleotides 1-4977 of SEQ ID NO: 8, or nucleotides 56-5022 of SEQ ID NO: 6.

[0132] The specific use of this disclosure is for the preparation of agents for the treatment of Duchenne muscular dystrophy or Becker muscular dystrophy. For example, this disclosure provides the use of a dose of recombinant adenovirus-associated (rAAV) rAAV.MHCK7.microdystrophin for the preparation of agents for the treatment of Duchenne muscular dystrophy or Becker muscular dystrophy in human subjects requiring treatment of Duchenne muscular dystrophy or Becker muscular dystrophy, wherein the drug is formulated for administration by intravenous infusion over approximately 1 hour, and the dose of rAAV administered is approximately 2 × 10⁻¹⁶ 14 The value is vg / kg, and rAAV contains the AAVrh74.MHCK7.microdystrophin construct nucleotide sequence of SEQ ID NO: 9, nucleotides 55-5021 of SEQ ID NO: 3, nucleotides 1-4977 of SEQ ID NO: 8, or nucleotides 56-5022 of SEQ ID NO: 6.

[0133] In further embodiments, the disclosure provides the use of rAAV for the preparation of agents for reducing fibrosis in subjects requiring fibrosis reduction. For example, the subject in need may have a muscular dystrophy such as DMD or any other dystrophin-related muscular dystrophy.

[0134] In another embodiment, the disclosure provides the use of rAAV for the preparation of a drug to prevent fibrosis in subjects suffering from muscular dystrophy.

[0135] In addition, this disclosure provides the use of rAAV for the preparation of agents to increase muscle strength and / or muscle mass in subjects suffering from muscular dystrophy.

[0136] The present invention also provides the use of rAAV for the preparation of drugs for the treatment of muscular dystrophy.

[0137] This disclosure provides the use of an rAAV vector comprising the human microdystrophin nucleotide sequence of SEQ ID NO: 1 and the MHCK7 promoter nucleotide sequence of SEQ ID NO: 2 or SEQ ID NO: 7 for the preparation of a drug for the treatment of muscular dystrophy, or the use of an rAAV vector comprising the AAVrf74.MHCK7.microdystrophin construct nucleotide sequence of SEQ ID NO: 9, nucleotides 55-5021 of SEQ ID NO: 3, nucleotides 1-4977 of SEQ ID NO: 8, or nucleotides 56-5022 of SEQ ID NO: 6 for muscular dystrophy.

[0138] In any other embodiment of the use of this disclosure, the serum CK level in the subject decreases by a percentage level selected from the group below, compared to the serum CK level before administration of rAAV, after administration of rAAV to the subject: a) At least 78% within 90, 180, or 270 days after administration; b) At least 46%, 55%, 70%, or 95% within 270 days after administration; c) At least 72, 73, 74, or 95% within 180 days after administration; d) At least 87%, 88%, 93%, or 95% within 90 days after administration; e) At least 70% within 270 days after administration; f) 70-95% within 90, 180, or 270 days after administration; g) at least 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, or 95% within 90, 180, or 270 days after administration; and h) 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, or 95% by 90, 180, or 270 days after administration.

[0139] In any case of combination therapy, the use of compositions for treating muscular dystrophy, or the use of drugs for treating muscular dystrophy, the level of microdystrophin gene expression in the target cells increases after administration of the composition or drug. Microdystrophin gene expression in cells is detected by measuring microdystrophin protein levels by Western blotting in muscle biopsies taken before and after administration of the composition or drug. In particular, the level of microdystrophin protein increases by at least about 70% to at least about 80%, or at least about 70% to at least about 90%, or at least about 80% to at least about 90%, after administration of the composition or drug compared to the level of microdystrophin before administration of the composition or drug. For example, the level of microdystrophin protein increases by at least about 70%, at least about 71%, at least about 72%, at least about 73%, at least about 74%, at least about 75%, at least about 76%, at least about 77%, at least about 78%, at least about 79%, at least about 80%, at least about 81%, at least about 82%, at least about 83%, at least about 84%, or at least about 85% after administration of the composition or drug, compared to the level of microdystrophin before administration of the composition or drug.

[0140] In addition, intracellular microdystrophin gene expression is detected by measuring microdystrophin protein levels by immunohistochemistry in muscle biopsies before and after administration of the composition or drug. Microdystrophin protein levels increase by at least approximately 70% to at least approximately 80%, or at least approximately 70% to at least approximately 90%, or at least approximately 80% to at least approximately 90%, compared to the level of microdystrophin before administration of the composition or drug, after administration of rAAV. For example, microdystrophin protein levels increase by at least approximately 70%, at least approximately 71%, at least approximately 72%, at least approximately 73%, at least approximately 74%, at least approximately 75%, at least approximately 76%, at least approximately 77%, at least approximately 78%, at least approximately 79%, at least approximately 80%, at least approximately 81%, at least approximately 82%, at least approximately 83%, at least approximately 84%, or at least approximately 85%, compared to the level of microdystrophin before administration of the composition or drug.

[0141] In any of the combination therapies, compositions for treating muscular dystrophy, and drugs for treating muscular dystrophy, serum CK levels in subjects decrease after administration of rAAV compared to serum CK levels before administration of the composition or drug. For example, serum CK levels in subjects decrease by approximately 65% ​​to 90%, 65% to 95%, 75% to 90%, 80% to 90%, 85% to 95%, 87% to 95%, or 87% to 90% by 60 days after administration of rAAV compared to serum CK levels before administration of the composition or drug. In particular, in any of the combination therapies, compositions, and drugs for treating muscular dystrophy described herein, serum CK levels in subjects decrease by approximately 87% by 60 days after administration of rAAV compared to serum CK levels before administration of rAAV. In any of the combination therapies, compositions for treating muscular dystrophy, or agents for treating muscular dystrophy described herein, the serum CK level in the subject decreases by approximately 72% by 60 days after administration of rAAV compared to the serum CK level before administration of the composition or agent, or in any of the combination therapies, compositions for treating muscular dystrophy, or agents for treating muscular dystrophy described herein, the serum CK level in the subject decreases by approximately 73% by 60 days after administration of rAAV compared to the serum CK level before administration of rAAV, or in any of the combination therapies, compositions for treating muscular dystrophy, or agents for treating muscular dystrophy described herein. In either the use of a composition for treating dystrophy or an agent for treating muscular dystrophy, the serum CK level in the subject decreases by approximately 78% by 60 days after administration of rAAV compared to the serum CK level before administration of the combination therapy, composition, or agent, or in either the use of the combination therapy, composition for treating muscular dystrophy, or agent for treating muscular dystrophy as disclosed herein, the serum CK level in the subject decreases by approximately 95% by 60 days after administration of rAAV compared to the serum CK level before administration of the combination therapy, composition, or agent.In any case of combination therapy, composition for treating muscular dystrophy, or drug for treating muscular dystrophy, the number of microdystrophin-positive fibers in the target muscle tissue increases after administration of the combination therapy, composition, or drug compared to the number of microdystrophin-positive fibers before administration of rAAV. For example, the number of microdystrophin-positive fibers can be detected by measuring microdystrophin protein levels by Western blotting or immunohistochemistry in muscle biopsies before and after administration of the combination therapy, composition, or drug.

[0142] In any case involving combination therapy, compositions for treating muscular dystrophy, or the use of drugs for treating muscular dystrophy, administration of the composition or drug upregulates the expression of DAPC proteins such as alpha-sarcoglycans or beta-sarcoglycans. For example, the level of alpha-sarcoglycans in a subject increases after administration of rAAV compared to the level of alpha-sarcoglycans before administration of combination therapy, composition, or drug. The level of alpha-sarcoglycans is detected by measuring alpha-sarcoglycan or beta-sarcoglycan protein levels by Western blotting or immunohistochemistry in muscle biopsies before and after rAAV administration.

[0143] In any case of combination therapy, compositions for treating muscular dystrophy, or the use of drugs for treating muscular dystrophy, disease progression in subjects is delayed after administration of rAAV, as measured by any of the following: 6-minute walk test, stand-up time, 4-step rise, 4-step drop, North Star Ambulatory Assessment (NSAA), 10-meter timed test, 100-meter timed test, handheld dynamometry (HHD), Timed Up and Go, and / or Gross Motor Subtest Scaled (Bayley-III) score.

[0144] For example, after administration of any combination therapy, composition for treating muscular dystrophy, or drug for treating muscular dystrophy, subjects have an improvement of at least 6 points in their NSAA score at least 270 days after administration of the composition or drug, compared to their NSAA score before administration of rAAV. Furthermore, in any of the methods, combination therapy, composition for treating muscular dystrophy, or drug for treating muscular dystrophy, subjects have an improvement of at least about 0.8 seconds in their rise time at least 270 days after administration of rAAV, compared to their rise time before administration of the combination therapy, composition, or drug. In addition, in any of the methods, combination therapy, composition, or use of the present disclosure, subjects have an improvement of at least about 1.2 seconds in their four-step rise test time at least 270 days after administration of rAAV, compared to their four-step rise test time before administration of the combination therapy, composition, or drug. In addition, in any of the methods, combination therapies, compositions, or uses of this disclosure, the subject has an improvement of at least about 7 seconds in the 100m timing test at least 270 days after administration of rAAV compared to the 100m timing test before administration of rAAV.

[0145] In another embodiment, the Disclosure provides a composition for expressing the microdystrophin gene in patient cells, comprising the AAVrh74.MHCK7.microdystrophin construct nucleotide sequence of SEQ ID NO: 9, nucleotides 55-5021 of SEQ ID NO: 3, nucleotides 1-4977 of SEQ ID NO: 8, or nucleotides 56-5022 of SEQ ID NO: 6. In a further embodiment, the Disclosure provides the use of doses of the composition AAVrh74.MHCK7.microdystrophin construct nucleotide sequence of SEQ ID NO: 9, nucleotides 55-5021 of SEQ ID NO: 3, nucleotides 1-4977 of SEQ ID NO: 8, or nucleotides 56-5022 of SEQ ID NO: 6 for the preparation of a drug for expressing the microdystrophin gene in patient cells. For example, the expression of the microdystrophin gene in patient cells is detected by measuring microdystrophin protein levels by Western blotting or immunohistochemistry in muscle biopsies before and after administration of the rAAV.MHCK7.microdystrophin construct. In addition, microdystrophin gene expression is measured in patients by detecting more vector genomes per nucleus, with one vector genome per nucleus corresponding to approximately 50% microdystrophin expression, and more than one copy per nucleus corresponding to microdystrophin expression levels. For example, cells may have 1.2 vector copies per nucleus, or 1.3 vector copies per nucleus, or 1.4 vector copies per nucleus, or 1.5 vector copies per nucleus, or 1.6 vector copies per nucleus, or 1.7 vector copies per nucleus, or 1.8 vector copies per nucleus, or 1.9 vector copies per nucleus.

[0146] In further embodiments, the Disclosure provides a composition for lowering serum CK levels in patients requiring a reduction in serum CK levels, the composition comprising the AAVrh74.MHCK7.microdystrophin construct nucleotide sequence of SEQ ID NO: 9, nucleotides 55-5021 of SEQ ID NO: 3, nucleotides 1-4977 of SEQ ID NO: 8, or nucleotides 56-5022 of SEQ ID NO: 6. In addition, the Disclosure provides the use of doses of the AAVrh74.MHCK7.microdystrophin construct nucleotide sequence of SEQ ID NO: 9, nucleotides 55-5021 of SEQ ID NO: 3, nucleotides 1-4977 of SEQ ID NO: 8, or nucleotides 56-5022 of SEQ ID NO: 6 for the preparation of a drug for lowering serum CK levels in patients requiring a reduction in serum CK levels. For example, serum CK levels in patients decrease by at least approximately 65% ​​to 90%, 65% to 95%, 75% to 90%, 80% to 90%, 85% to 95%, 87% to 95%, or 87% to 90% by 60 days after administration of the composition or drug, compared to serum CK levels before administration of the composition or drug. In particular, the serum CK level in the subjects decreases by approximately 87% within 60 days after administration of the composition or drug compared to the serum CK level before administration of the composition or drug, or decreases by approximately 72% within 60 days after administration of the composition or drug compared to the serum CK level before administration of the composition or drug, or decreases by approximately 73% within 60 days after administration of the composition or drug compared to the serum CK level before administration of the composition or drug, or decreases by approximately 78% within 60 days after administration of the composition or drug compared to the serum CK level before administration of the composition or drug, or decreases by approximately 95% within 60 days after administration of the composition or drug compared to the serum CK level before administration of the composition or drug.

[0147] This disclosure also provides compositions that increase microdystrophin-positive fibers in patient muscle tissue, comprising the AAVrh74.MHCK7.microdystrophin construct nucleotide sequence of SEQ ID NO: 9, nucleotides 55-5021 of SEQ ID NO: 3, nucleotides 1-4977 of SEQ ID NO: 8, or nucleotides 56-5022 of SEQ ID NO: 6. In addition, this disclosure provides the use of doses of the AAVrh74.MHCK7.microdystrophin construct nucleotide sequence of SEQ ID NO: 9, nucleotides 55-5021 of SEQ ID NO: 3, nucleotides 1-4977 of SEQ ID NO: 8, or nucleotides 56-5022 of SEQ ID NO: 6 for the preparation of agents that increase microdystrophin-positive fibers in patient muscle tissue. For example, the number of microdystrophin-positive fibers is detected by measuring dystrophin protein levels by Western blotting or immunohistochemistry in muscle biopsies before and after administration of the composition or agent. In addition, microdystrophin gene expression is measured in patients by detecting more vector genomes per nucleus, with one vector genome per nucleus corresponding to approximately 50% microdystrophin expression, and more than one copy per nucleus corresponding to microdystrophin expression levels. For example, cells may have 1.2 vector copies per nucleus, or 1.3 vector copies per nucleus, or 1.4 vector copies per nucleus, or 1.5 vector copies per nucleus, or 1.6 vector copies per nucleus, or 1.7 vector copies per nucleus, or 1.8 vector copies per nucleus, or 1.9 vector copies per nucleus.

[0148] In another embodiment, the Disclosure provides a composition for increasing alpha-sarcoglycan expression in patients requiring alpha-sarcoglycan expression, comprising the AAVrh74.MHCK7.microdystrophin construct nucleotide sequence of SEQ ID NO: 9, nucleotides 55-5021 of SEQ ID NO: 3, nucleotides 1-4977 of SEQ ID NO: 8, or nucleotides 56-5022 of SEQ ID NO: 6. The Disclosure also provides the use of doses of the AAVrh74.MHCK7.microdystrophin construct nucleotide sequence of SEQ ID NO: 9, nucleotides 55-5021 of SEQ ID NO: 3, nucleotides 1-4977 of SEQ ID NO: 8, or nucleotides 56-5022 of SEQ ID NO: 6 for the preparation of a drug for increasing alpha-sarcoglycan expression in patients requiring alpha-sarcoglycan expression. For example, alpha-sarcoglycan levels are detected by measuring alpha-sarcoglycan protein levels by Western blotting or immunohistochemistry in muscle biopsies before and after administration of the composition or drug.

[0149] In addition, this disclosure provides a composition for increasing beta-sarcoglycan expression in patients requiring beta-sarcoglycan expression, comprising the AAVrh74.MHCK7.microdystrophin construct nucleotide sequence of SEQ ID NO: 9, nucleotides 55-5021 of SEQ ID NO: 3, nucleotides 1-4977 of SEQ ID NO: 8, or nucleotides 56-5022 of SEQ ID NO: 6. This disclosure also provides the use of the AAVrh74.MHCK7.microdystrophin construct nucleotide sequence of SEQ ID NO: 9, nucleotides 55-5021 of SEQ ID NO: 3, nucleotides 1-4977 of SEQ ID NO: 8, or nucleotides 56-5022 of SEQ ID NO: 6 for the preparation of a drug for increasing beta-sarcoglycan expression in patients requiring beta-sarcoglycan expression. For example, beta-sarcoglycan levels are detected by measuring beta-sarcoglycan protein levels by Western blotting or immunohistochemistry in muscle biopsies before and after administration of the composition or drug.

[0150] This disclosure also provides the use of doses of the AAVrh74.MHCK7.microdystrophin construct nucleotide sequence of SEQ ID NO: 9, nucleotides 55-5021 of SEQ ID NO: 3, nucleotides 1-4977 of SEQ ID NO: 8, or nucleotides 56-5022 of SEQ ID NO: 6 for the preparation of drugs for treating patients with Duchenne muscular dystrophy or Becker muscular dystrophy, such that the administration of a drug causing disease progression in the patient is measured by one of the following: 6-minute walk test, stand-up time, 4-step rise, 4-step rise, North Star Ambulatory Assessment (NSAA), 10-meter timed test, 100-meter timed test, handheld dynamometry (HHD), Timed Up and Go, and / or Gross Motor Subtest Scaled (Bayley-III) score.

[0151] For example, a subject shows an improvement of at least 6 points in their NSAA score at least 270 days after rAAV administration compared to their NSAA score before rAAV administration. Furthermore, a subject shows an improvement of at least approximately 0.8 seconds in their rise time at least 270 days after rAAV administration compared to their rise time before rAAV administration. In addition, a subject shows an improvement of at least approximately 1.2 seconds in their 4-step rise test time at least 270 days after rAAV administration compared to their 4-step rise test time before administration of the composition or drug. Furthermore, a subject shows an improvement of at least approximately 7 seconds in their 100m timing test at least 270 days after rAAV administration compared to their 100m timing test time before administration of the composition or drug. The present invention provides, for example, the following items: (Item 1) A method for treating muscular dystrophy in human subjects requiring treatment for muscular dystrophy, comprising the step of administering recombinant adenovirus-related (rAAV) and an anti-inflammatory steroid, wherein the rAAV is selected from the group consisting of rAAV.MHCK7.microdystrophin, AAVrh.74.tMCK.CAPN3, rAAVrh.74.MHCK7.DYSF, scAAVrh.74.MHCK7.hSGCG, AAVrh74.tMCK.hSCGA, scAAVrh74.MHCK7.HSGCB, and rAAVrh.74.MHCK7.huAN05. (Item 2) The method according to item 1, wherein the muscular dystrophy is Duchenne muscular dystrophy and the rAAV is rAAV.MHCK7.microdystrophin. (Item 3) The method according to item 1, wherein the muscular dystrophy is limb-girdle muscular dystrophy, and the rAAV is selected from the group consisting of AAVrh.74.tMCK.CAPN3, rAAVrh.74.MHCK7.DYSF, scAAVrh.74.MHCK7.hSGCG, AAVrh74.tMCK.hSCGA, scAAVrh74.MHCK7.HSGCB, and rAAVrh.74.MHCK7.huAN05. (Item 4) The method according to any one of items 1 to 3, wherein the anti-inflammatory steroid is administered approximately 24 hours before the administration of the rAAV. (Item 5) The method according to any one of items 1 to 3, wherein the anti-inflammatory steroid is administered at least once a day for about 14 days prior to the administration of the rAAV. (Item 6) The method according to any one of items 1 to 5, wherein the anti-inflammatory steroid is administered before the administration of the rAAV, and the anti-inflammatory steroid is administered at least once a day from day 1 to day 30 after the administration of the rAAV, or at least once a day from day 1 to day 60 after the administration of the rAAV. (Item 7) The method according to any one of items 1 to 6, wherein an anti-inflammatory steroid is administered orally. (Item 8) The method according to any one of items 1 to 7, wherein the anti-inflammatory steroid is a glucocorticoid. (Item 9) The method according to any one of items 1 to 7, wherein the anti-inflammatory steroid is prednisone, prednisolone, betamethasone, dexamethasone, hydrocortisone, methylprednisolone, or deflazacort. (Item 10) The method according to any one of items 1 to 9, further comprising the step of administering an anti-CD20 specific antibody before administering the rAAV. (Item 11) The method according to item 10, wherein the anti-CD-20 specific antibody is administered at least 7 days before the administration of the rAAV. (Item 12) The method according to item 10 or 11, wherein the anti-CD20 specific antibody is administered at least 14 days before the administration of the rAAV. (Item 13) The method according to item 10, wherein the anti-CD20 specific antibody is administered approximately 14 days before the administration of the rAAV, approximately 7 days before the administration of the rAAV, and within approximately 24 hours of the administration of the rAAV. (Item 14) The method according to any one of items 10 to 13, further comprising the step of administering an anti-CD20 specific antibody after the administration of the rAAV. (Item 15) The method according to any one of items 10 to 14, wherein the anti-CD20 specific antibody is rituximab, ocrelizumab, or ofatumumab. (Item 16) The method according to any one of items 1 to 15, further comprising the step of administering an immunosuppressive macrolide. (Item 17) The method according to item 16, wherein the immunosuppressive macrolide is administered at least once daily for at least 3 days prior to the administration of the rAAV. (Item 18) The method according to item 16 or 17, wherein the immunosuppressive macrolide is administered after the administration of the rAAV. (Item 19) The method according to any one of items 16 to 18, wherein the immunosuppressive macrolide is administered orally. (Item 20) The method according to any one of items 16 to 19, wherein the immunosuppressive macrolide is tacrolimus, pinecrolimus, or sirolimus. (Item 21) A method for treating muscular dystrophy in human subjects requiring treatment for muscular dystrophy, comprising administering recombinant adenovirus-related (rAAV) and an immunosuppressive regimen, wherein the immunosuppressive regimen comprises administering one or more of the following: an anti-inflammatory steroid, an anti-CD20 antibody, and an immunosuppressive macrolide, and the rAAV is selected from the group consisting of AAVrh.74.MHCK7.microdystrophin, AAVrh.74.tMCK.CAPN3, rAAVrh.74.MHCK7.DYSF, scAAVrh.74.MHCK7.hSGCG, AAVrh74.tMCK.hSCGA, scAAVrh74.MHCK7.HSGCB, and rAAVrh.74.MHCK7.huAN05. (Item 22) The method according to item 21, wherein the muscular dystrophy is Duchenne muscular dystrophy and the rAAV is rAAV.MHCK7.microdystrophin. (Item 23) The method according to item 21, wherein the muscular dystrophy is limb-girdle muscular dystrophy, and the rAAV is AAVrh.74.tMCK.CAPN3, rAAVrh.74.MHCK7.DYSF, scAAVrh.74.MHCK7.hSGCG, AAVrh74.tMCK.hSCGA, scAAVrh74.MHCK7.HSGCB, and rAAVrh.74.MHCK7.huAN05. (Item 24) The method according to any one of items 21 to 23, wherein the immunosuppressive regimen comprises administering an anti-inflammatory steroid, an anti-CD20 antibody, and an immunosuppressive macrolide. (Item 25) The method according to any one of items 21 to 24, wherein the anti-inflammatory steroid is administered approximately 24 hours before the administration of the rAAV. (Item 26) The method according to any one of items 21 to 25, wherein the anti-inflammatory steroid is administered before the administration of the rAAV, and the anti-inflammatory steroid is administered at least once a day from day 1 to day 30 after the administration of the rAAV. (Item 27) The method according to any one of items 21 to 26, wherein the anti-inflammatory steroid is administered orally. (Item 28) The method according to any one of items 21 to 27, wherein the anti-inflammatory steroid is a glucocorticoid. (Item 29) The method according to any one of items 21 to 28, wherein the anti-inflammatory steroid is prednisone, prednisolone, betamethasone, dexamethasone, hydrocortisone, methylprednisolone, or deflazacort. (Item 30) The method according to any one of items 21 to 295, wherein the anti-CD20 specific antibody is administered before the administration of the rAAV. (Item 31) The method according to item 30, wherein the anti-CD20 specific antibody is administered at least 14 days prior to the administration of the rAAV. (Item 32) The method according to item 30, wherein the anti-CD20 specific antibody is administered approximately 14 days before the administration of the rAAV, approximately 7 days before the administration of the rAAV, and approximately 24 hours before the administration of the rAAV. (Item 33) The method according to any one of items 21 to 32, wherein the immunosuppressive regimen further comprises administering an anti-CD20 specific antibody after administration of the rAAV. (Item 34) The method according to any one of items 21 to 33, wherein the anti-CD20 antibody is administered by intravenous infusion. (Item 35) The method according to any one of items 21 to 34, wherein the anti-CD20 specific antibody is rituximab, ocrelizumab, or ofatumumab. (Item 36) The method according to any one of items 21 to 35, wherein the immunosuppressive macrolide is administered at least once daily for at least 3 days prior to the administration of the rAAV. (Item 37) The method according to any one of items 21 to 36, further comprising administering an immunosuppressive macrolide after administering the rAAV. (Item 38) The method according to any one of items 21 to 37, wherein the immunosuppressive macrolide is administered orally. (Item 39) The method according to any one of items 21 to 38, wherein the immunosuppressive macrolide is tacrolimus, pinecrolimus, or sirolimus. (Item 40) A method for treating muscular dystrophy in human subjects requiring treatment for muscular dystrophy, comprising administering a recombinant adenovirus-associated (rAAV) selected from the group consisting of AAVrh.74.MHCK7.microdystrophin, AAVrh.74.tMCK.CAPN3, rAAVrh.74.MHCK7.DYSF, scAAVrh.74.MHCK7.hSGCG, AAVrh74.tMCK.hSCGA, scAAVrh74.MHCK7.HSGCB, and rAAVrh.74.MHCK7.huAN05, and an immunosuppressive regimen, wherein the immunosuppressive regimen is i) Orally administer an anti-inflammatory steroid approximately 24 hours before administering the rAAV, and administer the anti-inflammatory steroid at least once a day from day 1 to day 30 after the administration of the rAAV, or from day 1 to day 60 after the administration of the rAAV. ii) The steps of intravenously administering an anti-CD20 antibody approximately 14 days before the administration of rAAV, approximately 7 days before the administration of rAAV, and approximately 24 hours before the administration of rAAV, and optionally administering the anti-CD20 antibody after the administration of rAAV, iii) A method comprising the steps of orally administering an immunosuppressive macrolide at least once daily for at least 3 days prior to the administration of the rAAV, and optionally administering the immunosuppressive macrolide after the administration of the rAAV. (Item 41) The method according to item 40, wherein the muscular dystrophy is Duchenne muscular dystrophy and the rAAV is AAVrh.74.MHCK7.microdystrophin. (Item 42) The method according to item 40, wherein the muscular dystrophy is limb-girdle muscular dystrophy, and the rAAV is AAVrh.74.tMCK.CAPN3, rAAVrh.74.MHCK7.DYSF, scAAVrh.74.MHCK7.hSGCG, AAVrh74.tMCK.hSCGA, scAAVrh74.MHCK7.HSGCB, or rAAVrh.74.MHCK7.huAN05. (Item 43) The method according to any one of items 40 to 42, wherein the anti-inflammatory steroid is prednisone, prednisolone, betamethasone, dexamethasone, hydrocortisone, methylprednisolone, or deflazacort. (Item 44) The method according to any one of items 40-43, wherein the anti-CD20 specific antibody is rituximab, ocrelizumab, or ofatumumavon. (Item 45) The method according to any one of items 40 to 42, wherein the immunosuppressive macrolide is tacrolimus, pinecrolimus, or sirolimus. (Item 46) The method according to any one of items 40 to 42, wherein the anti-inflammatory steroid is prednisolone, the anti-CD20 antibody is rituximab, and the immunosuppressive macrolide is sirolimus. (Item 47) A method for treating muscular dystrophy in a human subject requiring treatment for muscular dystrophy, comprising providing the plasma of the subject to at least one therapeutic plasmapheresis (TPE) before administering a second dose of a recombinant adenovirus-related substance (rAAV) selected from the group consisting of AAVrh.74.MHCK7.microdystrophin, AAVrh.74.tMCK.CAPN3, rAAVrh.74.MHCK7.DYSF, scAAVrh.74.MHCK7.hSGCG, AAVrh74.tMCK.hSCGA, scAAVrh74.MHCK7.HSGCB, and rAAVrh.74.MHCK7.huAN05, wherein the subject has been administered a first dose of rAAV before being subjected to TPE. (Item 48) A method for treating muscular dystrophy in human subjects requiring treatment for muscular dystrophy, a) A step of administering a first dose of recombinant adenovirus-related agent selected from the group consisting of AAVrh.74.MHCK7.microdystrophin, AAVrh.74.tMCK.CAPN3, rAAVrh.74.MHCK7.DYSF, scAAVrh.74.MHCK7.hSGCG, AAVrh74.tMCK.hSCGA, scAAVrh74.MHCK7.HSGCB, and rAAVrh.74.MHCK7.huAN05, b) The step of providing the target plasma for at least one therapeutic plasma exchange (TPE), c) A method comprising the step of administering a second dose or rAAV. (Item 49) The method according to item 47 or 48, wherein the muscular dystrophy is Duchenne muscular dystrophy and the rAAV is AAVrh.74.MHCK7.microdystrophin. (Item 50) The method according to item 47 or 48, wherein the muscular dystrophy is limb-girdle muscular dystrophy, and the rAAV is AAVrh.74.tMCK.CAPN3, rAAVrh.74.MHCK7.DYSF, scAAVrh.74.MHCK7.hSGCG, AAVrh74.tMCK.hSCGA, scAAVrh74.MHCK7.HSGCB, and rAAVrh.74.MHCK7.huAN05. (Item 51) The method according to any one of items 47 to 50, wherein the target plasma is subjected to at least two TPEs or at least three TPEs before administration of the second dose or rAAV. (Item 52) A method for treating muscular dystrophy in human subjects requiring treatment for muscular dystrophy, a) The step of providing the target plasma for at least one therapeutic plasma exchange (TPE) before administering recombinant adenovirus-associated (rAAV), b) a step of administering rAAV, A method wherein the rAAV is rAAV.MHCK7.microdystrophin, AAVrh.74.tMCK.CAPN3, rAAVrh.74.MHCK7.DYSF, scAAVrh.74.MHCK7.hSGCG, AAVrh74.tMCK.hSCGA, scAAVrh74.MHCK7.HSGCB, or rAAVrh.74.MHCK7.huAN05. (Item 53) The method according to item 52, wherein the target plasma is subjected to at least two TPEs, at least three TPEs, at least four TPEs, at least five TPE rAAVs, at least six TPEs, or at least seven TPEs before administration. (Item 54) The method according to item 52 or 53, wherein the target plasma is subjected to TPE at least 9 days before administration of the rAAV, at least 7 days before administration, 5 days before administration, or 2 days before administration. (Item 55) The method according to any one of items 52 to 54, wherein the plasma of the subject is subjected to TPE on the day the rAAV is administered. (Item 56) The method according to any one of items 52 to 55, wherein the target plasma is subjected to at least two TPEs, with approximately 48 hours between the TPEs. (Item 57) The method according to any one of items 52 to 56, wherein the subject is administered an anti-inflammatory steroid approximately 24 hours before the administration of the rAAV. (Item 58) The method according to any one of items 52 to 57, wherein the subject is administered an anti-inflammatory steroid at least once a day from day 1 to day 60 after administration of the rAAV. (Item 59) The method according to item 57 or 58, wherein the anti-inflammatory steroid is administered orally. (Item 60) The method according to any one of items 57 to 59, wherein the anti-inflammatory steroid is a glucocorticoid. (Item 61) The method according to any one of items 57 to 60, wherein the anti-inflammatory steroid is prednisone, prednisolone, betamethasone, dexamethasone, hydrocortisone, methylprednisolone, or deflazacort. (Item 62) The method according to any one of items 1 to 61, wherein the rAAV is administered by a systemic route. (Item 63) The systemic administration route is intravenous, and the dose of rAAV administered is approximately 2 × 10⁻⁶ 14 The method described in item 62, which is vg / kg. (Item 64) The method according to any one of items 1 to 63, wherein the dose of rAAV is administered at a concentration of approximately 10 mL / kg. (Item 65) The method according to any one of items 1 to 64, wherein the rAAV is administered by injection, infusion, or implantation. (Item 66) The method according to any one of items 1 to 65, wherein the rAAV is administered by infusion over a period of approximately one hour. (Item 67) The method according to any one of items 1 to 65, wherein the rAAV is administered via an intravenous route through the veins of the peripheral limbs. (Item 68) The method according to any one of items 1 to 67, wherein the rAAV is of serotype AAVrh.74. (Item 69) The method according to any one of items 1 to 68, wherein the rAAV comprises the human microdystrophin nucleotide sequence of SEQ ID NO: 1. (Item 70) The method according to any one of items 1 to 69, wherein the rAAV comprises the MHCK7 promoter sequence of SEQ ID NO: 2 or SEQ ID NO: 7. (Item 71) The method according to any one of items 1 to 70, wherein the rAAV comprises the nucleotide sequence of SEQ ID NO: 44. (Item 72) The method according to any one of items 1 to 68, wherein the rAAV comprises the AAVrh74.MHCK7.microdystrophin construct nucleotide sequence of SEQ ID NO: 9 or nucleotides 55 to 5021 of SEQ ID NO: 3. (Item 73) The aforementioned human subject suffers from Duchenne muscular dystrophy, and the rAAV is approximately 2 × 10⁻⁶ 14 The method according to any one of items 1 to 68, wherein the rAAV is administered by intravenous infusion over approximately 1 hour at a dose of vg / kg, and the rAAV comprises the AAVrh74.MHCK7.microdystrophin construct nucleotide sequence of SEQ ID NO: 9 or nucleotides 55-5021 of SEQ ID NO: 3. (Item 74) The method according to any one of items 1 to 68, wherein the muscular dystrophy is LGMD2E and the rAAV is scAAVrh74.MHCK7.HSGCB. (Item 75) The aforementioned human subject was infected with LGMD2E, and the rAAV was approximately 2 × 10⁻⁶ 14 The method according to any one of items 1 to 68, wherein the rAAV is an rAAV comprising the nucleotide sequence scAAVrh74.MHCK7.HSGCB, which contains the nucleotide sequence of SEQ ID NO: 44. (Item 76) The method according to any one of items 1 to 75, wherein the level of microdystrophin gene expression in the target cells increases after administration of rAAV compared to the level of microdystrophin gene expression before administration of rAAV. (Item 77) The method according to any one of items 1 to 76, further comprising the step of determining the presence of anti-AAVrh.74 antibodies in the serum or plasma of the subject. (Item 78) The method according to item 77, wherein the step of determining is performed before the step of administering the immunosuppressive regimen or TPE. (Item 79) The method according to item 78, wherein the determining step is performed before administering any of the AAVs to the subject. (Item 80) The method according to item 79, wherein the determining step is performed before administering aAAVrh.74 to the subject. (Item 81) The method described in any one of items 77-80, wherein the aforementioned determination is quantitative. (Item 82) The method according to item 81, further comprising the step of comparing the level of anti-AAVrh.74 antibody in the serum or plasma of the subject with that of a positive control. (Item 83) The method described in item 82, wherein the positive control utilizes an anti-AAVrh.74 monoclonal antibody. (Item 84) The method according to any one of items 77 to 83, wherein the determining step includes utilizing an anti-AAVrh.74 monoclonal antibody. (Item 85) The method according to any one of items 77 to 84, wherein the determination step includes utilizing an immunofluorescence assay, immunohistochemical assay, Western blot, direct enzyme-linked immunosorbent assay (ELISA), indirect ELISA, sandwich ELISA, competitive ELISA, reverse ELISA, chemiluminescence assay, radioimmunoassay, or immunoprecipitation assay. (Item 86) The method according to any one of items 83 to 85, wherein the monoclonal antibody comprises a VH CDR1 amino acid sequence selected from the group consisting of NYGMN (SEQ ID NO: 20), DYGMN (SEQ ID NO: 22), YTFTNYGMN (SEQ ID NO: 21), and YTFTKYGMN (SEQ ID NO: 23). (Item 87) The method according to any one of items 83 to 85, wherein the monoclonal antibody comprises a VH CDR2 amino acid sequence selected from the group consisting of WINTYTGEPTYADDFKG (SEQ ID NO: 24), WINTNTGEPTYGDDFKG (SEQ ID NO: 25), and WMGWINTYTGEPTY (SEQ ID NO: 26). (Item 88) The method according to any one of items 83 to 85, wherein the monoclonal antibody contains a VH CDR3 amino acid sequence selected from the group consisting of GVAHYSDSRFAFDY (SEQ ID NO: 27), GNAHPGGSAFVY (SEQ ID NO: 28), RGSYYYDSSPAWFAY (SEQ ID NO: 29), RGVDSSGYGAFAY (SEQ ID NO: 30), and TRGTSTMISTFAFVY (SEQ ID NO: 31). (Item 89) The method according to any one of items 83 to 85, wherein the monoclonal antibody comprises a VL CDR1 amino acid sequence selected from the group consisting of SVSSSVSYMH (SEQ ID NO: 32), SASSGVTYMH (SEQ ID NO: 33), SSVSYMH (SEQ ID NO: 34), and SSVRYMH (SEQ ID NO: 35). (Item 90) The method according to any one of items 83 to 85, wherein the monoclonal antibody contains a VL CDR2 amino acid sequence selected from the group consisting of YTSNLAS (SEQ ID NO: 36), RTSNLAS (SEQ ID NO: 37), LWIYSTSNLAS (SEQ ID NO: 38), and VWIYSTSNLAS (SEQ ID NO: 39). (Item 91) The method according to any one of items 83 to 85, wherein the monoclonal antibody comprises a VH CDR3 amino acid sequence selected from the group consisting of QQRSSYPFT (SEQ ID NO: 40), QQRSTYPF (SEQ ID NO: 41), QQRSFYPF (SEQ ID NO: 42), and QQRTYYPF (SEQ ID NO: 43). (Item 92) The method according to any one of items 83 to 85, wherein the monoclonal antibody comprises a variable heavy chain (VH) sequence shown in SEQ ID NO: 10, 12, 14, 16, or 18. (Item 93) The method according to any one of items 83 to 85, wherein the monoclonal antibody comprises a variable light chain (VL) sequence shown in SEQ ID NOs: 11, 13, 15, 17, or 19. (Item 94) The method according to any one of items 83 to 85, wherein the monoclonal antibody comprises a variable heavy chain (VH) sequence shown in SEQ ID NO: 10, 12, 14, 16, or 18, and a variable light chain (VL) sequence shown in SEQ ID NO: 11, 13, 15, 17, or 19. (Item 95) The method according to any one of items 83 to 85, wherein the determination is quantitative, the subject is identified as serologically positive for anti-AAVrh.74 based on the quantitative determination, and the immunosuppressive regimen or TPE is selectively administered to the serologically positive subject. [Brief explanation of the drawing]

[0152] [Figure 1] The rAAV.MHCK7.microdystrophin construct is shown. In this construct, the AAV2 terminal inversion sequence (ITR) is flanked by the cDNA expression cassette. The construct is characterized by in-frame rod deletions (R4-R23) and maintains hinges 1, 2, and 4 (H1, H2, and H4) and cysteine-rich domains to produce a 138 kDa protein. Expression of the microdystrophin protein (3579 bp) is induced by the MHCK7 promoter (795 bp). The intron and 5'UTR are derived from plasmid pCMVβ (Clontech). The microdystrophin cassette had a consensus cossack immediately before the ATG start and a small 53 bp synthetic poly(A) signal for mRNA termination. As previously described by Harper et al. (Nature Medicine 8, 253-261 (2002)), the human microdystrophin cassette contained the (R4~R23 / Δ71~78) domain. [Figure 2-1] This provides the nucleic acid sequence (SEQ ID NO: 3) rAAVrh74.MHCK7.microdystrophin. [Figure 2-2] This provides the nucleic acid sequence (SEQ ID NO: 3) rAAVrh74.MHCK7.microdystrophin. [Figure 2-3] This provides the nucleic acid sequence (SEQ ID NO: 3) rAAVrh74.MHCK7.microdystrophin. [Figure 2-4] This provides the nucleic acid sequence (SEQ ID NO: 3) rAAVrh74.MHCK7.microdystrophin. [Figure 3] This provides a pNLREP2-Caprh74 AAV helper plasmid map. [Figure 4] Provides the Ad Helper plasmid pHELP. [Figure 5] This shows the rAAV.MCK.microdystrophin plasmid construct. [Figure 6-1] This provides the nucleic acid sequence (SEQ ID NO: 5) rAAVrh74.MCK.microdystrophin. [Figure 6-2] This provides the nucleic acid sequence (SEQ ID NO: 5) rAAVrh74.MCK.microdystrophin. [Figure 6-3] This provides the nucleic acid sequence (SEQ ID NO: 5) rAAVrh74.MCK.microdystrophin. [Figure 6-4] This provides the nucleic acid sequence (SEQ ID NO: 5) rAAVrh74.MCK.microdystrophin. [Figure 7-1] This provides the nucleic acid sequence (SEQ ID NO: 9) rAAVrh74.MHCK7.microdystrophin. [Figure 7-2] This provides the nucleic acid sequence (SEQ ID NO: 9) rAAVrh74.MHCK7.microdystrophin. [Figure 7-3] This provides the nucleic acid sequence (SEQ ID NO: 9) rAAVrh74.MHCK7.microdystrophin. [Figure 8] This shows the AAVrh74.MHCK7.microdystrophin plasmid construct. [Figure 9-1] This document provides the nucleic acid sequence (SEQ ID NO: 8) of the rAAVrh74.MHCK7.microdystrophin plasmid construct containing the kanamycin resistance gene. [Figure 9-2] This document provides the nucleic acid sequence (SEQ ID NO: 8) of the rAAVrh74.MHCK7.microdystrophin plasmid construct containing the kanamycin resistance gene. [Figure 9-3] This document provides the nucleic acid sequence (SEQ ID NO: 8) of the rAAVrh74.MHCK7.microdystrophin plasmid construct containing the kanamycin resistance gene. [Figure 9-4] This document provides the nucleic acid sequence (SEQ ID NO: 8) of the rAAVrh74.MHCK7.microdystrophin plasmid construct containing the kanamycin resistance gene. [Figure 10]This provides a schematic diagram of a therapeutic β-sarcoglycan transgene cassette. It is a self-complementary AAV vector containing the codon-optimized human β-sarcoglycan gene (hSGCB). A muscle-specific MHCK7 promoter drives expression. The cassette also includes a chimeric intron to enhance processing and polyadenylation signals for stability. [Figure 11] This graph shows antibody titers against AAVrh74 in NHP after readmission of rAAVrh74.MHCK7.microdystrophin. The dotted line represents the selection criteria for total AAVrh74 antibody titer levels, which were a threshold of 1:400 against AAVrh74. [Figure 12] This provides a fold change in microdystrophin protein expression after TPE compared to before TPE in NHP patients who were re-administered rAAVrh74.MHCK7.microdystrophin after TPE. [Figure 13] We offer a course of plasma antibodies following plasma volume (PV) removal over a 10-day TPE course. [Modes for carrying out the invention]

[0153] This disclosure relates to identifying doses, durations, and immunosuppressive regimens for enhancing gene expression after intravascular delivery of rAAV.rh74.MHCK7.microdystrophin, and to identifying techniques for enhancing gene expression after or after administration of rAAV, in conjunction with removing existing AAV antibodies using TPE, and evaluating re-administration without the use of TPE. The method of the present invention involves administering an immunosuppressive regimen and / or TPE before administration of any of the rAAV.rh74.MHCK7.microdystrophin, AAVrh.74.tMCK.CAPN3, rAAVrh.74.MHCK7.DYSF, scAAVrh.74.MHCK7.hSGCG, AAVrh74.tMCK.hSCGA, scAAVrh74.MHCK7.HSGCB, or rAAVrh.74.MHCK7.huAN05 described herein. This method includes administering an immunosuppressive regimen and / or TPE before readmission of rAAV.rh74.MHCK7.microdystrophin, AAVrh.74.tMCK.CAPN3, rAAVrh.74.MHCK7.DYSF, scAAVrh.74.MHCK7.hSGCG, AAVrh74.tMCK.hSCGA, scAAVrh74.MHCK7.HSGCB, or rAAVrh.74.MHCK7.huAN05 as described herein.

[0154] This disclosure provides a gene therapy vector overexpressing human microdystrophin, such as an rAAV vector, and a method for mitigating and preventing fibrosis in patients with muscular dystrophy. Muscle biopsies taken at the earliest age of diagnosis of DMD reveal significant connective tissue proliferation. Muscle fibrosis is detrimental in several ways. It reduces the normal passage of nutrients through the endomysium across the connective tissue barrier, reduces blood flow, deprives muscles of vascular nutrients, and is a functional cause of early loss of walking due to limb contractures. Over time, the treatment challenges increase as a result of significant muscle fibrosis. This can be observed in muscle biopsies comparing connective tissue proliferation at successive time points. This process continues to worsen, leading to loss of walking and accelerating uncontrollable progression, especially in wheelchair-dependent patients.

[0155] Without early treatment, including parallel approaches to mitigate fibrosis, the benefits of exon skipping, stop-codon read-through, or gene replacement therapy are unlikely to be fully realized. Even small molecule or protein replacement strategies may fail without approaches to mitigate myofibrosis. Previous studies in aged mdx mice with pre-existing fibrosis treated with AAV. microdystrophin have shown that complete functional recovery cannot be achieved (Liu, M., et al., Mol Ther 11, 245-256 (2005)). Progression of DMD cardiomyopathy is also known to be accompanied by scarring and fibrosis of the ventricular wall.

[0156] The implementation of this invention will, unless otherwise indicated, utilize conventional methods of virology, microbiology, molecular biology, and recombinant DNA technology, within the scope of the art of those skilled in the art. Such techniques are fully described in the literature. For example, Sambrook et al. Molecular Cloning: A Laboratory Manual (Current Edition), DNA Cloning: A Practical Approach, Vol. I & II (D. Glover, ed.), Oligonucleotide Synthesis (N. Gait, ed., Current Edition), Nucleic Acid Hybridization (B. Hames & S. Higgins, eds., Current Edition), Transcription and Translation (B. Hames & S. Higgins, eds., Current Edition), CRC Handbook of Parvoviruses, vol. I & II (P. Tijssen, ed.), Fundamental Virology, 2nd Edition, vol. I & II (BNFields and DMKnipe, eds.), Freshney Culture of Animal Cells, A Manual of Basic Technique (Wiley-Liss, Third Edition), and Ausubel et al. al. (1991) Current Protocols in Molecular Biology (Wiley Interscience, NY).

[0157] All publications, patents, and patent applications cited herein, whether in whole or otherwise, are incorporated herein by reference.

[0158] definition The singular forms "a," "an," and "the" include plural referents unless otherwise specified in the context. For example, a reference to "cells" includes multiple such cells, and a reference to "culture" includes one or more cultures and their equivalents as known to those skilled in the art. A reference to "recombinant AAV" includes a mixture of two or more rAAV virions. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which this invention pertains.

[0159] The use of the term “or” in the claims is used to mean “and / or” unless expressly indicated to mean only the alternatives, or unless the alternatives are mutually exclusive; however, this disclosure supports the definition that refers only to the alternatives and “and / or.”

[0160] Throughout this application, the term “approximately” is used to indicate that the value includes the statistical experimental error (standard deviation of the error) to the device or method used to determine the value.

[0161] The term "vector" refers to any genetic element that can replicate when associated with appropriate regulatory elements and can transfer gene sequences between cells, such as plasmids, phages, transposons, cosmids, chromosomes, viruses, and virions. In one embodiment, the vector is a viral vector.

[0162] As used herein, the term "AAV" is a common abbreviation for adeno-associated virus. Adeno-associated viruses are single-stranded DNA parvoviruses that grow only in cells, provided with certain functions by co-infecting helper viruses. Currently, there are 13 serotypes of AAV that have been characterized. General information and an overview of AAV can be found, for example, in Carter, 1989, Handbook of Parvoviruses, Vol. 1, pp. 169-228, and Berns, 1990, Virology, pp. 1743-1764, Raven Press, (New York). However, since it is well known that various serotypes are very closely related both structurally and functionally, even at the genetic level, it is quite expected that these same principles may apply to additional AAV serotypes. (See, for example, Blacklowe, 1988, pp. 165-174 of Parvoviruses and Human Disease, JR Pattison, ed., and Rose, Comprehensive Virology 3:1-61 (1974)). For example, all AAV serotypes clearly exhibit very similar replication characteristics mediated by homologous rep genes, all possessing three related capsid proteins, such as those expressed in AAV2. The degree of relatedness is further suggested by heteroduplex analysis, revealing extensive cross-hybridization between serotypes along genome length and the presence of similar self-annealing segments at the terminals corresponding to "inverted terminal repeats" (ITRs). Similar infectivity patterns also suggest that replication function in each serotype is under similar regulatory control.

[0163] As used herein, “AAV vector” refers to one or more target polynucleotides (or transgenes) adjacent to an AAV terminal repeat sequence (ITR). Such an AAV vector can be replicated and packaged into infectious viral particles when present in a host cell transfected with a vector encoding and expressing rep and cap gene products. In one embodiment, the AAV vector is a vector derived from adeno-associated virus serotypes, including, but not limited to, AAV-1, AAV-2, AAV-3, AAV-4, AAV-5, AAV-6, AAV-7, AAV-8, AAV-9, AAV-10, AAV-11, AAV-12, AAV-13, AAV rh10, and AAVrh.74. The AAV vector is preferably a rep and / or cap gene, in which one or more of the AAV wild-type genes are deleted in whole or in part, but which can retain a functional adjacent ITR sequence. Functional ITR sequences are necessary for the rescue, replication, and packaging of AAV virions. Therefore, AAV vectors are defined herein to contain at least those sequences required in cis for viral replication and packaging (e.g., functional ITRs). ITRs do not need to be wild-type nucleotide sequences and can be modified, for example, by nucleotide insertions, deletions, or substitutions, as long as the sequence provides functional rescue, replication, and packaging.

[0164] The term "AAV helper function" refers to AAV-derived coding sequences that can be expressed to provide the AAV gene product that then functions in trans for productive AAV replication. Thus, AAV helper functions include the major AAV open reading frame (ORF), rep, and cap. Rep expression products have been shown to possess many functions, including, among others, recognition, binding, and nicking of AAV origins in DNA replication, DNA helicase activity, and regulation of transcription from AAV (or other heterologous) promoters. Cap expression products provide the necessary packaging functions. AAV helper functions are used herein to complement the trans AAV functions lost from AAV vectors.

[0165] A "recombinant virus" refers to a virus that has been genetically modified, for example, by adding or inserting a different nucleic acid sequence into the viral particle.

[0166] "AAV virion," "AAV virus particle," or "AAV vector particle" refers to a virus particle consisting of at least one AAV capsid protein and a polynucleotide AAV vector enclosed in the capsid. In one embodiment, the AAV virion contains heterologous polynucleotides (i.e., polynucleotides other than the wild-type AAV genome, such as a transgene delivered to a mammalian cell). In some embodiments, the production of an AAV virus particle involves the production of an AAV vector, for example, the vector being contained within the AAV vector particle.

[0167] AAV genomes, such as transgenes delivered to mammalian cells, are typically referred to as "AAV vector particles" or simply "AAV vectors." Therefore, since such vectors are contained within AAV vector particles, the production of AAV vector particles inevitably involves the production of AAV vectors.

[0168] For example, wild-type (wt) AAV virus particles contain a linear single-stranded AAV nucleic acid genome associated with the AAV capsid protein coat. AAV virions can be either single-stranded (ss) AAV or self-complementary (SC) AAV. In one embodiment, a single-stranded AAV nucleic acid molecule, either a complementary sense, e.g., a "sense" or "antisense" strand, may be packaged in an AAV virion, and both strands are equally infectious.

[0169] The terms “recombinant AAV” or “rAAV” are defined herein as infectious replication-deficient viruses comprising an AAV protein shell in which an AAV ITR encapsulates a heterologous nucleotide sequence of interest flanked on both sides. In one embodiment, rAAV is produced in a suitable host cell, which has an AAV vector introduced therein, AAV helper function, and accessory function. Thus, the host cell can encode an AAV polypeptide required to package the AAV vector (containing the recombinant nucleotide sequence of interest) into infectious recombinant virion particles for subsequent gene delivery.

[0170] The term "transfection" refers to the uptake of foreign DNA by cells, and cells are "transfected" when exogenous DNA is introduced into the cell membrane. Many transfection techniques are commonly known in this field. See, for example, Graham et al. (1973) Virology, 52:456, Sambrook et al. (1989) Molecular Cloning, a laboratory manual, Cold Spring Harbor Laboratories, New York, Davis et al. (1986) Basic Methods in Molecular Biology, Elsevier, and Chu et al. (1981) Gene 13:197. Using such techniques, one or more exogenous DNA portions, such as nucleotide insertion vectors and other nucleic acid molecules, can be introduced into suitable host cells.

[0171] The term "transduction" refers to the delivery of DNA molecules to recipient cells, either in vivo or in vitro, via a replication-deficient viral vector, such as recombinant AAV virions.

[0172] The term “host cell” means, for example, microorganisms, yeast cells, insect cells, and mammalian cells that can or have been used as recipients of AAV helper constructs, AAV vector plasmids, accessory functional vectors, or other transfer DNA. This term includes offspring of the transfected original cell. Thus, as used herein, “host cell” generally refers to a cell transfected with an exogenous DNA sequence. It is understood that offspring of a single parent cell may not necessarily be completely identical in morphology or genomic or whole DNA complement due to natural, accidental, or intentional mutations.

[0173] "Muscle cells" or "muscle tissue" means cells or groups of cells derived from any type of muscle (e.g., skeletal and smooth muscle derived from the digestive tract, bladder, blood vessels, or cardiac tissue). Such muscle cells may be differentiated or undifferentiated, including myoblasts, myocytes, myotubes, cardiomyocytes, and cardiac muscle cells.

[0174] The term "heterogeneous," when relating to nucleic acid sequences such as coding and regulatory sequences, refers to sequences that are not normally bound together and / or are not normally associated with a particular cell. Therefore, the "heterogeneous" region of a nucleic acid construct or vector is a segment of nucleic acid within or attached to another nucleic acid molecule that is not found in nature in association with other molecules. For example, the heterogeneous region of a nucleic acid construct may include a coding sequence adjacent to a coding sequence that is not found in association with a naturally occurring coding sequence. Another example of a heterogeneous coding sequence is a construct where the coding sequence itself is not found in nature (e.g., a synthetic sequence with codons different from those in a native gene). Similarly, a cell transformed with a construct that is not normally present in the cell would be considered heterogeneous for the purposes of this invention. As used herein, allelic mutations or naturally occurring mutational events do not produce heterogeneous DNA.

[0175] A "coding sequence," or sequence that "codes" a particular protein, is a nucleic acid sequence that, when placed under the control of appropriate regulatory sequences, is transcribed into a polypeptide (in the case of DNA) and translated (in the case of mRNA) in vitro or in vivo. The boundaries of a coding sequence are determined by a start codon at the 5' (amino) end and a translation stop codon at the 3' (carboxy) end. Coding sequences may include, but are not limited to, cDNA from prokaryotic or eukaryotic mRNA, genomic DNA sequences from prokaryotic or eukaryotic DNA, and even synthetic DNA sequences. The transcription termination sequence will typically be located on the 3' side of the coding sequence.

[0176] Nucleic acid sequences refer to DNA or RNA sequences. Nucleic acids include 4-acetylcytosine, 8-hydroxy-N6-methyladenosine, aziridinylcytosine, pseudoisocytosine, 5-(carboxyhydroxylmethyl)uracil, 5-fluorouracil, 5-bromouracil, 5-carboxymethylaminomethyl-2-thiouracil, 5-carboxymethylaminomethyluracil, dihydrouracil, inosine, N6-isopentenyladenine, 1-methyladenine, 1-methylpseuduracil, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-methyladenine, 7-methylguanine, and 5-methylaminomethyluracil. DNA and RNA base analogs include, but are not limited to, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylkeosin, 5'-methoxycarbonylmethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetate methyl ester, uracil-5-oxyacetic acid, oxybutoxosin, pseudouracil, queosin, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetate methyl ester, uracil-5-oxyacetic acid, pseudouracil, queosin, 2-thiocytosine, and 2,6-diaminopurines.

[0177] The term DNA “regulatory sequences” collectively refers to promoter sequences, polyadenylation signals, transcription termination sequences, upstream regulatory domains, origins of replication, internal ribosome entry sites ("IRESs"), enhancers, etc., which collectively provide for the replication, transcription, and translation of coding sequences in recipient cells. Not all of these regulatory sequences are always necessary, as long as the selected coding sequence can be replicated, transcribed, and translated in a suitable host cell.

[0178] The term “promoter” is used herein in its usual sense to refer to a nucleotide region containing a DNA regulatory sequence, the regulatory sequence being derived from a gene that can bind to RNA polymerase and initiate transcription of a downstream (3'-direction) coding sequence. Transcription promoters may include “inducible promoters” (where the expression of a polynucleotide sequence operably linked to the promoter is induced by an analyte, cofactor, regulatory protein, etc.), “repressive promoters” (where the expression of a polynucleotide sequence operably linked to the promoter is induced by an analyte, cofactor, regulatory protein, etc.), and “constitutive promoters.” In one embodiment, the promoter is a muscle-specific promoter, which includes, but is not limited to, human skeletal actin gene elements, cardiac actin gene elements, desmin promoter, skeletal alpha-actin (ASKA) promoter, troponin I (TNNI2) promoter, muscle cell-specific enhancer-binding factor (mef) binding element, muscle creatine kinase (MCK) promoter, truncated MCK (tMCK) promoter, myosin heavy chain (MHC) promoter, hybrid α-myosin heavy chain enhancer / MCK enhancer promoter (MHCK7) promoter, C5-12 promoter, mouse creatine kinase enhancer elements, skeletal fast-twitch muscle troponin c gene elements, slow-twitch muscle cardiac troponin c gene elements, slow-twitch muscle troponin i gene elements, hypoxia-inducible nuclear factor (HIF) response elements (HRE), steroid-inducible elements, and glucocorticoid-inducible elements (gre). In another embodiment, the promoter is the MCK promoter, tMCK promoter, or MHCK7 promoter.

[0179] The term "operably linked" refers to the arrangement of elements configured so that the components described in this way perform their normal functions. Thus, control sequences operably linked to a coding sequence can influence the expression of the coding sequence. Control sequences do not need to be adjacent to the coding sequence as long as they function to direct its expression. For example, an intervening untranslated but transcribed sequence can exist between a promoter sequence and a coding sequence, and the promoter sequence can still be considered "operably linked" to the coding sequence.

[0180] When RNA polymerase binds to a promoter sequence, transcribes the coding sequence into mRNA, and then translates it into the polypeptide encoded by the coding sequence, the promoter "directs the transcription" of the coding sequence within the cell.

[0181] An “expression cassette” or “expression construct” refers to an assembly that can direct the expression of a sequence or gene of interest. An expression cassette, as described above, includes regulatory elements such as a promoter that is operablely linked to the sequence or gene of interest (to direct transcription), and often also includes a polyadenylated sequence. In certain embodiments of the present invention, the expression cassettes described herein may be contained within a plasmid construct. In addition to the components of an expression cassette, a plasmid construct may also include one or more selectable markers, signals that enable the plasmid construct to exist as single-stranded DNA, at least one multicloning site, and a “mammalian” origin of replication (e.g., SV40 or an adenovirus origin of replication).

[0182] When referring to a nucleotide sequence, "isolated" means that the indicated molecule exists in the substantial absence of other nucleotide sequences, chromatin material, or other biological macromolecules. Therefore, an "isolated nucleic acid molecule encoding a particular polypeptide" refers to a nucleic acid molecule that substantially contains no other nucleic acid molecules that do not encode the polypeptide in question, however, the molecule may contain some additional bases or parts that do not adversely affect the fundamental properties of the composition.

[0183] When a particular nucleotide sequence is described as being located "upstream," "downstream," "3," or "5" relative to another sequence, for the purpose of describing the relative position of a nucleotide sequence within a particular nucleic acid molecule throughout this application, it should be understood that this refers to the position of the sequence in the "sense" or "coding" strand of the DNA molecule, as is customary in the art.

[0184] In the context of nucleic acid sequences or amino acid sequences, the terms “sequence identity,” “sequence identity ratio,” or “ratio of identity” refer to residues in two sequences that are identical when aligned to the greatest extent possible. The length of the sequence identity comparison can be the full length of the genome, the full length of the gene coding sequence, or preferably a fragment of at least about 500–5000 nucleotides. However, identity between smaller fragments, such as at least about 9 nucleotides, usually at least about 20–24 nucleotides, at least about 28–32 nucleotides, or at least about 36 or more nucleotides, may also be desired. The sequence identity ratio can be determined by techniques known in the art. For example, homology can be determined by directly comparing the sequence information of two polypeptide molecules by aligning the sequence information and using readily available computer programs such as ALIGN, ClustalW2, and BLAST. In one embodiment, when BLAST is used as an alignment tool, the following default parameters are used: Genetic code = standard; filter = none; strand = both; cutoff = 60; prediction = 10; matrix = BLOSUM62; description = 50 sequences; sort = high score; database = non-redundant, GenBank+EMBL+DDBJ+PDB+GenBank CDS translation+Swissprotein+Spupdate+PIR.

[0185] The term “subject” refers to any member of the animal kingdom, including, but not limited to, humans and non-human primates such as chimpanzees and other apes and monkey species, domesticated animals such as cattle, sheep, pigs, goats and horses, domesticated mammals such as dogs and cats, and experimental animals such as rodents such as mice, rats and guinea pigs. In some embodiments, the subject is a human being in the range of birth to 2 years, 1 to 10 years, or 4 to 15 years, or 10 to 19 years, or 20 to 40 years, or 15 to 29 years or 25 to 55 years, or 40 to 60 years, or 50 years or older, or 60 years or older, or 65 years or older, or 70 years or older.

[0186] AAVAdeno-associated virus (AAV) is a replication-deficient parvovirus whose single-stranded DNA genome is approximately 4.7 kb long and contains a 145-nucleotide terminal inversion (ITR). Multiple serotypes of AAV exist. The nucleotide sequences of the AAV serotype genomes are known. For example, the nucleotide sequence of the AAV serotype 2 (AAV2) genome is presented in Srivastava et al., J Virol, 45:555-564 (1983), modified by Ruffing et al., J Gen Virol, 75:3385-3392 (1994). As other examples, the complete genome of AAV-1 is presented under GenBank acceptance number NC_002077, the complete genome of AAV-3 is presented under GenBank acceptance number NC_1829, the complete genome of AAV-4 is presented under GenBank acceptance number NC_001829, the genome of AAV-5 is presented under GenBank acceptance number AF085716, the complete genome of AAV-6 is presented under GenBank acceptance number NC_001862, at least portions of the genomes of AAV-7 and AAV-8 are presented under GenBank acceptance numbers AX753246 and AX753249, respectively (see also U.S. Patent Nos. 7,282,199 and 7,790,449 for AAV-8), and the genome of AAV-9 is presented by Gao et al. The AAV-10 genome was presented in al., J. Virol., 78:6381-6388 (2004), the AAV-11 genome in Mol. Ther., 13(1):67-76 (2006), and the AAV-11 genome in Virology, 330(2):375-383 (2004). Cloning of AAVrh.74 serotypes is described in Rodino-Klapac., et al. Journal of Translational Medicine 5, 45 (2007). The Cis action sequence, which directs viral DNA replication (rep), capsid formation / packaging, and host cell chromosome integration, is contained within the ITR. Three AAV promoters (named p5, p19, and p40 relative to their relative map locations) drive the expression of two AAV internal open reading frames encoding the rep and cap genes.Coupled with differential splicing of a single AAV intron (e.g., at nucleotides 2107 and 2227 of AAV2), two rep promoters (p5 and p19) result in the production of four rep proteins (rep78, rep68, rep52, and rep40) from the rep gene. The rep proteins possess multiple enzymatic properties that ultimately contribute to the replication of the viral genome. The cap gene is expressed from the p40 promoter and encodes three capsid proteins: VP1, VP2, and VP3. Alternative splicing and non-consensus translation initiation sites contribute to the production of these three related capsid proteins. A single-consensus polyadenylation site is located at map position 95 of the AAV genome. The life cycle and genetics of AAV are outlined in Muzyczka, Current Topics in Microbiology and Immunology, 158:97-129 (1992).

[0187] AAV possesses unique characteristics that make it attractive, for example, as a vector for delivering foreign DNA to cells in gene therapy. AAV infection of cells in culture is non-cellular, and natural infection in humans and other animals is silent and asymptomatic. Furthermore, AAV can infect many mammalian cells and allows for the potential to target many different tissues in vivo. Additionally, AAV can transduce slow-dividing and non-dividing cells and persist essentially throughout the lifespan of those cells as a transcriptionally active nuclear episome (extrachromosomal element). The AAV proviral genome is infectious as cloned DNA in a plasmid, enabling the construction of recombinant genomes. Furthermore, because signals directing AAV replication, genomic capsid formation, and integration are contained within the ITR of the AAV genome, some or all of the approximately 4.3 kb inside the genome (encoding the replication and structural capsid proteins, rep-cap) can be replaced with foreign DNA, such as a gene cassette containing the promoter, the DNA of interest, and polyadenylation signals. The rep and cap proteins can be supplied trans. Another important characteristic of AAV is that it is an extremely stable and robust virus. This means it readily withstands the conditions used to inactivate adenoviruses (56°C–65°C for several hours), reducing the importance of chilling AAV. AAV can be freeze-dried. Finally, AAV-infected cells do not show resistance to co-infection.

[0188] Multiple studies have demonstrated long-term (over 1.5 years) recombinant AAV-mediated protein expression in muscle. See Clark et al., Hum Gene Ther, 8:659-669 (1997); Kessler et al., Proc Nat. Acad Sc. USA, 93:14082-14087 (1996), and Xiao et al., J Virol, 70:8098-8108 (1996). Also see Chao et al., Mol Ther, 2:619-623 (2000), and Chao et al., Mol Ther, 4:217-222 (2001). Furthermore, because muscles are highly angiogenic, recombinant AAV transduction resulted in the emergence of the transgene product in systemic circulation following intramuscular injection, as described by Herzog et al., Proc Natl Acad Sci USA, 94:5804-5809 (1997) and Murphy et al., Proc Natl Acad Sci USA, 94:13921-13926 (1997). In addition, Lewis et al., J Virol, 76:8769-8775 (2002) demonstrated that skeletal muscle fibers possess the necessary cellular factors for correct antibody glycosylation, folding, and secretion, showing that muscles are capable of stable expression of secreted protein therapeutics.

[0189] The recombinant AAV genomes of this disclosure include the nucleic acid molecule and one or more AAV ITRs adjacent to the nucleic acid molecule. The AAV DNA of the rAAV genome may be derived from any AAV serotype capable of inducing recombinant viruses, including but not limited to AAV serotypes AAVrh.74, AAV-1, AAV-2, AAV-3, AAV-4, AAV-5, AAV-6, AAV-7, AAV-8, AAV-9, AAV-10, AAV-11, AAV-12, AAV-13, and AAVrh.74. The generation of pseudotyped rAAV is disclosed, for example, in WO01 / 83692. Other types of rAAV variants, e.g., rAAV with capsid mutations, are also intended. See, for example, Marsic et al., Molecular Therapy, 22(11):1900-1909 (2014). As described in the background information section above, the nucleotide sequences of various AAV serotype genomes are known in the art. AAVrh.74 can be used to promote muscle-specific expression.

[0190] The DNA plasmid of this disclosure comprises the rAAV genome of this disclosure. The DNA plasmid is transferred to a cell tolerant of infection with an AAV helper virus (e.g., adenovirus, E1 deletion adenovirus, or herpesvirus) for assembly of the rAAV genome into infectious viral particles. Techniques for producing rAAV particles, in which the AAV genome, rep and cap genes, and helper virus function are provided to the cell to be packaged, are standard in the art. The production of rAAV requires that the following components, the rAAV genome, the AAV rep and cap genes isolated from (i.e., not present in) the rAAV genome, and the helper virus function be present in a single cell (referred to herein as the packaging cell). The rep and cap genes of AAV may originate from any AAV serotype from which the recombinant virus may originate, and may originate from AAV serotypes different from the rAAV genome ITR, such as AAV serotypes AAV-1, AAV-2, AAV-3, AAV-4, AAV-5, AAV-6, AAV-7, AAVrh.74, AAV-8, AAV-9, AAV-10, AAV-11, AAV-12, and AAV-13, among others. The production of pseudotyped rAAV is disclosed, for example, in WO01 / 83692, which is incorporated in its entirety herein by reference.

[0191] The method for generating packaging cells involves creating a cell line that stably expresses all the components necessary for AAV particle production. For example, a plasmid (or multiple plasmids) containing an rAAV genome lacking the AAV rep and cap genes, the AAV rep and cap genes isolated from the rAAV genome, and selectable markers such as the neomycin resistance gene, is incorporated into the cell's genome. The AAV genome has been introduced into bacterial plasmids by methods such as GC tailing (Samulski et al., 1982, Proc. Natl. Acad. S6. USA, 79:2077-2081), addition of a synthetic linker containing restriction endonuclease cleavage sites (Laughlin et al., 1983, Gene, 23:65-73), or direct blunt-end ligation (Senapathy & Carter, 1984, J. Biol. Chem., 259:4661-4666). Next, the packaging cell line is infected with a helper virus such as adenovirus. The advantage of this method is that the cells are selectable and it is suitable for large-scale production of rAAV. Another example of a preferred method is to use adenovirus or baculovirus instead of plasmids to introduce the rAAV genome and / or rep and cap genes into the packaging cells.

[0192] The general principles of rAAV production are outlined, for example, in Carter, 1992, Current Opinions in Biotechnology, 1533-539, and Muzyczka, 1992, Curr. Topics in Microbial. and Immunol., 158:97-129). Various approaches include Ratschin et al., Mol. Cell. Biol. 4:2072 (1984), Hermonat et al., Proc. Natl. Acad. Sci. USA, 81: 6466 (1984), Tratschin et al., Mo 1. Cell. Biol. al., J. Virol., 62:1963 (1988), and Lebkowski et al., Mol. Cell. Biol., 7:349 (1988), Samulski et al. al., J. Virol., 63:3822-3828 (1989), U.S. Patent No. 5,173,414, WO95 / 13365, and corresponding U.S. Patent No. 5,658,776, WO95 / 13392, WO96 / 17947, PCT / US98 / 18600, WO97 / 09441 (PCT / US96 / 14423), WO97 / 08298 (PCT / US96 / 13872), WO97 / 21825 (PCT / US96 / 20777), WO97 / 06243 (PCT / FR96 / 01064), WO99 / 11764, Perrin et al. Vaccine 13:1244-1250 (1995), Paul et al. This is described in al. Human Gene Therapy 4:609-615 (1993), Clark et al. Gene Therapy 3:1124-1132 (1996), U.S. Patent Nos. 5,786,211, 5,871,982, and 6,258,595. The aforementioned documents are incorporated herein by reference in their entirety, with particular emphasis on the portions relating to rAAV production.

[0193] Accordingly, this disclosure provides packaging cells that produce infectious rAAV. In one embodiment, the packaging cells may be stably transformed cancer cells such as HeLa cells, 293 cells, and PerC.6 cells (allogeneic 293 strain). In another embodiment, the packaging cells may be non-transformed cancer cells, such as low-passage 293 cells (human fetal kidney cells transformed with adenovirus E1), MRC-5 cells (human fetal fibroblasts), WI-38 cells (human fetal fibroblasts), Vero cells (monkey kidney cells), and FRhL-2 cells (rhesus macaque fetal lung cells).

[0194] The recombinant AAVs of this disclosure (i.e., infectious capsidized rAAV particles) comprise an rAAV genome. In exemplary embodiments, the genomes of both rAAVs lack the rep and cap DNA of AAV, i.e., there is no rep or cap DNA of AAV between the ITRs of the genome. Examples of rAAVs that can be constructed to comprise the nucleic acid molecules of this disclosure are described in International Patent Application No. PCT / US2012 / 047999 (WO2013 / 016352), which is incorporated herein by reference in its entirety.

[0195] In exemplary embodiments, the recombinant AAV vector of this disclosure is produced by a triple transfection method using the AAV vector plasmid rAAV.MHCK7.microdystrophin, pNLRep2-Caprh74, and pHelp (Xiao et al., J Virol 72, 2224-2232 (1998)), where rAAV contains a microdystrophin gene expression cassette flanked by the AAV2 reverse terminal repeat (ITR). This sequence is capsidized to AAVrh.74 virions. The plasmid contains the microdystrophin sequence and a core promoter element consisting of the MHCK7 enhancer and muscle-specific promoter that drive gene expression. The expression cassette also contains an SV40 intron (SD / SA) that promotes high levels of gene expression, and a bovine growth hormone polyadenylation signal is used for efficient transcription termination.

[0196] pNLREP2-Caprh74 is an AAV helper plasmid encoding four wild-type AAV2 rep proteins and three wild-type AAV VP capsid proteins derived from serotype rh74. A schematic diagram of the pNLREP2-Caprh74 plasmid is shown in Figure 3.

[0197] The pHELP adenovirus helper plasmid is 11,635 bp long and was obtained from Applied Viromics. This plasmid contains regions of the adenovirus genome important for AAV replication, namely E2A, E4ORF6, and VA RNA (adenovirus E1 function is provided by 293 cells). The adenovirus sequences present in this plasmid represent only about 40% of the adenovirus genome and do not include cis elements important for replication, such as the terminal repeat sequences of the adenovirus. Therefore, infectious adenovirus is not expected to be produced from such a production system. A schematic diagram of the pHELP plasmid is shown in Figure 4.

[0198] rAAV can be purified by methods standard in the art, such as by column chromatography or cesium chloride gradient. Methods for purifying rAAV vectors from helper viruses are known in the art and include, for example, the methods disclosed in Clark et al., Hum. Gene Ther., 10(6):1031-1039 (1999), Schenpp and Clark, Methods Mol. Med., 69 427-443 (2002), U.S. Patent No. 6,566,118, and WO98 / 09657.

[0199] In another embodiment, the Disclosure envisions a composition comprising rAAV of the Disclosure. The composition of the Disclosure comprises rAAV and a pharmaceutically acceptable carrier. The composition may also include other components such as diluents and adjuvants. The acceptable carrier, diluent, and adjuvant are nontoxic to the recipient, preferably inert at the adopted dosage and concentration, and include buffers and surfactants such as Pluronic®.

[0200] The titer of rAAV administered by the method of this disclosure will vary depending, for example, on the specific rAAV, mode of administration, therapeutic target, targeted individual, and cell type, and may be determined by standard methods in the art. The titer of rAAV is approximately 1 × 10⁶ per ml. 6 , about 1×10 7 , about 1×10 8 , about 1×10 9 , about 1×10 10 , about 1×10 11 , about 1×10 12 , about 1×10 13 , about 1×10 14 The range may be from or above the DNase-resistant particle (DRP) range. Dosage may be expressed in units of viral genome (vg). One exemplary method for determining the encapsulated vector genome titer is to use quantitative PCR, such as the method described in (Pozsgai et al., Mol.Ther. 25(4):855-869, 2017). Unless otherwise specified, the dosages described herein correspond to doses determined by supercoiled DNA standards.

[0201] A method for transducing target cells with rAAV in vivo or in vitro is contemplated by this disclosure. The in vivo method comprises the step of administering a composition comprising an effective dose or effective multiple doses of the rAAV of this disclosure to an animal (including humans) in need thereof. If the dose is administered before the onset of the disorder / disease, the administration is prophylactic. If the dose is administered after the onset of the disorder / disease, the administration is therapeutic. In embodiments of this disclosure, the effective dose is a dose that alleviates (eliminates or reduces) at least one symptom associated with the disorder / disease condition being treated, delays or prevents progression to the disorder / disease condition, reduces the severity of the disease, results in remission (partial or complete) of the disease, and / or prolongs survival. An example of a disease contemplated for prevention or treatment by the method of this disclosure is DMD.

[0202] Combination therapies are also contemplated in this disclosure. The combinations used herein include both concurrent and sequential therapies. In particular, combinations of the methods disclosed herein with standard medical treatments (e.g., corticosteroids), such as in combination with novel therapies, are contemplated.

[0203] The administration of an effective dose of the composition, combination therapy, or formulation may be by a route standard in the art, including but not limited to intramuscular, parenteral, intravenous, oral, buccal, nasal, pulmonary, intracranial, intraosseous, intraocular, rectal, or vaginal. The route of administration and serotype of the AAV components of the rAAV of this disclosure (in particular, AAV ITR and capsid protein) may be selected and / or adapted by those skilled in the art, taking into account the disease condition being infected and / or treated, as well as the target cells / tissues expressing the microdystrophin protein.

[0204] This disclosure provides topical and systemic administration of effective doses of the rAAV, formulations, and compositions of this disclosure. For example, systemic administration means administration to the circulatory system so that the whole body is affected. Systemic administration includes enteral administration, such as absorption through the gastrointestinal tract, and parenteral administration through injection, infusion, or transplantation.

[0205] In particular, the practical administration of rAAV according to this disclosure can be achieved by using any physical method for transporting the rAAV recombinant vector to the target tissue of an animal. Administration according to this disclosure includes, but is not limited to, intramuscular injection and injection into the bloodstream. It has been demonstrated that simply resuspending rAAV in phosphate-buffered saline is sufficient to provide a vehicle useful for muscle tissue expression, and there are no known limitations on carriers or other components that may be administered co-administered with rAAV (however, compositions that degrade DNA should be avoided in the usual manner with rAAV). The capsid protein of rAAV may be modified so that rAAV is targeted to a specific target tissue of interest, such as muscle. See, for example, WO02 / 053703, the disclosure of which is incorporated herein by reference. The pharmaceutical composition can be prepared as an injectable formulation or as a topical formulation delivered to muscle by transdermal transport. Numerous formulations for both intramuscular injection and transdermal transport have been developed in advance and may be used when carrying out this disclosure. rAAV can be used with any pharmaceutically acceptable carrier to facilitate administration and handling.

[0206] In one embodiment of the present disclosure, the AAVrh74.MHCK7.microdystrophin described herein is formulated in a buffer containing 20 mM Tris (pH 8.0), 1 mM magnesium chloride (MgCl2), 200 mM sodium chloride (NaCl), and 0.001% poloxamer 188.

[0207] The dose of rAAV administered by the methods disclosed herein may vary depending, for example, on the specific rAAV, administration method, therapeutic goal, individual, and targeted cell type, and may be determined by standard methods in the art. The potency of each rAAV administered is approximately 1 × 10⁶ per ml. 6 , about 1×10 7 , about 1×10 8 , about 1×10 9 , about 1×10 10 , about 1×10 11 , about 1×10 12 , about 1×10 13 , about 1×1014 , 2×10 14 From, or approximately 1 × 10 15 The above range of DNase-resistant particles (DRPs) may also apply. The dosage is also measured in units of viral genome (vg) (i.e., 1 × 10⁻⁶ units each). 7 vg, 1×10 8 vg, 1×10 9 vg, 1×10 10 vg, 1×10 11 vg, 1×10 12 vg, 1×10 13 vg, 1×10 14 vg, 2×10 14 vg, 1×10 15 The dosage may also be expressed in units of viral genomes (vg) per kilogram (kg) of body weight (i.e., 1 × 10⁻¹⁶). 10 vg / kg, 1 × 10 11 vg / kg, 1 × 10 12 vg / kg, 1 × 10 13 vg / kg, 1 × 10 14 vg / kg, 1.25 × 10 14 vg / kg, 1.5 × 10 14 vg / kg, 1.75 × 10 14 vg / kg, 2.0 × 10 14 vg / kg, 2.25 × 10 14 vg / kg, 2.5 × 10 14 vg / kg, 2.75 × 10 14 vg / kg, 3.0 × 10 14 vg / kg, 3.25 × 10 14 vg / kg, 3.5 × 10 14 vg / kg, 3.75 × 10 14 vg / kg, 4.0 × 10 14 vg / kg, 1 × 10 15 It may also be expressed in vg / kg. The method for titrating AAV is described in Clark et al., Hum. Gene Ther., 10:1031-1039 (1999).

[0208] In particular, the practical administration of rAAV according to this disclosure can be achieved by using any physical method for transporting the rAAV recombinant vector to the target tissue of an animal. Administration according to this disclosure includes, but is not limited to, intramuscular injection and injection into the bloodstream. It has been demonstrated that simply resuspending rAAV in phosphate-buffered saline is sufficient to provide a vehicle useful for muscle tissue expression, and there are no known limitations on carriers or other components that may be administered co-administered with rAAV (however, compositions that degrade DNA should be avoided in the usual manner with rAAV). The capsid protein of rAAV may be modified so that rAAV is targeted to a specific target tissue of interest, such as muscle. See, for example, WO02 / 053703, the disclosure of which is incorporated herein by reference. The pharmaceutical composition can be prepared as an injectable formulation or as a topical formulation delivered to muscle by transdermal transport. Numerous formulations for both intramuscular injection and transdermal transport have been developed in advance and may be used when carrying out this disclosure. rAAV can be used with any pharmaceutically acceptable carrier to facilitate administration and handling.

[0209] For intramuscular injection, adjuvant solutions such as sesame oil or peanut oil, aqueous propylene glycol solutions, and sterile aqueous solutions can be used. Such aqueous solutions can be buffered as needed, and the liquid diluent is first isotonicized with physiological saline or glucose. Solutions of rAAV as free acid (DNA contains acidic phosphate groups) or pharmacokinetically acceptable salts can be prepared in water suitably mixed with a surfactant such as hydroxypropyl cellulose. Dispersions of rAAV can also be prepared in glycerol, liquid polyethylene glycol, and mixtures thereof, as well as in oil. Under normal storage and use conditions, these formulations contain preservatives to prevent microbial growth. In this regard, all sterile aqueous media used are readily available by standard techniques well known to those skilled in the art.

[0210] Pharmaceutical carriers, diluents, or excipients suitable for injection applications include sterile aqueous solutions or dispersions, and sterile powders for the immediate preparation of sterile injection solutions or dispersions. In all cases, the form must be sterile and fluid enough to allow for easy syringe use. The form must be stable under manufacturing and storage conditions and protected against contamination by microorganisms such as bacteria and fungi. Carriers may be solvents or dispersion media containing, for example, water, ethanol, polyols (e.g., glycerol, propylene glycol, liquid polyethylene glycol, etc.), suitable mixtures thereof, and vegetable oils. Adequate fluidity can be maintained, for example, by the use of coating agents such as lecithin, by maintaining the required particle size in the case of dispersants, and by the use of surfactants. Prevention of microbial action can be achieved by various antimicrobial and antifungal agents, such as parabens, chlorobutanol, phenol, sorbic acid, thimerosal, etc. In many cases, it would be preferable to include isotonic agents, such as sugars or sodium chloride. The prolonged absorption of injectable compositions can be achieved by using absorption-delaying agents, such as aluminum monostearate and gelatin.

[0211] Sterile injectable solutions are prepared by combining the required amount of rAAV in a suitable solvent, along with various other components listed above as needed, and then sterilizing by filtration. Generally, dispersions are prepared by mixing the sterilized active ingredient with a sterile vehicle containing a basic dispersion medium and other required components from those listed above. For sterile powders for the preparation of sterile injectable solutions, preferred methods of preparation are vacuum drying and freeze-drying techniques, which yield a powder of the active ingredient plus any additional desired components from those solutions that have been previously sterilized and filtered.

[0212] Transduction with rAAV can also be performed in vitro. In one embodiment, desired target muscle cells are isolated from the target, transduced with rAAV, and reintroduced into the target. Alternatively, syngeneic or heterologous muscle cells may be used if those cells do not produce an inappropriate immune response in the target.

[0213] Suitable methods for transduction into a target and reintroduction of transduced cells are known in the art. In one embodiment, cells can be transduced in vitro, for example, by combining rAAV with muscle cells in a suitable culture medium and screening cells with the desired DNA using conventional techniques such as Southern blotting and / or PCR, or by using a selectable marker. The transduced cells can then be formulated into a pharmaceutical composition, which can be introduced into a target by various techniques, such as intramuscular, intravenous, subcutaneous, and intraperitoneal injection, or by injection into smooth muscle and cardiac muscle using a catheter, for example.

[0214] Transduction of cells with rAAVs of this disclosure results in sustained expression of the microdystrophin protein. Therefore, this disclosure provides methods for administering / delivering rAAVs expressing the microdystrophin protein to animals, preferably humans. These methods include transducing tissues (including, but not limited to, tissues such as muscle, organs such as the liver and brain, and glands such as salivary glands) with one or more rAAVs of this disclosure. Transduction may be carried out with a gene cassette containing tissue-specific regulatory elements. For example, one embodiment of the present disclosure provides a method for transducing muscle cells and muscle tissue directed by muscle-specific regulatory elements, which include, but are not limited to, actin and myosin gene families, e.g., those derived from the myoD gene family (see Weintraub et al., Science, 251:761-766 (1991)), muscle cell-specific enhancer binding factor MEF-2 (Cserjesi and Olson, Mol. Cell. Biol., 11:4854-4862 (1991)), regulatory elements derived from human skeletal actin genes (Muscat et al., Mol. Cell. Biol., 7:4089-4099 (1987)), cardiac actin genes, muscle creatine kinase sequence elements (Johnson et al. See al., Mol. Cell. Biol., 9:3393-3399 (1989), as well as regulatory elements derived from mouse creatine kinase enhancer (mCK) elements, skeletal fast-twitch muscle troponin C gene, slow-twitch muscle cardiac troponin C gene and slow-twitch muscle troponin I gene, hypoxia-induced nuclear factors (Semenza et al., Proc. Natl. Acad. Sci. USA 88:5680-5684 (1991)), steroid-induced elements and promoters including glucocorticoid response elements (GRE) (see Mader and White, Proc. Natl. Acad. Sci. USA 90:5603-5607 (1993)), and other regulatory elements.

[0215] Muscle tissue is an attractive target for in vivo DNA delivery because it is not a vital organ and is easily accessible. This disclosure aims to achieve sustained expression of microdystrophin derived from transduced muscle fibers.

[0216] Accordingly, this disclosure provides a method for administering an effective dose of rAAV (or essentially concurrently administered doses or interval doses) encoding microdystrophin to a patient in need thereof.

[0217] Immunosuppressive regimen This disclosure provides a method for treating muscular dystrophy in a subject receiving an immunosuppressive regimen. The term immunosuppressive regimen refers to a therapeutic method that suppresses or modulates the immune system of a subject. This regimen comprises the administration of one or more immunosuppressants. In any of these methods, the immunosuppressive regimen comprises at least one immunosuppressant, or at least two immunosuppressants, or at least three immunosuppressants, or at least four immunosuppressants, or at least five immunosuppressants.

[0218] Immunosuppressive regimens are administered prophylactically, either before gene therapy or before the onset of an immune response to rAAV in subjects after gene therapy. The immune response may include an adverse immune response or inflammatory response to the administered rAAV. The immune response may also be the production of antibodies in the subject in response to the administered rAAV, such as an anti-AAVrh.74 antibody.

[0219] Prophylactic administration includes the administration of an immunosuppressive regimen concurrently with gene therapy, for example, within 24 hours, 12 hours, 6 hours, 5 hours, 4 hours, 3 hours, 2 hours, or within 1 hour of gene therapy administration. Immunosuppressants are any drugs that inhibit, reduce the effectiveness of, or modulate the activity or effectiveness of the target immune system.

[0220] In other embodiments, immunosuppressive regimens are administered therapeutically. For example, immunosuppressants are administered to subjects after gene therapy has been administered, following the onset of an immune response to rAAV. The immune response in a subject may include adverse immune or inflammatory responses that follow or are triggered by the administration of rAAV to the subject. The immune response may also be the production of antibodies in the subject in response to the administered rAAV, for example, an anti-AAVrh.74 antibody.

[0221] In other embodiments, the immunosuppressive regimen is administered before the second dose of gene therapy. In some embodiments, the second dose is administered after therapeutic plasmapheresis (TPE).

[0222] Examples of immunosuppressants include cell proliferation inhibitors such as glucocorticosteroids, Janus kinase inhibitors, calcineurin inhibitors, mTOR inhibitors, purine analogs, methotrexate and cyclophosphamide, inosine monophosphate dehydrogenase (IMDH) inhibitors, biologics such as monoclonal antibodies or fusion proteins and polypeptides, and polypeptides.

[0223] Immunosuppressants may be anti-inflammatory steroids, which are steroids that reduce inflammation and suppress or modulate the target immune system. Exemplary anti-inflammatory steroids are glucocorticoids such as prednisone, prednisolone, betamethasone, dexamethasone, hydrocortisone, methylprednisolone, deflazacort, budesonide, or prednisone.

[0224] Janus kinase inhibitors are inhibitors of the JAK / STAT signaling pathway that target one or more enzymes in the Janus kinase family. Exemplary Janus kinase inhibitors include tofacitinib, baricitinib, upadacitinib, peficitinib, and oclacitinib.

[0225] Calcineurin inhibitors bind to cyclophylline and inhibit the activity of calcineurin. Exemplary calcineurin inhibitors include cyclosporine, tacrolimus, and piceclorimus.

[0226] mTOR inhibitors reduce or inhibit the serine / threonine-specific protein kinase mTOR. Exemplary mTOR inhibitors include sirolimus, everolimus, and temsirolimus.

[0227] Immunosuppressants include immunosuppressive macrolides. The term "immunosuppressive macrolide" refers to macrolide agents that suppress or modulate the target immune system. Macrolides are a class of drugs that contain a large macrocyclic lactone ring to which one or more deoxy sugars, such as cladinose or desamine, are attached. The lactone ring is usually 14, 15, or 16 members long. Macrolides belong to the polyketide class of drugs and can be natural products. Examples of immunosuppressive macrolides include tacrolimus, pimecrolimus, and sirolimus.

[0228] Purine analogs inhibit nucleotide synthesis and include IMDH inhibitors. Exemplary purine analogs include azathioprine, mycophenolic acid, and lefnomide.

[0229] Examples of immunosuppressive biologics include abatacept, adalimumab, anakinra, certolizumab, etanercept, golimumab, infliximab, isekizumab, natalizumab, rituximab, secukinumab, tocilizumab, ustekinenumab, vedolizumab, basiliximab, belatacept, and daclizumab.

[0230] In particular, immunosuppressants are anti-CD20 antibodies. The term anti-CD20-specific antibody refers to an antibody that specifically binds to CD20 or inhibits or reduces the expression or activity of CD20. Exemplary anti-CD20 antibodies include rituximab, ocrelizumab, or ofatumumab.

[0231] Examples of additional immunosuppressive antibodies include anti-CD25 antibodies (or anti-IL2 antibodies or anti-TAC antibodies) such as basiliximab and daclizumab, as well as anti-CD3 antibodies such as muromonab-CD3, otelixizumab, teprizumab and bicilizumab, and anti-CD52 antibodies such as alemtuzumab.

[0232] In embodiments of the present invention, the immunosuppressant (immunosuppressive antibody) used in one or more of the methods of this disclosure may be administered as nanoparticles. Methods for preparing and / or compounding nanoparticles, and nanoparticles usable by the methods of the present disclosure, include, for example, polymers (Patil et al., Pharmaceutical Nanotechnol. 367:195-203, 2009; Yang et al., ACS Appl. Mater. Interfaces, doi:10.1021 / acsami.6b16556, 2017; Perepelyuk et al., Mol. Ther. Nucleic Acids 6:259-268, 2017), liposomes (Buyens et al., J. Control Release 158(3):362-370, 2012; Scarabel et al., Expert Opin. Drug Deliv. 17:1-14, 2017), and micelles (Tangsangasaksri et al., Bio Macromolecules 17:246-255,2016; Wu et al., Nanotechnology, doi:10.1088 / 1361-6528 / aa6519,2017), as a microemulsion (WO 11 / 004395), as a nanoemulsion or solid lipid nanoparticle (Sahay et al., Nature Biotechnol. 31:653-658,2013; and Lin et al., Nanomedicine 9(1):105-120,2014), as well as WO2008 / 066965, WO2011 / 143201, WO2008 / 014478, WO2020 / 081938, WO2013 / 016058, WO2013 / 086373, WO2019 / 177550, WO2013 / 016126, WO2 019 / 089828, WO99 / 39741, WO2017 / 117528, WO2017 / 004143, WO2017 / 075531, WO2015 / 199952, WO2014 / 008334, WO2013 / 086373, WO2013 / 086322, WO201 3 / 016058, WO2013 / 086373, WO2011 / 141705 and WO2001 / 07548, U.S. Patent Applications 2004 / 0142025, 2007 / 0042031, 2016 / 0199485, 2016 / 0009637, and 201 5 / 0273068, 2015 / 0265708, 2015 / 0203446, 2015 / 0005363, 2 014 / 0308304, 2014 / 0200257, 2013 / 086373, 2013 / 0338210, 2 013 / 0323269, 2013 / 0245107, 2013 / 0195920, 2013 / 0123338, No. 2013 / 0022649, No. 2013 / 0017223, No. 2012 / 0295832, No. 2012 / 0183581 , 2012 / 0172411, 2012 / 0027803, 2012 / 0058188, 2011 / 031158 No. 3, No. 2011 / 0311582, No. 2011 / 0262527, No. 2011 / 0216622, No. 2011 / 01171 No. 25, No. 2011 / 0091525, No. 2011 / 0076335, No. 2011 / 0060032, No. 2010 / 013 No. 0588, No. 2007 / 0042031, No. 2006 / 0240093, No. 2006 / 0083780, No. 2006 / 00 Nos. 08910, 2005 / 0175682, 2005 / 017054, 2005 / 0118253, 2005 / 0064595, 2004 / 0142025, 2007 / 0042031, 1999 / 009076, and U.S. 8,This includes the provisions described in publications 569,256 and 5,965,542, the entire contents of which are incorporated herein by reference.

[0233] Therapeutic plasma exchange Therapeutic plasma exchange (TPE) is an extracorporeal blood purification technique designed to remove high molecular weight substances, such as antibodies. After an initial systemic administration of a certain dose of rAAV, a subject may develop antibodies against AAV serotypes; for example, a subject may develop antibodies against AAVrh74 after administration of rAAV.MHCK7.microdystrophin. By removing these antibodies using TPE, safe and effective readmission of the rAAV vector becomes possible. In the TPE process, whole blood is removed via vascular access and subsequently spun by a centrifuge in an apheresis machine from which the plasma (antibodies) is removed. Red blood cells are delivered back along with a replacement fluid (human albumin) for the subject's maintenance fluid.

[0234] The amount of plasma exchanged during a TPE session is determined in relation to the patient's estimated plasma volume (EPV). Many formulas can be used to calculate EPV (see, for example, Inkley et al., J. Lab Clin. Med. 45:841-850, 1955; Retzlaff et al., Blood 33:649-887, 1969; Feldschuh et al., Circulation 56:605-612, 1977; Spenger et al., Predication of patient's plasma volume in plasma exchange therapy, In: Smeby et al. ed. Immune and Metabolic Aspects of Therapeutic Blood Purification Systems. Basel, Switzerland: Krager. 1986, pp. 394-402). An exemplary method for estimating EPV is calculated using the subject's weight and hematocrit according to the following formula, described in Kaplan et al. Kidney Intl. 38:160-166, 1990, which is incorporated herein by reference in its entirety. EPV = [0.065 x body weight (kg)] x [1 - hemocrit]

[0235] The protocol described in Example 5 was developed based on the dynamics of IgG antibodies, showing a rebound after 48 hours, with approximately 50-60% of the antibodies removed in the previous step rebounding. For the purposes of the method described herein, in one embodiment, it was determined that the antibody titer had to be reduced to an AAVrh.74 antibody level <1:100 to enable gene delivery.

[0236] For example, a method of subject plasma being subjected to TPE removes at least approximately 50% of the anti-rAAV antibodies in the target intravascular space, or at least approximately 55% of the anti-rAAV antibodies in the target intravascular space, or at least approximately 60% of the anti-rAAV antibodies in the target intravascular space, or at least approximately 63% of the anti-rAAV antibodies in the target intravascular space, or at least approximately 64% of the anti-rAAV antibodies, or at least approximately 65% ​​of the anti-rAAV antibodies in the target intravascular space, or the anti-rAAV antibodies in the target intravascular space Remove at least approximately 69% of the rAAV antibodies, or remove at least approximately 70% of the anti-rAAV antibodies in the target intravascular space, or remove at least approximately 74% of the anti-rAAV antibodies in the target intravascular space, or remove at least approximately 75% of the anti-rAAV antibodies in the target intravascular space, or remove at least approximately 85% of the anti-rAAV antibodies in the target intravascular space, or remove at least approximately 90% of the anti-rAAV antibodies in the target intravascular space, or remove at least approximately 95% of the anti-rAAV antibodies in the target intravascular space.

[0237] The disclosed method includes subjecting the plasma to at least one TPE session, or at least two TPE sessions, or at least three TPE sessions, or at least five TPE sessions, or at least six TPE sessions, or at least seven TPE sessions, or at least eight TPE sessions, or at least nine TPE sessions, or at least ten TPE sessions. In addition, the TPE sessions are performed once a day over a period of approximately 1 to 5 days, or approximately 1 to 10 days, or approximately 5 to 10 days, or approximately 5 to 7 days, or approximately 7 to 10 days. The TPE sessions are performed once a day for two consecutive days, or once a day for three consecutive days, or once a day for four consecutive days, or once a day for five consecutive days, or once a day for six consecutive days, or once a day for seven consecutive days, or once a day for seven consecutive days, or once a day for eight consecutive days, or once a day for nine consecutive days, or once a day for ten consecutive days.

[0238] TPE is performed using techniques employed in blood bank procedures that utilize membrane plasma separation (MPS) using highly permeable filters and dialysis equipment as described in Gurland et al., Nephron 36:173-182, 1984, or selective cell removal (cell adsorption therapy) as described in Gurland et al., Int. J. Artif Organs 7:35-38, 1984. Additional methods for performing TPE are described in Sowada et al. (Available removal systems: State-of-the-art technology. In Nydegger UE, editor. Therapeutic Hemapheresis in the 1990s. Current Studies in Hematology and Blood Transfusions, Vol 57. Basal Switzerland: Karger. 1990 pp. 57-113). These references are incorporated herein by reference in their entirety.

[0239] Embodiments of the present invention include treatment of a subject with (rAAV)rAAV.MHCK7.microdystrophin gene therapy comprising (rAAV)rh74MHCK7.microdystrophin, and further treatment of the subject with an immunosuppressive regimen, TPE, or both, in which the subject's serum or plasma, including that of a human patient, may contain pre-existing anti-AAVrh.74 antibodies and therefore may be identified as serologically positive for AAVrh.74 before receiving any gene therapy treatment, and determination of the presence of anti-AAVrh.74 antibodies in the serum or plasma of the subject in question. It is further recognized that subjects, including human patients, may become serologically positive by receiving AAV-based gene therapy. Therefore, the determination may be used to monitor the presence and levels of anti-AAVrh.74 antibodies in the serum or plasma of such subjects and may be further used in determining whether an immunosuppressive regimen, TPE, or both should be administered to such subjects before treatment with rAAV.MHCK7.microdystrophin comprising AAVrh74.MHCK7.microdystrophin. In this context, rAAV.MHCK7.microdystrophin, including AAVrh74.MHCK7.microdystrophin, may be used as initial gene therapy treatment or as additional gene therapy, including re-administration treatment. In this context, serological positivity in such serum or plasma may be used to determine whether a subject is suitable for initial gene therapy treatment with rAAV.MHCK7.microdystrophin, including AAVrh74.MHCK7.microdystrophin, whether a subject requires an immunosuppressive regimen and / or TPE, and whether treatment with an immunosuppressive regimen has resulted in a level of clarification of the subject with anti-AAVrh74 antibody-derived serum or plasma sufficient to make the subject suitable for treatment or re-treatment with rAAV.MHCK7.microdystrophin, including AAVrh74.MHCK7.microdystrophin.Methods and compositions useful for such determination of the presence of anti-AAVrh.74 antibodies in the serum or plasma of a subject include those described in Griffin et al., Adeno-associated Virus Serotype rh74 Prevalence in Muscular Dystrophy Population, American Society of Gene and Cell Therapy, 22nd annual meeting, 2019, and International Patent Application PCT / US2021 / 037314, filed on 15 June 2021, corresponding to U.S. Patent Application No. 63 / 038957, the entire contents of which are incorporated herein by reference.

[0240] Examples of antibodies used to determine the presence of anti-AAVrh.74 antibodies in the serum or plasma of the subject include, or are otherwise described herein: [Table 2]

[0241] Further examples of antibodies used to determine the presence of anti-AAVrh.74 antibodies in the target serum or plasma include NYGMN (SEQ ID NO: 20), DYGMN (SEQ ID NO: 22), and YTFTNYGMN (SEQ ID NO: 20). 21A VH CDR1 amino acid sequence selected from the group consisting of ), YTFTKYGMN (SEQ ID NO: 23), and YTFTNYGMN (SEQ ID NO: 21), and / or a VH CDR2 amino acid sequence selected from the group consisting of WINTYTGEPTYADDFKG (SEQ ID NO: 24), WINTNTGEPTYGDDFKG (SEQ ID NO: 25), and WMGWINTYTGEPTY (SEQ ID NO: 26), and / or a VH CDR1 amino acid sequence selected from the group consisting of GVAHYSDSRFAFDY (SEQ ID NO: 27), GNAHPGGSAFVY (SEQ ID NO: 28), RGSYYYDSSPAWFAY (SEQ ID NO: 29), RGVDSSGYGAFAY (SEQ ID NO: 30), and TRGTSTMISTFAFVY (SEQ ID NO: 31). The CDR3 amino acid sequence and / or a VL CDR1 amino acid sequence selected from the group consisting of SVSSSVSYMH (SEQ ID NO: 32), SASSGVTYMH (SEQ ID NO: 33), SSVSYMH (SEQ ID NO: 34), SSVSYMH (SEQ ID NO: 34), and SSVRYMH (SEQ ID NO: 35), and / or a VL CDR2 amino acid sequence selected from the group consisting of YTSNLAS (SEQ ID NO: 36), RTSNLAS (SEQ ID NO: 37), LWIYSTSNLAS (SEQ ID NO: 38), and VWIYSTSNLAS (SEQ ID NO: 39), and / or a VH CDR3 amino acid sequence selected from the group consisting of QQRSSYPFT (SEQ ID NO: 40), QQRSTYPF (SEQ ID NO: 41), QQRSFYPF (SEQ ID NO: 42), and QQRTYYPF (SEQ ID NO: 43).

[0242] Treatment of muscular dystrophy, including Duchenne muscular dystrophy ("DMD") or Becker muscular dystrophy ("BMD"), with rAAVs containing microdystrophin. The present invention encompasses a method for treating muscular dystrophy in human subjects requiring treatment for muscular dystrophy, comprising the steps of administering a recombinant adenovirus-associated (rAAV) containing a heterogeneous nucleotide sequence encoding microdystrophin, and further comprising administering an immunosuppressive regimen. In various embodiments of the present invention, the method comprises administering a recombinant adenovirus-associated (rAAV) containing a heterogeneous nucleotide sequence encoding microdystrophin, and further comprising administering an anti-inflammatory steroid, such as prednisone.

[0243] In all embodiments of the present invention, which are intended to treat muscular dystrophy with rAAVs containing microdystrophin and further involve the administration of an immunosuppressive regimen or anti-inflammatory steroids, the rAAVs or microdystrophins encoding nucleotide sequences available in the method of the present invention include those described in WO-2020 / 123645, WO-2019 / 209777, WO-2019 / 195362, WO-2016 / 115543, WO-2019118806, WO-2017 / 221145, the contents of which are incorporated herein by reference, and include SGT-001, zildistrogene varoparvovec, and PF-06939926.

[0244] Treatment of limb-girdle muscular dystrophy The treatment of limb-girdle muscular dystrophy ("LGMD") is an aspect of the present invention. The methods of the present invention described herein are recognized as being usable for the treatment of limb-girdle muscular dystrophy by using rAAV vectors useful for treating such dystrophy. Such rAAV vectors include PCT / US2019 / 039893 (WO2020 / 06458) containing AAVrh.74.tMCK.CAPN3, U.S. Patent Application No. 63 / 024,338 containing rAAVrh.74.MHCK7.DYSF.DV, PCT / US2019 / 015779 (WO2019 / 15474) containing scAAVrh.74.MHCK7.hSGCG, and AAVrh74.tM This includes the information contained in PCT / US2020 / 47339, which includes CK.hSCGA; PCT / US2020 / 019892 (WO2020 / 176614), which includes scAAVrh74.MHCK7.HSGCB; and PCT / US2016 / 061703 (WO2017 / 083776), which includes rAAVrh.74.MHCK7.huAN05, the contents of which are incorporated herein by reference.

[0245] Combination therapy for treating muscular dystrophy This disclosure provides combination therapies for treating muscular dystrophy in human subjects in need, including the treatment of DMD, Becker muscular dystrophy, and limb-girdle muscular dystrophy, the combination therapies comprising rAAV and anti-inflammatory steroids. This disclosure also provides the use of combination therapies comprising rAAV and anti-inflammatory steroids for the preparation of agents for treating muscular dystrophy, including the treatment of DMD, Becker muscular dystrophy, and limb-girdle muscular dystrophy.

[0246] This disclosure provides combination therapies and agents comprising rAAV rAAV.MHCK7.microdystrophin and anti-inflammatory steroids administered in combination, including simultaneously, consecutively, or at different time points. This disclosure provides combination therapies and agents comprising rAAV selected from the group consisting of AAVrh.74.tMCK.CAPN3, rAAVrh.74.MHCK7.DYSF, scAAVrh.74.MHCK7.hSGCG, AAVrh74.tMCK.hSCGA, scAAVrh74.MHCK7.HSGCB, and rAAVrh.74.MHCK7.huAN05 and anti-inflammatory steroids administered simultaneously, consecutively, or at different time points. For example, the anti-inflammatory steroid is a glucocorticoid. In some embodiments, the anti-inflammatory steroid is prednisone, prednisolone, betamethasone, dexamethasone, hydrocortisone, methylprednisolone, or deflazacort. In some embodiments, anti-inflammatory steroids are formulated for oral administration. In combination therapies and drug use, anti-inflammatory steroids may be administered both before and after administration of rAAV. Alternatively, anti-inflammatory steroids may be administered either only before or only after administration of rAAV.

[0247] In some combination therapies and medications, anti-inflammatory steroids are administered approximately 12 hours, 24 hours, 36 hours, 48 ​​hours, 60 hours, 72 hours, or 96 hours before rAAV administration. In some combination therapies and medications, inflammatory steroids are administered approximately 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, or 30 days before rAAV administration.

[0248] In some combination therapies and medications, anti-inflammatory steroids are administered at least once daily for about 7 days prior to rAAV administration, or at least once daily for about 14 days prior to rAAV administration, or at least once daily for 21 days prior to rAAV administration, or at least once daily for about 28 days prior to rAAV administration, or at least once daily for about 30 days prior to rAAV administration, or at least once daily for about 45 days prior to rAAV administration, or at least once daily for about 60 days prior to rAAV administration. In some compositions and medications, anti-inflammatory steroids are administered 30 to 60 days prior to rAAV administration.

[0249] In exemplary combination therapies and medications, anti-inflammatory steroids are administered before rAAV administration, or at least once daily from day 1 to day 30 after rAAV administration, or at least once daily from day 1 to day 60 after rAAV administration, or at least once daily from day 1 to day 7 after rAAV administration, or at least once daily from day 1 to day 14 after rAAV administration, or at least once daily from day 1 to day 21 after rAAV administration, or at least once daily from day 1 to day 24 after rAAV administration, or at least once daily from day 1 to day 28 after rAAV administration, or at least from day 1 to day 30 after rAAV administration, or at least from day 30 to day 60 after rAAV administration.

[0250] In any of the combination therapies and agents disclosed herein, the combination therapy or agent may also include an anti-CD20-specific antibody administered in combination with rAAV and an anti-inflammatory steroid. The anti-CD20-specific antibody is administered before administration of rAAV. In some compositions, the anti-CD20-specific antibody is administered at least 7 days before administration of rAAV. Exemplary anti-CD20 antibodies include rituximab, ocrelizumab, or ofatumumab.

[0251] In some combination therapies and drugs, anti-CD20-specific antibodies are administered approximately 60 days before rAAV administration, or approximately 45 days before rAAV administration, or approximately 30 days before rAAV administration, or approximately 14 days before rAAV administration, approximately 7 days before rAAV administration, and within approximately 24 hours of rAAV administration. In some compositions, anti-CD20 antibodies are administered 30 to 60 days before rAAV administration. In some combination therapies and drugs, anti-CD20-specific antibodies are administered after rAAV administration. For example, anti-CD20-specific antibodies are administered both before and after rAAV administration. Alternatively, anti-CD20-specific antibodies are administered either before rAAV administration or after rAAV administration.

[0252] In addition, in all of the disclosed combination therapies and agents, immunosuppressive macrolides are administered to the target in combination with rAAV and anti-inflammatory steroids, and optionally, an anti-CD-20 antibody. Examples of immunosuppressive macrolides include tacrolimus, pimecrolimus, and sirolimus. In some combination therapies and agents, immunosuppressive macrolides are formulated for oral administration. In some combination therapies and agents, immunosuppressive macrolides may be administered both before and after rAAV administration. Alternatively, immunosuppressive macrolides may be administered before administration, or rAAV or immunosuppressive macrolides may be administered after rAAV administration.

[0253] In some combination therapies and medications, immunosuppressive macrolides are administered at least once daily for at least 3 days prior to rAAV administration, or at least 4 days prior to rAAV administration, or at least 5 days prior to rAAV administration, or at least 6 days prior to rAAV administration, or at least 7 days prior to rAAV administration, or at least 10 days prior to rAAV administration, or at least 14 days prior to administration, or at least 30 days prior to rAAV administration, or at least 45 days prior to rAAV administration, or at least 60 days prior to rAAV administration. In some combination therapies and medications, immunosuppressive macrolides are administered 30 to 60 days prior to rAAV administration.

[0254] This disclosure also provides combination therapies for treating muscular dystrophy in human subjects requiring treatment for muscular dystrophy, including the co-administration of rAAV and immunosuppressive regimens, including the treatment of DMD, Becker muscular dystrophy, and limb-girdle muscular dystrophy, where one or more components of rAAV and immunosuppressive regimens are administered simultaneously, sequentially, or at different time points. In addition, this disclosure also provides the use of combination therapies including rAAV and immunosuppressive regimens for the preparation of agents for treating muscular dystrophy in human subjects requiring treatment for muscular dystrophy, including the treatment of DMD, Becker muscular dystrophy, and limb-girdle muscular dystrophy, where one or more components of rAAV and immunosuppressive regimens are administered simultaneously, sequentially, or at different time points. For example, this disclosure provides a combination therapy for treating muscular dystrophy comprising rAAV, MHCK7, microdystrophin, and an immunosuppressive regimen, the immunosuppressive regimen comprising one or more of an anti-inflammatory steroid, an anti-CD20 antibody, and an immunosuppressive macrolide, and rAAV and one or more components of the immunosuppressive regimen are administered simultaneously, sequentially, or at different time points. For example, the present disclosure provides a combination therapy for treating muscular dystrophy comprising an rAAV selected from the group consisting of AAVrh.74.tMCK.CAPN3, rAAVrh.74.MHCK7.DYSF, scAAVrh.74.MHCK7.hSGCG, AAVrh74.tMCK.hSCGA, scAAVrh74.MHCK7.HSGCB, and rAAVrh.74.MHCK7.huAN05, and an immunosuppressive regimen, wherein the immunosuppressive regimen comprises one or more of the following: an anti-inflammatory steroid, an anti-CD20 antibody, and an immunosuppressive macrolide, and the rAAV and one or more components of the immunosuppressive regimen are administered simultaneously, sequentially, or at different time points.

[0255] For example, this disclosure provides the use of combination therapy comprising rAAV.MHCK7.microdystrophin and an immunosuppressive regimen for the preparation of a drug for treating muscular dystrophy, wherein the immunosuppressive regimen comprises one or more of the following: an anti-inflammatory steroid, an anti-CD20 antibody, and an immunosuppressive macrolide, and rAAV and one or more components of the immunosuppressive regimen are administered simultaneously, consecutively, or at different time points. For example, this disclosure provides the use of rAAV and immunosuppressive regimens for the treatment of muscular dystrophy, wherein the rAAV is selected from the group consisting of AAVrh.74.tMCK.CAPN3, rAAVrh.74.MHCK7.DYSF, scAAVrh.74.MHCK7.hSGCG, AAVrh74.tMCK.hSCGA, scAAVrh74.MHCK7.HSGCB, and rAAVrh.74.MHCK7.huAN05, and the immunosuppressive regimen comprises one or more of the following: anti-inflammatory steroids, anti-CD20 antibodies, and immunosuppressive macrolides, and one or more of the components of the rAAV and immunosuppressive regimen are administered simultaneously, sequentially, or at different time points.

[0256] The term immunosuppressive regimen refers to a therapeutic method that suppresses or modulates the immune system of a target. This regimen includes the administration of one or more immunosuppressants. In some embodiments, the immunosuppressive regimen includes the administration of anti-inflammatory steroids, anti-CD20 antibodies, and immunosuppressive macrolides.

[0257] In an exemplary combination therapy or drug, the immunosuppressive regimen includes an anti-inflammatory steroid administered approximately 24 hours before administration of rAAV. In another exemplary combination therapy or drug, the immunosuppressive regimen includes an anti-inflammatory steroid administered before administration of rAAV, and the anti-inflammatory steroid is administered at least once daily from day 1 to day 30 after administration of rAAV, or at least once daily from day 1 to day 60 after administration of rAAV. In another embodiment, a glucocorticoid anti-inflammatory steroid such as prednisone is administered for at least 60 days after administration of rAAV at 1 mg / kg.

[0258] In any of the disclosed combination therapies and agents, in immunosuppressive therapy, the anti-inflammatory steroid is a glucocorticoid such as prednisone, prednisolone, betamethasone, dexamethasone, hydrocortisone, methylprednisolone, or deflazacort. In some combination therapies, the anti-inflammatory steroid is formulated for oral administration.

[0259] Further exemplary combination therapies and agents include immunosuppressive regimens that include anti-CD20 specific antibodies administered prior to rAAV administration. For example, the anti-CD20 antibody is formulated for intravascular administration. Exemplary anti-CD20 specific antibodies include rituximab, ocrelizumab, or ofatumumab.

[0260] In some combination therapies and drugs, anti-CD20-specific antibodies are administered at least 14 days before rAAV administration. In another embodiment, anti-CD20-specific antibodies are administered approximately 60 days before rAAV administration, approximately 45 days before rAAV administration, approximately 30 days before rAAV administration, 14 days before rAAV administration, approximately 7 days before rAAV administration, and within approximately 24 hours of rAAV administration. In addition, anti-CD20-specific antibodies are administered for 30–60 days prior to rAAV administration. The disclosed immunosuppressive regimens also include administering anti-CD20-specific antibodies after rAAV administration.

[0261] In addition, the disclosed immunosuppressive regimens include an immunosuppressive macrolide administered at least once daily for at least three days prior to the administration of rAAV. The immunosuppressive regimens may also include an immunosuppressive macrolide administered after the administration of rAAV. In any of the disclosed immunosuppressive regimens, the immunosuppressive macrolide is formulated for oral administration. Exemplary immunosuppressive macrolides include tacrolimus, pinecrolimus, or sirolimus.

[0262] In some embodiments, the disclosed immunosuppressive regimen is administered 30 to 60 days before rAAV administration. In addition, the immunosuppressive regimen is administered approximately 60 days, 45 days, 30 days, 14 days, 7 days, 24 hours, or 12 hours before rAAV administration.

[0263] In certain embodiments, the Disclosure provides a combination therapy for treating muscular dystrophy in human subjects requiring treatment for muscular dystrophy, the combination therapy comprising rAAV and an immunosuppressive regimen, the immunosuppressive regimen comprising i) an anti-inflammatory steroid administered orally about 24 hours before administration of rAAV, and an anti-inflammatory steroid administered at least once daily from day 1 to day 30 after administration of rAAV, or an anti-inflammatory steroid administered at least once daily from day 1 to day 60 after administration of rAAV, ii) an anti-CD20 antibody (and optionally an anti-CD20 antibody administered after administration of rAAV) administered intravenously about 14 days before administration of rAAV, about 7 days before administration of rAAV, and about 24 hours after administration of rAAV, and iii) an immunosuppressive macrolide (and optionally an immunosuppressive macrolide administered after administration of rAAV) administered orally once daily for at least 3 days before administration of rAAV. For example, the anti-inflammatory steroid is prednisone, prednisolone, betamethasone, dexamethasone, hydrocortisone, methylprednisolone, or deflazacort, and the anti-CD20 specific antibody is rituximab, ocrelizumab, or ofatum mavon, or a higher anti-inflammatory steroid, an anti-CD20 antibody, and an immunosuppressive macrolide, and the immunosuppressive macrolide is tacrolimus, pinecrolimus, or sirolimus. In exemplary embodiments, the immunosuppressive regimen comprises the anti-inflammatory steroid prednisone or prednisolone, the anti-CD20 antibody rituximab, and the immunosuppressive macrolide sirolimus.

[0264] In certain embodiments, the Disclosure provides the use of a combination therapy comprising rAAV and an immunosuppressive regimen for the treatment of limb-girdle muscular dystrophy in human subjects requiring treatment for limb-girdle muscular dystrophy, wherein the rAAV is selected from the group consisting of AAVrh.74.tMCK.CAPN3, rAAVrh.74.MHCK7.DYSF, scAAVrh.74.MHCK7.hSGCG, AAVrh74.tMCK.hSCGA, scAAVrh74.MHCK7.HSGCB, and rAAVrh.74.MHCK7.huAN05, and the combination therapy comprises rAAV and an immunosuppressive regimen, wherein the immunosuppressive regimen is administered i) approximately 24 hours prior to the administration of rAAV. The treatment comprises: ii) an anti-inflammatory steroid administered orally, and an anti-inflammatory steroid administered at least once daily from day 1 to day 30 after rAAV administration, or an anti-inflammatory steroid administered at least once daily from day 1 to day 60 after rAAV administration; ii) an anti-CD20 antibody administered intravenously approximately 14 days before rAAV administration, approximately 7 days before rAAV administration, and approximately 24 hours after rAAV administration (and optionally an anti-CD20 antibody administered after rAAV administration); and iii) an immunosuppressive macrolide administered orally once daily for at least 3 days before rAAV administration (and optionally an immunosuppressive macrolide administered after rAAV administration). For example, the anti-inflammatory steroid is prednisone, prednisolone, betamethasone, dexamethasone, hydrocortisone, methylprednisolone, or deflazacort, and the anti-CD20 specific antibody is rituximab, ocrelizumab, or ofatum mavon, or a higher anti-inflammatory steroid, an anti-CD20 antibody, and an immunosuppressive macrolide, and the immunosuppressive macrolide is tacrolimus, pinecrolimus, or sirolimus. In exemplary embodiments, the immunosuppressive regimen comprises the anti-inflammatory steroid prednisone or prednisolone, the anti-CD20 antibody rituximab, and the immunosuppressive macrolide sirolimus.

[0265] This disclosure also provides a combination therapy for treating muscular dystrophy in human subjects in need, the combination therapy comprising a dose of rAAV, e.g., a second dose, wherein the subject's plasma is subjected to at least one therapeutic plasmapheresis (TPE) prior to administration of the second dose of recombinant adenovirus-associated (rAAV), and the subject is administered a first dose of rAAV prior to TPE. For example, the rAAV is rAAV.MHCK7.microdystrophin, AAVrh.74.tMCK.CAPN3, rAAVrh.74.MHCK7.DYSF, scAAVrh.74.MHCK7.hSGCG, AAVrh74.tMCK.hSCGA, scAAVrh74.MHCK7.HSGCB, or rAAVrh.74.MHCK7.huAN05. The muscular dystrophy is DMD, Becker muscular dystrophy, or limb-girdle muscular dystrophy.

[0266] In addition, this disclosure provides the use of combination therapy for the preparation of a drug for treating muscular dystrophy in human subjects in need, the combination therapy comprising a dose of rAAV, e.g., a second dose of rAAV, wherein the subject's plasma is subjected to at least one therapeutic plasmapheresis (TPE) prior to administration of the second dose of recombinant adenovirus-related (rAAV), and the subject is administered a first dose of rAAV prior to TPE. For example, rAAV is rAAV.MHCK7.microdystrophin, AAVrh.74.tMCK.CAPN3, rAAVrh.74.MHCK7.DYSF, scAAVrh.74.MHCK7.hSGCG, AAVrh74.tMCK.hSCGA, scAAVrh74.MHCK7.HSGCB, or rAAVrh.74.MHCK7.huAN05. Muscular dystrophy can be classified as DMD, Becker muscular dystrophy, or limb-girdle muscular dystrophy.

[0267] In any of the disclosed combination therapies and uses, the plasma in question is subjected to at least two or at least three TPEs before the second dose or administration of rAAV. In some embodiments, the plasma in question is subjected to at least four TPEs before the second dose of rAAV, or five TPEs before the second dose of rAAV, or six TPEs before the second dose of rAAV, or seven TPEs before the second dose of rAAV.

[0268] This disclosure provides a combination therapy for treating muscular dystrophy in human subjects requiring treatment for muscular dystrophy, the combination therapy comprising rAAV administered to the subject, the subject's plasma being subjected to at least one therapeutic plasmapheresis (TPE) prior to administration of rAAV, rAAV.MHCK7.microdystrophin, AAVrh.74.tMCK.CAPN3, rAAVrh.74.MHCK7.DYSF, scAAVrh.74.MHCK7.hSGCG, AAVrh74.tMCK.hSCGA, scAAVrh74.MHCK7.HSGCB, or rAAVrh.74.MHCK7.huAN05. The muscular dystrophy is DMD, Becker muscular dystrophy, or limb-girdle muscular dystrophy.

[0269] This disclosure provides the use of combination therapy for the preparation of agents for treating muscular dystrophy in human subjects requiring treatment for muscular dystrophy, the combination therapy comprising rAAV administered to the subject, the subject's plasma being subjected to at least one therapeutic plasmapheresis (TPE) prior to administration of rAAV, rAAV.MHCK7.microdystrophin, AAVrh.74.tMCK.CAPN3, rAAVrh.74.MHCK7.DYSF, scAAVrh.74.MHCK7.hSGCG, AAVrh74.tMCK.hSCGA, scAAVrh74.MHCK7.HSGCB, or rAAVrh.74.MHCK7.huAN05. The muscular dystrophy is DMD, Becker muscular dystrophy, or limb-girdle muscular dystrophy.

[0270] In any of the disclosed combination therapies and uses, the subject's plasma is subjected to at least two TPEs, at least three TPEs, at least four TPEs, at least five TPEs, at least six TPEs, and at least seven TPEs before administering rAAV. In these disclosed combination therapies and uses, the subject is administered an anti-inflammatory steroid approximately 24 hours before administering rAAV. In addition, in some embodiments, the subject is administered an anti-inflammatory steroid at least once daily from day 1 to day 60 after administering rAAV. For example, the anti-inflammatory steroid is formulated for oral administration. In addition, the anti-inflammatory steroid is a glucocorticoid such as prednisone, prednisolone, betamethasone, dexamethasone, hydrocortisone, methylprednisolone, or deflazacort.

[0271] In any of the disclosed combination therapies and uses, the subject plasma is subjected to TPE at least 9 days, 7 days, 5 days, or 2 days before administration of rAAV. In addition, there is approximately 24 to 48 hours between TPE sessions performed on the subject plasma before administration of rAAV. In certain embodiments, the subject plasma is subjected to at least two TPE sessions before administration of rAAV, with approximately 48 hours between TPE sessions.

[0272] In any of the combination therapies and uses described herein, the subject has an anti-AAVrh.74 antibody level of approximately 1:400 or less at the time of rAAV administration. For example, the subject has an anti-AAVrh.74 antibody level of approximately 1:100 to 1:400, or approximately 1:100 to 1:300, or approximately 1:100 to 1:200, or approximately 1:250 to 1:500, or approximately 1:200 to 1:400 at the time of rAAV administration. Antibody titer is determined as the total antibody-binding titer. In any of the disclosed combination therapies and uses for the treatment of muscular dystrophy, the presence of anti-AAVrh.74 antibodies was determined in the serum or plasma of the subject before administration of rAAV, after administration of rAAV, before an immune response or adverse event was observed, or after an immune response or adverse event was observed. In addition, the presence of anti-AAVrh.74 antibodies was determined before the step of administering an immunosuppressive regimen or TPE. For example, the presence of anti-AAVrh.74 antibodies was determined before any administration of any combination therapy or agent containing AAV to the subject, or before any combination therapy or agent containing AAVrh.74 to the subject.

[0273] In addition, in the disclosed combination therapies and uses, the level of anti-AAVrh.74 antibody in the serum or plasma of the subject is used as a positive control. For example, the positive control utilizes an anti-AAVrh.74 monoclonal antibody, such as one of the anti-AAVrh.74 monoclonal antibodies described herein.

[0274] In both the disclosed information and the use thereof, the presence of anti-AAVrh.74 antibodies in subjects is determined using quantitative methods, the subjects are identified as seropositive for anti-AAVrh.74 antibodies based on such quantification, and the immunosuppressive regimen or TPE is selectively administered to seropositive subjects.

[0275] This disclosure provides the following additional aspects:

[0276] Claim 1. A method for treating muscular dystrophy in a human subject requiring treatment for muscular dystrophy, comprising the step of administering a substitute adenovirus-associated (rAAV) and an anti-inflammatory steroid, wherein the rAAV is serotype AAVrh.74 and the rAAV comprises an expression cassette of SEQ ID NO: 9.

[0277] Claim 2.rAAV is 1.33 × 10 14 The method according to claim 1, administered at a dose of vg / kg. 1.33 × 10 14 The dose is determined by a supercoiled qPCR DNA standard for titer determination (2 × 10⁻¹⁰). 14 This is determined using the corresponding linear qPCR DNA standard.

[0278] Claim 3. The method according to claim 1 or 2, wherein a control has Duchenne muscular dystrophy, has not previously received rAAVrh.74-based gene therapy, and has been determined to be serologically positive for rAAV.rh74 antibodies.

[0279] Claim 4. The method according to Claim 3, wherein the subject is determined to be serum-positive for rAAVrh.74 antibody based on an ELISA immunoassay, and the subject exhibits an absorbance ratio of 2.00 at a serum dilution of 1:400 or higher.

[0280] Claim 5. The method according to any one of claims 1 to 3, further comprising the step of determining the presence of anti-AAVrh.74 antibodies in the serum or plasma of a subject before any administration of rAAVrh74 to the subject.

[0281] Claim 6. The method according to claim 5, wherein the presence of an anti-AAVrh.74 antibody is determined by an ELISA immunoassay, and the subject exhibits an absorbance ratio of 2.00 or higher at a serum dilution of 1:400.

[0282] Claim 7. The method according to any one of claims 1 to 6, wherein the anti-inflammatory steroid is administered orally.

[0283] Claim 8. The method according to any one of claims 1 to 7, wherein an anti-inflammatory steroid is administered about 12 hours before the administration of rAAV.

[0284] Claim 9. The method according to any one of claims 1 to 7, wherein an anti-inflammatory steroid is administered at least 12 hours before the administration of rAAV.

[0285] Claim 10. The method according to any one of claims 1 to 7, wherein an anti-inflammatory steroid is administered at least 12 hours before the administration of rAAV.

[0286] Claim 11. The method according to any one of claims 1 to 7, wherein an anti-inflammatory steroid is administered at least 24 hours before the administration of rAAV.

[0287] Claim 12. The method according to any one of claims 1 to 11, wherein an anti-inflammatory steroid is administered at least once a day from day 1 to about 30 days after administration of rAAV, or at least once a day from day 1 to 60 days after administration of rAAV.

[0288] Claim 13. The method according to any one of claims 1 to 11, wherein an anti-inflammatory steroid is administered at least once daily for at least 30 days after administration of rAAV.

[0289] Claim 14. The method according to any one of claims 1 to 11, wherein an anti-inflammatory steroid is administered at least once daily for at least 60 days after administration of rAAV.

[0290] Claim 15. The method according to any one of claims 1 to 14, wherein the anti-inflammatory steroid is a glucocorticoid.

[0291] Claim 16. The method according to claim 13, wherein the immune cell is prednisone.

[0292] In addition, this disclosure provides the following additional aspects:

[0293] Claim 1. A method for treating muscular dystrophy in a human subject requiring treatment for muscular dystrophy, a) The step of providing the target plasma for at least one therapeutic plasma exchange (TPE) before administering recombinant adenovirus-associated (rAAV), b) A method comprising the step of administering rAAV, wherein the rAAV is serotype rhAAVrh.74 and the rAAV comprises an expression cassette of SEQ ID NO: 9.

[0294] Claim 2. The method according to Claim 1, wherein the target plasma is subjected to at least two TPEs, at least three TPEs, at least four TPEs, at least five TPE rAAVs, at least six TPEs, or at least seven TPEs before administration.

[0295] Claim 3. The method according to claim 1 or 2, wherein the target plasma is subjected to TPE at least 9 days before administration of rAAV, at least 7 days before administration, 5 days before administration, or 2 days before administration.

[0296] Claim 4. The method according to any one of claims 1 to 3, wherein the target plasma is subjected to TPE on the day in which rAAV is administered.

[0297] Claim 5. The method according to any one of claims 1 to 4, wherein the plasma in question is subjected to at least two TPEs, with approximately 48 hours between the TPEs.

[0298] Claim 6.rAAV is 1.33 × 10 14 The method according to any one of claims 1 to 5, administered in the dose of 1.33 × 10 14 The dose is determined by a supercoiled qPCR DNA standard for titer determination (2 × 10⁻¹⁰). 14 This is determined using the corresponding linear qPCR DNA standard.

[0299] Claim 7. The method according to any one of claims 1 to 6, wherein the control has Duchenne muscular dystrophy and has been determined to be serologically positive for rAAVrh.74 antibody.

[0300] Claim 8. The method according to claim 7, wherein the subject is administered AAVrh.74 at least once prior to the administration step of claim 1b.

[0301] Claim 9. The method according to claim 7, wherein the subject is determined to be serum-positive for rAAVrh7 antibody based on an ELISA immunoassay, and the subject exhibits an absorbance ratio of 2.00 or higher at a 1:100 serum dilution.

[0302] Claim 10. The method according to any one of claims 1 to 9, further comprising the step of determining the presence of anti-AAVrh.74 antibodies in the serum or plasma of the subject before administration of rAAVrh.74.

[0303] Claim 11. The method according to claim 10, wherein the presence of an anti-AAVrh.74 antibody is determined by an ELISA immunoassay, and the subject exhibits an absorbance ratio of 2.00 or higher at a 1:100 serum dilution.

[0304] Claim 12. The method according to any one of claims 1 to 11, further comprising administering an anti-inflammatory steroid.

[0305] Claim 13. The method according to claim 12, wherein the anti-inflammatory steroid is administered orally.

[0306] Claim 14. The method according to claim 12 or 13, wherein an anti-inflammatory steroid is administered about 12 hours before the administration of rAAV.

[0307] Claim 15. The method according to claim 12 or 13, wherein an anti-inflammatory steroid is administered at least 12 hours before the administration of rAAV.

[0308] Claim 16. The method according to claim 12 or 13, wherein an anti-inflammatory steroid is administered at least 12 hours before the administration of rAAV.

[0309] Claim 17. The method according to claim 12 or 13, wherein an anti-inflammatory steroid is administered at least 24 hours before the administration of rAAV.

[0310] Claim 18: The method according to any one of claims 12 to 17, wherein an anti-inflammatory steroid is administered at least once a day from day 1 to about 30 days after administration of rAAV, or at least once a day from day 1 to about 30 days after administration of rAAV.

[0311] Claim 19. The method according to any one of claims 12 to 17, wherein an anti-inflammatory steroid is administered at least once daily for at least 30 days after administration of rAAV.

[0312] Claim 20. The method according to any one of claims 12 to 17, wherein an anti-inflammatory steroid is administered at least once daily for at least 60 days after administration of rAAV.

[0313] Claim 21. The method according to any one of claims 12 to 17, wherein the anti-inflammatory steroid is a glucocorticoid.

[0314] Claim 22. The method according to claim 21, wherein the immune cell is prednisone.

[0315] The following examples are provided as illustrations, not limitations. The numerical ranges described include each integer value within each range, including the minimum and maximum integers described. [Examples]

[0316] Example 1 A) Generation of AAVrh74.MHCK7.microdystrophin control The AAVrh74.MHCK7.microdystrophin plasmid contains a human microdystrophin cDNA expression cassette flanked by an AAV2 terminal inversion sequence (ITR) (see Figure 1). The microdystrophin construct is characterized by in-frame rod deletions (R4-R23), with hinges 1, 2, and 4, as well as a cysteine-rich domain, maintaining the production of a 138 kDa protein. Expression of the microdystrophin protein (3579 bp) was induced by the MHCK7 promoter (795 bp). Plasmids were constructed from the rAAV.MCK.microdystrophin plasmid by removing the MCK promoter and inserting the MHCK7 promoter. Following the core promoter, a 53 bp endogenous mouse MCK Exon 1 (untranslated) is present for efficient transcription initiation, followed by an SV40 late 16S / 19S splice signal (150 bp) and a small 5'UTR (61 bp). The intron and 5'UTR are derived from plasmid pCMVβ (Clontech). The microdystrophin cassette had a consensus cossack immediately before the ATG start and a small 53 bp synthetic polyA signal for mRNA termination. As previously described by Harper et al. (Nature Medicine 8, 253-261 (2002)), the human microdystrophin cassette contained the (R4~R23 / Δ71~78) domain. The complementary DNA was codon-optimized for human use and synthesized by GenScript (Piscataway, NJ) (Mol Ther 18, 109-117 (2010)). The only viral sequence included in this vector was the terminal inversion sequence of AAV2, which is necessary for both viral DNA replication and packaging. The microdystrophin cassette has a small 53 bp synthetic polyA signal for mRNA termination.

[0317] Previous studies have demonstrated cardiac expression using the MHCK7 promoter (Salva et al. Mol Ther 15,320-329 (2007)), and AAVrh.74 has achieved expression in skeletal muscle, diaphragm, and cardiomyocyte (Sondergaard et al. Annals of Clinical and Transl Neurology 2,256-270 (2015)), with the construct sequence in Figure 1 being capsidized into AAVrh.74 virions. Molecular clones of the AAVrh.74 serotype were cloned from the lymph nodes of rhesus macaque and discussed in Rodino-Klapac et al. Journal of Translational Medicine 5,45 (2007). [Table 3]

[0318] B) Generation of AAVrh74.MHCK7 plasmids encoding microdystrophin control and kanamycin (Kan) resistance Cloning of MHCK7μDys.KAN was achieved by isolating the MHCK7.μDys fragment from the MHCK7.μDys.AMP plasmid and kanamycin backbone, and then annealing them using the NEBuilder cloning workflow. The MHCK7.μDys fragment was isolated by restriction enzyme digestion with SnaBI. Digestion was performed at 37°C for 1 hour in a total reaction of 50 μL in 1xCutSmart Buffer (NEB) and 1 μL of SnaBI. The resulting fragment was isolated by electrophoresis using a 1% agarose gel run at 105 volts for 1.5 hours. The band corresponding to the MHCK7μDys insert was excised and purified using a gel purification kit (Macherey-Nagel). The DNA concentration of the resulting fragment was 10 ng / μL. Kan backbone fragments were separated by XbaI restriction enzyme digestion in 50 μL reaction mixture using 1xCutSmart Buffer (NEB) and 1 μL XbaI at 37°C for 1 hour. The resulting fragments were isolated by electrophoresis using a 1% agarose gel run at 105 volts for 1.5 hours. The band corresponding to the Kan backbone was excised and purified using a gel purification kit (Macherey-Nagel). The DNA concentration of the resulting fragments was 8.1 ng / μL. The two fragments were annealed using the NEB Builder cloning workflow, which has the capability to join two fragments with overlapping sequences. The NEBuilder cloning reaction was performed according to the manufacturing automation at 50°C for 15 minutes, using a ratio of MHCK7.μDys of kanamycin backbone in 1xNEBuilder HiFi DNA Assembly Master Mix for a total reaction volume of 20 μL. The obtained clones were then transformed into NEB® Stable Competent E. coli (C3040) by adding 2.5 μL of the cloning product to the cells for 30 minutes on ice, then 30 seconds at 42°C, and an additional 5 minutes on ice. After transformation, 950 μL of growth medium was added to the cells, and they were grown at 30°C for 1.5 hours with shaking at 225 rpm.After proliferation, 450 μL of these cells were seeded onto 50 μg / mL kanamycin LB agar plates and incubated overnight at 30°C in a dry incubator. Colonies were harvested from these plates and grown overnight in LB containing 50 μg / mL kanamycin. DNA was isolated from 3 mL of this culture using the QIAprep® Spin Miniprep Kit (Qiagen). This DNA was used to confirm the cloning product. The cloning product was confirmed by restriction enzyme digestion with PmeI, MscI, and SmaI, followed by gel electrophoresis. The cloning product was further confirmed by sequencing. The resulting plasmid is shown in Sequence ID No. 8 and is shown in Figures 8 and 9. The sequence of the construct in Figure 7 corresponding to the sequence of Sequence ID No. 9, and nucleotides 1-4977 of Sequence ID No. 8, were capsidized to the above AAVrh.74 virion.

[0319] C) pAAV.MCK. Generation of Microdystrophin Structures The pAAV.MCK.microdystrophin plasmid was constructed by inserting an MCK expression cassette driving a codon-optimized human microdystrophin cDNA sequence into the AAV cloning vector psub201 (Samulski et al., J. Virol. 61(10):3096-3101). To drive muscle-specific gene expression, a muscle-specific regulatory element was included in the construct. This regulatory element consisted of a mouse MCK core enhancer (206 bp) fused to a 351 bp MCK core promoter (proximal). Following the core promoter, the construct included a 53 bp endogenous mouse MCK exon 1 (untranslated) for efficient transcription initiation, followed by an SV40 late 16S / 19S splice signal (97 bp) and a small 5'UTR (61 bp). The intron and 5'UTR were derived from plasmid pCMVβ (Clontech). The microdystrophin cassette has a consensus cossack immediately before the ATG start and a small 53 bp synthetic polyA signal for mRNA termination. As previously described by Harper et al. Nat. Med. 8(3):253-61, 2002, the human microdystrophin cassette contains a (R4~R23 / Δ71~78) domain.

[0320] The pAAV.MCK.microdystrophin plasmid contained a human microdystrophin cDNA expression cassette flanked by an AAV2 terminal inversion sequence (ITR) (see Figure 5). This sequence was capsidized into an AAVrh.74 virion. Molecular clones of the AAVrh.74 serotype were cloned from the lymph nodes of rhesus macaque and described in Rodino-Klapac et al. Journal of Tran. Med. 45 (2007).

[0321] D) Vector production The vectors for the studies described herein were produced under research-grade conditions using a triple transfection method of HEK293 cells. Post-production vector characterization included titration by qPCR, with supercoil standard analysis, endotoxin level measurement (EU / mL), and sterility assessment. The produced vectors were analyzed by SDS-PAGE to verify the agreement of the band pattern with the expected rAAV. The surrogate vector rAAVrh74.MCHK7.uDYS.FLAG used in these studies was constructed as described above by adding a C-terminal FLAG tag.

[0322] Example 2 Systemic gene delivery of rAAVrh74.MCHK7.microdystrophin by immunosuppression in non-human primate studies. The primary objective of this study was to identify the optimal dose, duration, and immunosuppressive regimen to optimize gene expression after intravascular delivery of rAAV.rh74.MHCK7.microdystrophin. The study was initiated using five cohorts of rhesus monkeys (n=3 per cohort) with varying durations of immunosuppression before and after vector administration (Table 1). Rhesus monkeys are referred to herein as “non-human primates” or NHP. [Table 4]

[0323] In Cohort 1, control monkeys received rAAVrh74, MHCK7, and microdystrophin in the cephalic or saphenous vein at a rate of 2 × 10⁻¹⁰ times, without the addition of immunosuppressants. 14 Intravascular administration was performed at vg / kg (n=2). In all other cohorts, rhesus monkeys received 2 × 10¹⁶ doses delivered via cephalic or saphenous vein, along with immunosuppression. 14 I also received intravascular injections of microdystrophin at a dose of vg / kg, rAAVrh74, MHCK7.

[0324] In Cohort 2, prednisone (2 mg / kg / day) was administered orally from one day before systemic gene transfer until 30 days after gene transfer (n=3). In Cohort 3, prednisone (2 mg / kg / day) was administered orally from one day before systemic gene transfer until 60 days after gene transfer (n=3). In Cohort 4, prednisone (2 mg / kg / day) was administered orally from 14 days before systemic gene transfer until 60 days after gene transfer (n=3).

[0325] In cohort 5 (n=3), a triple immunosuppression regimen was investigated. In this cohort, rituximab (750 mg / m2) was administered intravascularly in two dose sessions, 14 and 7 days prior to vector administration, with a third dose administered on the day of vector administration before gene transfer. If the antibody did not respond to the first three doses, rituximab could be administered four more times after infusion. Sirolimus (4 mg / m2) was administered three days before vector administration. 2 Oral administration of (2 mg / kg / day) was continued until the antibody levels decreased. Prednisone was administered orally from one day before vector administration until 30 days after vector administration (2 mg / kg / day).

[0326] After treatment, all cohorts underwent needle biopsies obtained from the tibialis anterior (TA) and / or gastrocnemius (gn) muscles. Biopsies were collected up to three times: before gene transfer and at 6, 8, and 12 weeks post-transfer. Blood samples for immunology, CBC, and chemistry tests were taken at least every other week.

[0327] The following hematological measurements were performed on blood samples: red blood cell count, hemoglobin, hematocrit, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, red blood cell distribution width, absolute reticulocyte count, platelet count, absolute basophil count, absolute number of large unstained cells, and blood smear.

[0328] The following clinical chemistry measurements were performed on blood samples: glucose, urea nitrogen, total protein, albumin, globulin, albumin:globulin ratio, total bilirubin, alanine aminotransferase, glutamate dehydrogenase, cholesterol, gamma-glutamyltransferase, aspartate aminotransferase, and alkaline phosphatase.

[0329] Safety profile and transduction efficiency The total antibody response to AAVrh.74 (anti-AAVrh.74 antibody) was similar across cohorts, with no evidence of abnormal observations, except for one NHP from Cohort 2 (NHP_03) that did not show an antibody response to AAVrh.74. In addition, NHPs in Cohort 5 showed an antibody response to AAVrh.74 similar to that observed in NHPs from Cohorts 1-4, despite being treated with a triple immunosuppression regimen. Adverse effects experienced by NHPs from Cohorts 1-4 included transient elevations of alanine transaminase (ALT) and aspartate transaminase (AST) liver enzymes. Two NHPs from Cohort 1 (NHP_12, NHP_13), one NHP from Cohort 3 (NHP_06), and one from Cohort 4 (NHP_07) showed elevations of ALT and AST liver enzymes 12 weeks after gene transfer. Regarding transduction efficiency, no statistically significant differences in vector genome copies (vg copies / μgDNA) were observed among NHP cohorts 1-5 12 weeks after gene transfer (P>0.05).

[0330] Example 3 Administration via therapeutic plasma exchange (TPE) The primary objective of this study was to optimize both technique and gene expression by using therapeutic plasma exchange (TPE) to remove existing AAV antibodies after readmission of rAAVrh74.MHCK7.dystrophin and to evaluate readmission without the use of TPE.

[0331] In the study described in Example 2, non-human primates (from cohorts 2, 3, and 4) pre-injected with rAAVrh74.MHCK7.microdystrophin underwent 2-3 TPEs during a single apheresis procedure. Four weeks and two weeks prior to TPE, the primates underwent their maximum blood draw (10% of the primate's body weight). The blood was stored in ACDA solution for up to 30 days and used on the day of TPE to prime the apheresis machine to prevent excessive blood loss during the procedure. In addition, the AAVrh.74-conjugated antibody titer was determined to confirm that the titer exceeded the threshold of 1:400, which is the selection criterion for the current clinical trial. After TPE, 2 × 10⁻⁶ 14 rAAVrh74.MHCK7.microdystrophin or rAAVrh74.MHCK7.microdystrophin.FLAG was delivered systemically via saphenous vein or cephalic vein at a dose of vg / kg.

[0332] These NHPs also received prednisone (2 mg / kg) once daily from one day before TPE until 30 days after TPE and gene transfer. Blood collection for chemistry, CBC, ELISA, and ELISpot assays was performed before TPE, after TPE before re-administration, and at least every other week until the endpoint. The endpoint occurred between 8 and 12 weeks after the second gene transfer and included a complete autopsy. Western blotting and qPCR, as well as FLAG immunofluorescence, were performed on the vector genome to assess efficacy.

[0333] Additionally, non-human primates (Cohort 5) previously injected during immunosuppressive therapy as described in Example 2 were re-administered with rAAVrh74.MHCK7.microdystrophin without the use of TPE, reducing existing antibodies toward AAVrh.74. Specifically, rituximab (750 mg / m²) was administered. 2 Sirolimus (4 mg / m² / day) is delivered intravascularly (IV) once on the day of injection, 7 and 14 days before gene transfer, and once after gene transfer. 2The drug ( / day) was delivered 3 days before gene transfer and continued until the end of the study. Sirolimus levels were monitored by blood sampling, varying between 3 and 14 ng / mL. Blood sampling for chemistry, CBC, sirolimus blood concentration, ELISA, and ELISpot assays was performed at least every other week until the endpoint. The endpoint occurred between 8 and 12 weeks after the second gene transfer and included a complete autopsy. Observations of each animal were performed daily. NHP body weight was monitored every other week, and immunosuppressant dosages were adjusted accordingly.

[0334] Therapeutic plasma exchange procedure: In the TPE process, whole blood was taken via vascular access and subsequently centrifuged in a centrifuge within an apheresis machine to remove plasma (antibodies). Red blood cells were delivered back together with a replacement fluid (human albumin) for the primate's maintenance fluid. Due to the small size of non-human primates (less than 10 kg), the apheresis machine was primed with stored blood before plasma exchange to ensure safety and reduce the amount of blood drawn from the primates. Maximum blood collection (10% of the non-human primate's circulating blood) was performed 28 and 14 days before apheresis. The collected whole blood was stored and kept in an anticoagulant acid-citric acid-dextrose (ACDA) solution at 4°C for up to 30 days. Additionally, NHP was supplied with extra iron-rich supplements and concentrates. On the day of apheresis, non-human primates were intramuscularly sedated with terazole (3-6 mg / kg), intubated, and fixed to a heated procedural table. Anesthesia maintenance was achieved with isoflurane at 1-4% oxygen. Vascular catheters were placed in both legs (saphenous veins), whole blood was collected through one access port, and the other access port was placed in the opposite leg to re-deliver red blood cells and replacement fluid. An additional catheter was placed in the arm (radial cephalic vein) to support fluid and blood collection throughout the procedure. After vascular access was obtained, the animals were administered heparin (50-100 U / kg) to maintain sufficient blood flow and prevent coagulation during apheresis. NHP was monitored using temperature, ECG, and respiration to determine the appropriate anesthetic surface.

[0335] As described above, NHP was connected to the COBE Spectra apheresis device via a catheter, and the device was primed with pre-collected blood. One total plasma exchange is equivalent to the removal and replacement of the entire volume of circulating blood in a single cycle. Two to three plasma exchanges were performed to achieve an estimated antibody removal rate of 98%. Blood was collected after each completed exchange for blood chemistry analysis and serum antibody testing. Immediately after plasma exchange, NHP was removed from the apheresis unit, and rAAVrh74, MHCK7, and microdystrophin were re-administered systemically. After vector delivery, all catheters were removed, and pressure was applied to control bleeding. The animals were monitored until they were fully able to walk.

[0336] Autopsy analysis At autopsy, NHP was detected in patients treated with Euthasol (1 mL / 10¹b) at the endpoint (which may occur between 8 and 12 weeks after re-administration). Blood was collected and sent for complete blood count (CBC) analysis, sirolimus level testing, and serological chemistry. Tissue was then collected and sent for analysis by an independent veterinary histopathologist to analyze gene and protein expression to assess efficacy and toxicity.

[0337] To evaluate the optimization of gene expression, 2 × 10 14Before and after muscle biopsies from NHP-derived primates were collected after intravenous administration and re-administration of vg / kg of rAAVrh74.MHCK7.microdystrophin or rAAVrh74.MHCK7.microdystrophin.FLAG. To detect specific sequences of vector DNA, DNA from both pre- and all post-myovascular tissues was extracted for real-time quantitative qPCR. All collected muscle-derived proteins were extracted and Western blotting was performed to detect microdystrophin protein (138kD) compared to pre-biopsy tissue. Additionally, naive full-length dystrophin (427kD) was used as a normal control and quantitatively compared with microdystrophin protein as a measure of outcome as gene expression. Immunofluorescence staining to observe the presence of FLAG expression was performed in primates injected with rAAVrh74.MHCK7.microdystrophin.FLAG.

[0338] To evaluate the safety of immunosuppressive regimens, vector administration, and readmission, blood samples were collected at baseline and every other week until the endpoint. Serum chemistry, CBC, and sirolimus levels were monitored every other week throughout both study objectives. T cell responses to both AAVrh.74 peptide and microdystrophin peptide were evaluated using ELISpot analysis. Finally, anti-AAVrh.74 antibody responses were monitored every other week throughout both study objectives.

[0339] The following hematological measurements were performed on blood samples: red blood cell count, hemoglobin, hematocrit, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, red blood cell distribution width, absolute reticulocyte count, platelet count, absolute basophil count, absolute number of large unstained cells, and blood smear.

[0340] The following clinical chemistry measurements were performed on blood samples: glucose, urea nitrogen, total protein, albumin, globulin, albumin:globulin ratio, total bilirubin, alanine aminotransferase, glutamate dehydrogenase, cholesterol, gamma-glutamyltransferase, aspartate aminotransferase, and alkaline phosphatase.

[0341] result The total antibody titers against AAVrh.74 in NHP before and after TPE (before re-administration with rAAVrh74.MHCK7.microdystrophin) are shown in the table below. Figure 11 shows the antibody titers against AAV74 in NHP after re-administration with rAAVrh74.MHCK7.microdystrophin. The number of TPC cycles that can be performed on NHP is limited due to the scarcity of available donor blood. In humans, multiple rounds of TPE can be administered. The titers detected in Example 2 were obtained 12 weeks after the initial gene transfer (*). The titers detected in Example 3 were obtained before the re-administration injection of rAAVrh74.MHCK7.microdystrophin ( + NHP_03 was readjusted without prior TPE due to insufficient antibody response to AAVrh.74. NHP_06 received only 0.5 cycles of TPE due to its small size and poor access to blood vessels. [Table 5]

[0342] The TPE procedure was generally well-tolerated. There were no abnormal immunological observations, as assessed by IFN-γ spot-forming cell (SCF) levels and peripheral blood mononuclear cell-derived microdystrophin peptides for AAVrh.74. Post-TPE re-administration resulted in increased liver enzyme levels (ALT / AST) in the following NHPs: NHP_01 and NHP_02, Cohort 2; NHP_04, Cohort 3; NHP_08 and NHP_09, Cohort 4). This was resolved by continuing daily administration of prednisone.

[0343] NHPs from Cohort 5 did not undergo TPE due to incompatibility with prior rituximab treatment, and two NHPs (NHP_10, NHP_11) were readjusted. Cohort 5 had total antibody titers against AAVrh.74 exceeding 1:51,200 prior to readjustment. NHPs readjusted with high antibody titers (Cohort 5) experienced the following adverse events: increased heart rate and ventilator rate, vomiting, rash near the delivery site, pallor, and shallow breathing; these resolved after administration of diphenhydramine and dexamethasone.

[0344] Seven NHPs underwent 2-3 consecutive cycles of TPE, resulting in a decrease in circulating antibody levels against AAVrh.74. Immediately after TPE, the NHPs successfully received readjustment of rAAVrh74, MHCK7, and microdystrophin. Two NHPs from Cohort 4 (NHP_08 and NHP_09) achieved antibody titers of 1:200.

[0345] As shown in Figure 12, compared to pre-TPE expression from biopsies at 12 weeks, increased microdystrophin protein expression was observed in all NHP-derived tissue samples that were re-administered with rAAVrh74.MHCK7.microdystrophin after TPE (as described in Example 2). Increased microdystrophin protein expression was observed in skeletal muscle (egg abdominal muscle), heart, and diaphragm.

[0346] Example 4 Alternatively, the tests and studies described in Examples 2 and 3 above may be carried out using the rAAVrh74.MHCK7.microdystrophin construct described in Sequence ID No. 9, nucleotides 1-4977 described in Sequence ID No. 8, and nucleotides 56-5022 described in Sequence ID No. 6.

[0347] Example 5 Gene therapy for DMD using existing AAVrh.74 antibodies after therapeutic plasma exchange (TPE) A Phase 1 clinical trial will be conducted in humans to investigate gene therapy for DMD in patients with an existing AAVrh.74 antibody following therapeutic plasmapheresis (TPE). It is hypothesized that five cycles of TPE will reduce antibody binding to AAVrh.74 (also referred herein as “anti-AAVrh.74 antibody”), enabling safe and efficient muscle transduction using AAVrh74.MHCK7.microdystrophin to achieve mean expression levels >50% compared to baseline.

[0348] The objective and primary outcome of this study is the safe delivery of rAAV carrying the microdystrophin gene (AAVrh74.MHCK7.microdystrophin). Secondary objectives are the expression of the microdystrophin gene in the muscles of subjects suffering from DMD, and clinical improvement of muscular dystrophy using the North Star Ambulatory Assessment (NSAA) as a functional outcome measure.

[0349] The treatment plan is a two-stage (weekly) protocol (Table 1) that combines safety and efficacy, first reducing AAVrh.74 antibodies by apheresis over a 10-day schedule, followed by intravenous delivery of AAVrh74.MHCK7.microdystrophin. In week 1, TPE is administered on three separate days: Monday (9th day after gene therapy infusion), Wednesday (7th day), and Friday (5th day). In week 2, TPE is administered every other day for two days, followed by intravenous infusion of AAVrh74.MHCK7.microdystrophin on Monday (2nd day) and Wednesday (1st day), with AAVrh74.MHCK7.microdystrophin (1st day) delivered on the same day as the subsequent TPE. Patients are transported to the outpatient apheresis unit according to the schedule in Table 1. Patients are admitted to the pediatric intensive care unit (PICU) on day 1 for inpatient gene therapy infusion and are scheduled to be discharged on day 2. [Table 6]

[0350] This protocol was developed based on the dynamics of IgG antibodies, showing a rebound after 48 hours, with approximately 50-60% of the antibodies removed in the previous step being recovered, thus supporting TPE over a 10-day course every other day, followed by gene delivery on the final day of TPE (designated as day 1 for gene therapy) (see Figure 13 and Exchange Volumes). The timing of these steps follows a similar course to other known antibody-mediated diseases (Padmanabhan et al., J Clin Apheresis 34:171-354, 2019).

[0351] As this protocol is being developed for a new indication, it is appropriate to follow existing established guidelines that recommend repeating 5-6 treatments (Padmanabhan et al., J Clin Apheresis 34:171-354, 2019) to 5-7 treatments (Pham et al., Transfusion and Apheresis Science 58:237-246, 2019). Additional support applicable to subjects in this protocol taking prednisone for immunosuppression is that, as a result of concurrent immunosuppressive therapy, a negligible rate of immunosuppression is assumed, and the rate of extravascular equilibrium is assumed to be approximately 1-2 percent per hour compared to the rate of intravascular equilibrium, and then five individual procedures over 7-10 days should be necessary to remove 90 percent of the initial total immunoglobulin load in the body. Additional treatment may be necessary if new antibody production occurs. (Fridey & Kaplan Therapeutic apheresis(plasma exchange or cytapheresis):Indications and technology.American Society for Apheresis Guidelines UPTODATE May 2020(available on-line)(Kaplan et al.J Clin Apheresis 28:3-10,2013)

[0352] protocol Patient characteristics for this protocol: Selection Criteria • Targeting walking males, of any ethnicity, and aged 4-10 years (including borderline age) at the time of screening. • Confirm DMD frameshift or early stop codon gene mutations. CK>1000U / L • Below the predicted 95th percentile for age in the 100m walk test indicating symptomatic disease. • Ability to cooperate with athletic ability assessment tests • Weaknesses demonstrated based on a history of difficulty running, jumping, and climbing stairs. • Oral corticosteroid equivalents are expected to be stable for at least 12 weeks prior to screening, and the dose is expected to remain constant throughout the study (excluding potential changes to accommodate weight changes). Patients with an AAVrh.74 antibody titer greater than 1:400 as determined by ELISA immunoassay at baseline screening (days 40-10) Exclusion criteria • Signs of cardiomyopathy, including ECHO, with LVEF less than 40% • Serological evidence of human immunodeficiency virus (HIV) infection or hepatitis B or C infection • Diagnosis (or ongoing treatment) of autoimmune diseases • Abnormal clinical laboratory values ​​considered clinically important (gamma-glutamyl transferase, more than 3 times the upper limit of normal, bilirubin ≥ 3 mg / dL, creatinine ≥ 1.8 mg / dL, hemoglobin < 8 g / dL or > 18 g / dL, white blood cell count > 18,500 / cmm, platelets ≤ 50,000 / microliter). • PI's opinion is that this creates unnecessary risks associated with gene transfer, such as the need for comorbidities or chronic drug treatments. • A severe infection within the past four weeks (e.g., pneumonia, pyelonephritis, meningitis). Within six months of screening, the patient received either an investigational drug (other than a corticosteroid) or an exon skipping agent (including EXONDYS51®). • Received any type of gene therapy, cell-based therapy (e.g., stem cell transplantation), or CRISPR / Cas9 therapy. • The family does not want to disclose the patient's participation in the research to their primary care physician and other healthcare providers.

[0353] Screening / Baseline Period The screening / baseline period extends up to four weeks prior to day 9. After obtaining informed consent, the patient will be assessed for eligibility. Screening includes demographic and medical history collection, vital sign measurement, physical examination, electrocardiogram (ECG), and echocardiogram (ECHO) and cardiac MRI. Blood and urine samples are collected for clinical and safety laboratory evaluation. Blood samples are also collected for antibodies against hepatitis B and C, human immunodeficiency virus (HIV), and AAVrh.74, as well as antigen-specific T cells against AAVrh.74 capsid and microdystrophin. A pretreatment muscle biopsy, including the calf muscle or a muscle selected by the attending physician (PI), is performed after eligibility and before day 9. Parents / caregivers are asked to complete the PROMIS questionnaire. Physical function assessments include the North Star Ambulatory Assessment (NSAD) for muscular dystrophy, and timed functional tests including standing up from the floor, climbing a standard four-step ladder, a 10-meter walk / run test, and a 100-meter walk / run test.

[0354] Therapeutic plasma exchange Transcatheter plasma exchange (TPE) involves removing the patient's plasma and replacing it with 5% albumin. Fresh frozen plasma (FFP) may be used during the TPE procedure if necessary for patient safety. Plasma removed during plasma exchange is not used for transfusion to another individual, in accordance with U.S. Food and Drug Administration (FDA) regulations.

[0355] protocol TPE is performed via a peripheral vein, if possible. More likely, patients will have a tunneled centerline inserted by the interventional radiologist. Parents will be instructed on how to care for the catheter between appointments.

[0356] Exchange volume - A plasma exchange of 1.0–1.5 plasma volumes is performed for each procedure. A single plasma exchange reduces plasma macromolecular weight levels by 63% (J Clin Apheresis 2019;34:171-354). IgG antibodies distributed in both intravascular and extravascular compartments require multiple exchanges to reduce total body storage, typically performed every other day to allow for redistribution between both compartments. The first 1.0–1.5 plasma volume exchange removes the maximum amount of target material, with the amount removed decreasing with each subsequent exchange. The same amount of exchange fluid is used for each single plasma exchange. In this protocol, 5% albumin is used as replacement fluid.

[0357] Immunosuppressive regimens are recommended to obtain a sustained response. Without immunosuppression, rebound may occur after the exchange; however, all DMD boys participating in this program will receive glucocorticoids as standard treatment for the disease. During the experimental protocol for plasma exchange, patients will receive glucocorticoids (1 mg / kg prednisone or equivalent corticosteroid) one day prior to TPE. Patients will maintain this dose for at least 60 days after gene delivery following gene transfer, unless the PI determines that initial tapering is within the patient's best interests (Table 1).

[0358] For the patient's further interest, an alternative plan (referred to as the “alternative schedule”) may be provided to delay gene delivery and allow the #7 TPE to proceed with gene therapy. If the AAVrh.74 titer of the target is not reached on day 1 following apheresis #4, TPE #5 will be performed, but gene delivery will not proceed. If the AAV antibody level is obtained on day 2 (Thursday), apheresis, TPE #6, and gene delivery will proceed on Friday. However, if the titer has not reached 1:100 of the target on Thursday (day 2), TPE or gene delivery on Friday will not proceed.

[0359] *** Gene delivery This is a 52-week open-label clinical trial. Six to twelve eligible patients will be enrolled and administered IV AAVrh74.MHCK7.microdystrophin. On day 1, as outpatients, a physical examination will be performed and vital signs, blood samples, and urine samples will be collected. On day 1, patients will be admitted to the hospital. The fifth and final TPE will be performed in the morning, and later that day, AAVrh74.MHCK7.microdystrophin will be administered IV over 1-2 hours according to the study operations manual used in previous protocols approved by the IRB and FDA. On the day following the infusion (day 2), patients will undergo a health check, vital signs will be collected, and blood and urine samples will be provided before discharge.

[0360] Patients are followed for 452 weeks, followed by a 5-year long-term follow-up. Patients complete follow-up visits at 1, 2, 4, 6, 8, 10, 12, 24, 36, and 48 weeks after gene delivery (compared to the infusion on day 1). In addition, at weeks 3 and 5, patients complete follow-up visits for evaluation of liver function tests. All patients undergo a muscle biopsy at week 12. The biopsy will include the gastrocnemius muscle or a muscle selected by the PI. Safety is assessed by monitoring treatment-induced adverse events (TEAEs), SAEs, and selected laboratory assessments.

[0361] Example 6 Determination of antibody sandwich ELISA in serum The materials for the sandwich ELISA assay are as follows: • Capture antibody = anti-AAVrh. 74 mAb • Test sample = serum or plasma, useful for detection • Antigen = AAVrh.74 capsid Blocking solution = 5% dry milk, 1% goat serum, 100 mL PBS • Washing buffer = 0.05% PBS-Tween® • Positive control = serum known to have anti-AAVrh.74 antibody Secondary antibody = Anti-human HRP-conjugated antibody ·Substrate=TMB ·Stop liquid = sulfuric acid

[0362] method All wells of a 96-well plate are coated overnight with capture antibody diluted in carbonate buffer at 4C. Discard the contents and block the plate in blocking solution at 37C for 1 hour. Discard the blocking solution and add two AAVrh.74 capsids to the capture antibody-coated wells. Additionally, carbonate buffer is added to replicate the wells and determine the background value. Discard the unbound capsids and add the test serum in blocking solution at a starting dilution of 1:25, then dilute sequentially. The positive control is diluted in blocking solution at a dilution of 1:400. After washing the plate with wash buffer, perform a secondary incubation with a dilution of 1:10,000 in blocking solution. Wash the plate, discard the buffer, add the substrate, and then terminate the assay with sulfuric acid. Read the absorbance of the plate at 450 nm.

[0363] Analysis and Results The absorbance ratio is determined by subtracting the OD of the uncoated wells from the mean optical density (OD) of the antigen-coated wells and dividing by the mean OD of the uncoated wells. A ratio of 2.00 or higher is considered a positive antibody response. The endpoint titer is determined by identifying the last serum dilution that yields a ratio of 2.00 or higher. The antibody cutoff is defined as a serum dilution greater than 1:400.

[0364] Example 7 Indirect ELISA: Determination of anti-AAVrh.74 antibody in serum material • Antigen = AAVrh.74 capsid • Blocking solution = 5% dry milk, 1% goat serum, 100 mL of PBS without calcium and magnesium • Washing buffer = 0.05% PBS-Tween® • Primary antibody = human test serum or plasma • Positive control = serum (or plasma) containing anti-AAVrh74 mAb, or optionally selected anti-rh74 antibody. • Negative control: Serum derived from a target that does not contain anti-AAVrh74 antibodies can be included as a negative control. Secondary antibody = anti-human antibod...

Claims

1. A composition for use in the treatment of muscular dystrophy in human subjects requiring treatment for muscular dystrophy, the composition comprising a second dose of a recombinant adeno-associated virus (rAAV) vector comprising a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 1 operably linked to an MHCK7 promoter sequence, wherein the composition is administered after a first dose of the rAAV vector and after the subject's plasma has been subjected to at least two therapeutic plasmapheresis (TPE) cycles, and the subject has a total antibody titer of at least 1:12,800 anti-AAVrh.74 antibodies after the administration of the first dose of the rAAV vector and before the subject's plasma has been subjected to at least two TPE cycles.

2. The composition for use according to claim 1, wherein the muscular dystrophy is Duchenne muscular dystrophy.

3. The composition for use according to claim 1 or 2, wherein the target plasma is subjected to TPE at least three times, at least four times, at least five times, or at least six times before administration of the second dose of the rAAV vector.

4. The composition for use according to claim 1 or 2, wherein the target plasma is subjected to 7, 8, 9, or 10 TPEs before administration of the second dose of the rAAV vector.

5. The composition for use according to any one of claims 1 to 4, wherein the target plasma is subjected to TPE at least 9 days before administration of the composition, at least 7 days before administration, 5 days before administration, or 2 days before administration, or the target plasma is subjected to TPE on the day the composition is administered.

6. The composition for use according to any one of claims 1 to 5, wherein the target plasma is subjected to TPE at least twice over a day.

7. The composition for use according to any one of claims 1 to 6, wherein the subject is administered an anti-inflammatory steroid about 24 hours before administration of the composition, or the subject is administered an anti-inflammatory steroid at least once a day from day 1 to day 60 after administration of the composition.

8. The composition for use according to any one of claims 1 to 7, wherein the composition is administered by a systemic route.

9. The systemic administration route is an intravenous route, and the composition is approximately 2 × 10 14 The composition for use according to claim 8, comprising a second dose of the rAAV vector in vg / kg.

10. The rAAV vector is a) The MHCK7 promoter sequence of SEQ ID NO: 2 or SEQ ID NO: 7, or b) Nucleotide sequence of SEQ ID NO: 9 or nucleotides 55-5021 of SEQ ID NO: 3 A composition for use according to any one of claims 1 to 9, comprising a polynucleotide containing a polynucleotide.

11. The aforementioned human subject suffers from Duchenne muscular dystrophy, and the composition is approximately 2 × 10 14 A composition for use according to any one of claims 1 to 10, administered by intravenous infusion over approximately one hour at a second dose of vg / kg, wherein the rAAV vector comprises a polynucleotide including the nucleotide sequence of SEQ ID NO: 9 or nucleotides 55 to 5021 of SEQ ID NO:

3.

12. The composition for use according to claim 9 or 11, wherein the second dose of the rAAV vector is determined using a supercoiled DNA standard.

13. The composition for use according to any one of claims 1 to 12, wherein the level of microdystrophin gene expression in the target cells increases after administration of the composition compared to the level of microdystrophin gene expression before administration of the composition.

14. A composition for use according to any one of claims 1 to 13, wherein each TPE exchanges about 1 to 1.5 plasma volumes.

15. The composition for use according to any one of claims 1 to 14, wherein after the plasma of the subject is subjected to the TPE at least twice and the second dose of the rAAV vector is administered, the subject has a total antibody titer of anti-AAVrh.74 antibodies of about 1:400 or less.

16. The composition for use according to any one of claims 1 to 14, wherein after the plasma of the subject is subjected to at least two TPEs and the second dose of the rAAV vector is administered, the subject has a total antibody titer of anti-AAVrh.74 antibodies of about 1:100 to about 1:

400.

17. The composition for use according to any one of claims 1 to 16, wherein the total antibody titer of the anti-AAVrh. 74 antibody in the subject is determined by using an immunofluorescence assay, immunohistochemical assay, Western blot, direct enzyme-linked immunosorbent assay (ELISA), indirect ELISA, sandwich ELISA, competitive ELISA, reverse ELISA, chemiluminescence assay, radioimmunoassay, or immunoprecipitation assay.

Citation Information

Patent Citations

  • Apheresis methods and uses

    WO2019018439A1

  • Adeno-associated virus vector delivery of muscle specific micro-dystrophin to treat muscular dystrophy

    WO2019245973A1